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ABSTRACT
With the increase in the prevalence of anabolic steroid (AS) use for non-medical
performance and image enhancement purposes, the impact of AS on cardiovascular
health is an issue of growing public concern. AS use has long been associated with a
number of negative CV outcomes such as acute myocardial infarction, stroke,
thrombo-embolisms and sudden death. These associations, however, are largely
assumed from case study findings where no cause and effect can be apportioned.
Small cohort studies have suggested a negative effect of AS on a number of
established CV disease risk factors including, blood pressure (BP), lipid profiles (e.g
total cholesterol, LDL and HDL), C-reactive proteins and homocysteine, although
data is limited both in number of studies and number of participants and is often
contradictory. Another potential mechanism to link AS use to cardiac events has
been to assess cardiac structure and function. Available data is contradictory but
recent developments in imaging technologies suggest that new mechanistic insights
could be developed and/or tested.
In study one we investigated the impact of AS use on a broad profile of CV risk
factors as well as an in-depth cardiac assessment utilising speckle tracking
echocardiography which can assess regional and global cardiac deformation in
multiple planes. In AS users we observed an increase in resting heart rate and low-
density lipoprotein concomitant to a decrease in high-density lipoprotein levels. 2D
and speckle-tracking echocardiography revealed a significant effect of AS use on
cardiac function, most notably a decreased diastolic (relaxation) function that
suggests a stiffer left ventricle in the AS users. This imposes a greater workload on
the heart and increases the risk of CV events.
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In study two we developed the assessment of cardiac structural assessment in AS
users by adopting state-of-the-art magnetic resonance imaging that provides a greater
accuracy in morphology assessment as well as allowing us to determine the presence
of perfusion defects and interstitial fibrosis. We observed that AS users had a
hypertrophy of both the left and right ventricles that was concomitant with diastolic
dysfunction in the left ventricle and a reduction in right ventricular contractility.
Despite these findings no AS user presented with any perfusion defect or evidence of
interstitial fibrosis, suggesting that these pathways to CV events were not apparent in
the current group of AS users.
The final study comprised two pilot or feasibility studies of the impact of resistance
exercise on left ventricular function in AS users. Trial 1 assessed blood pressure and
cardiac tissue velocities during an acute leg press with and without valsalva.
Systolic blood pressure was significantly elevated even after one repetition and this
was mediated by AS use. In trial 2 cardiac function and blood biomarkers of cardiac
cell damage were assessed before and after a standard resistance exercise training
session. Left ventricular systolic function was maintained in recovery in both AS and
NAS participants. Diastolic function was reduced in both groups with some evidence
that AS use exaggerated this effect. Multiple technical, design and participant
lessons were gained to take these feasibility studies forward to full studies.
Overall we add new data to the concept that AS use can place the participant at an
increased CV risk. It is probably not obligatory that AS use leads to increased CV
risk but in some the route from AS use to CV event may be mediated by changes in
structure and function of both the LV and RV. Exercise stress may add an additional
CV risk to the AS user.
II
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Chapter 1. Introduction
1.1 Anabolic Steroids (AS): Development and Use
Testosterone is a steroid hormone that is part of a group of androgen hormones. As
the principal male sex hormone it is responsible for the development of male
reproductive tissue as well as the development of secondary characteristics such as
musclelbone growth and the development of body hair. Most testosterone is
produced in the Leydig cells of the testes with a small amount released from the
adrenal cortex. A young adult male will produce between 3-10 mg of testosterone
per day (Basaria and Dobs, 2007). In stark contrast, an 80 year old male will produce
less than 50% of that of a 20 year old (Evans, 2004).
Anabolic-androgenic steroid (AAS), or anabolic steroid (AS) hormones as they have
become more commonly known, are synthetic derivatives of the male sex hormone
testosterone (van Amsterdam et al., 2010). These synthetic hormones have been
developed as a clinical therapy choice as testosterone has been identified as
influencing/controlling a number of physiological mechanisms such as muscle
metabolism, sexual and cognitive functions, kidney function, liver function and bone
metabolism (Cellotti and Cesi, 1992). AS mimic the effects of testosterone and are
primarily used in clinical scenarios to increase protein synthesis in muscle tissue and
therefore lead to an increase in muscle size and strength. The therapeutic use of
testosterone has been shown to have positive effects in patients where muscular
atrophy is a component of the disease, such as AIDS and HIV (Mulligan and
Schambelan, 2002), and has also been shown to have a positive effect on
cardiovascular (CV) disease risk (Ong et aI., 2000).
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Male hormones have long been of interest to individuals looking to improve both
their physical and mental performance. As far back as ancient Greece there are
reports suggesting athletes ate a concoction of substances including animal testes in
order to improve performance (Higgins, 2006). The first modem case report related
to "testosterone" use by the famous physiologist, Charles E. Brown-Sequard. In the
late 19th Century Brown-Sequard claimed that he had extracted a substance from dog
and guinea pig testicles that had increased his strength and improved his intellect
(Basaria et al., 2001). It wasn't until the 1930's, however, that the active anabolic
component that Brown-Sequard had consumed was isolated as testosterone by Adolf
Butenandt in 1936, following identification of testosterone in 1935 by Dingemanse,
Freud and Laquer (Hall, 2005, Freeman et al., 2001). The claims made by Brown-
Sequard were supported by evidence from scientists through the 1940's and in
particular in a book, The Male Hormone, by Paul du Kruif (Basaria et al., 2001).
Whilst AS were developed, and continue, to be used to treat a number of conditions
including depression, impotence and starvation (Dhar et al., 2005), their use outside
clinical treatment regimens has grown substantially. Historically, some
commentators have suggested that soldiers in Nazi Germany, at the 1936 Munich
Olympics, were subjected to systematic doping with AS to enhance their physical
performance and aggression, although this is unsubstantiated (Yesalis et al., 1989).
By the 1950's AS had entered the sporting realm. After dominating the World
Weightlifting Championships in Vienna, 1954, anecdotal reports claim that the then
Soviet team doctor revealed to the US team doctor, a Dr Ziegler, that the Soviet team
had used AS (Fair, 1993). Ziegler returned to the US and promptly began testing the
efficacy of AS on himself and his athletes. Since then the use of AS has remained a
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constant and controversial issue within the world of elite sport highlighted by high
profile cases such as those of Ben Johnson in the 1988 Seoul Olympics and the Bay
Area Laboratory Co-Operative (BALCO) scandal involving a number of athletes
including British sprinter Dwain Chambers. Many sports including cycling, baseball,
American football and combat sports have all experienced problems with AS use but
AS use is, perhaps, most often associated with bodybuilding where a culture of AS
use has become accepted, maybe more so than in any other sport (Yesalis et al.,
2000).
With the increase in media and societal pressures for individuals to improve their
physical appearance and performance in line with certain ideals, it is perhaps
unsurprising that AS use is no longer confined to those within elite sport. In fact, a
large majority of users of AS are recreational exercisers (Yesalis and Bahrke, 2005).
AS users now include; models, security personnel as well as prison and police
officers (Evans-Brown et al., 2008). The effect of AS on muscular growth and repair
in particular has led to its increased use in non-elite sport where performance and
image enhancement can be achieved from supra-physiological doses (Bhasin et al.,
1996, Bahrke and Yesalis, 2004). Indeed, it could even be argued that image
enhancement now supersedes performance enhancement as the ultimate training
outcome for many recreational users.
Despite the apparent increase in AS use, data on prevalence of use is difficult to
obtain and verify (McVeigh et al., 2003). In many countries, including the UK, AS
use falls within a legal grey area where possession is not illegal but supply or intent
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to supply is. This can make users reluctant to admit their use and therefore makes
quantification of the number of users, both nationally and internationally, very
difficult. However, reports from needle and syringe programmes (NEP's) have
indicated a large and continuing growth of AS use within the UK. Some estimates
have shown that the number of AS-injecting individuals attending NEP's has
increased 2000% from 1991-2006 (Evans-Brown et al., 2008). Surveys of gym's
have previously shown that around 5% of members (Korkia et al., 1993) were using
AS whilst the prevalence of use, or previous use, in gyms equipped for competitive
bodybuilding has been shown to be between 25-50% (Korkia and Stimson, 1997). At
a sporting level, 45% of all adverse findings from WADA-accredited laboratories in
2006, tested positive for AS (Kicman, 2008).
1.2 Pharmacokinetics
The mechanism by which AS are thought to exert their effect is important. All AS
exert both anabolic (increased protein synthesis) and androgenic (development of
secondary male sexual characteristics) effects on the body in differing proportions.
This has meant that there is a constant quest by manufacturers, both legal and illegal,
to maximise the anabolic whilst minimising the androgenic components of AS. A
purely anabolic agent has yet to be discovered (Bahrke and Yesalis, 2004). Whilst
AS come in many different forms, they are predominantly taken via either oral
ingestion or intra-muscular injection (transdermal patches/gels have also been used).
Due to the rapid breakdown of testosterone within the body one key development
with respect to AS has been to slow the rate of metabolism. This has been done by
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esterification of the 17 ~- hydroxyl group for intramuscular injection or alkylation at
the 170.position for oral administration.
Figure 1.1. 170. alkylation and 17 ~ esterification of testosterone. (Srinivas-Shankar
and Wu, 2006)
The addition of an ester at the 17 ~-hydroxy position causes an increase in the
hydrophobic/lipophilic properties of the AS that helps to slow down its absorption
and degradation when injected intramuscularly, with the length of the chain
determining the rate of breakdown. An AS that has a decanoate ester, for example,
will have a longer half-life than a phenylpropionate (Minto et aI., 1997), and
testosterone undecanoate has a longer half-life than testosterone enanthate
(Weinbauer et aI., 2003). Whilst there is limited scientific data concerning the active
half-lives of different AS, much of the values given come from anecdotal sources
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(Table 1.1). Those AS that have an ester added at the 17 a-hyrdoxy position are
used for oral ingestion as this minimises metabolism in the liver. It is believed that
this change to the structure of AS, to allow for oral ingestion, has a side effect linked
to hepatic and renal toxicity (Welder et al., 1995b, Applebaum-Bowden et aI., 1987).
Table 1.1. Half-lives of different oral and injectable AS and esters.
Oral Steroids
Drug Active half-life
Dianabol (methandrostenolone, methandienone)
Anavar (oxandrolone)
Anadrol / Anapolan50 (oxymetholone)
Winstrol (stanozolol)
Methyltestosterone
5 to 6 hours
9 hours
8 to 9 hours4
9 hours
4 days
Injectable steroids
Drug Active half-life
Winstrol (stanozolol)
Testosterone Suspension
Finaject (trenbolone acetate)
Testosterone Propionate
Testosterone Enanthate
Primobolan (methenolone enanthate)
Testosterone Cypionate
Equipoise
Deca-durabolin (Nandrolone decanate)
Sustanon or Omnadren
1 day
1 day
3 days
4.5 days
10.5 days
10.5 days
12 days
14 days
15 days
15 to 18 days
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Steroid esters:
Drug Active half-life
Formate 1.5 days
Acetate 3 days
Propionate 4.5 days
Phenylpropionate 4.5 days
Butyrate 6 days
Valerate 7.5 days
Hexanoate 9 days
Caproate 9 days
Isocaproate 9 days
Heptanoate 10.5 days
Enanthate 10.5 days
Octanoate 12 days
Cypionate 12 days
Nonanoate 13.5 days
Decanoate 15 days
Undecanoate 16.5 days
Once inside the body there are a number of different metabolic fates for AS
including reduction to dihydrotestosterone or aromatization to estradiol. In this latter
case they can then exert oestrogenic effects (secondary female sexual characteristics)
on the target cell.
The effects of AS on muscle cells (skeletal or cardiac) is mediated primarily by the
presence of androgen receptors (AR) present within the cytoplasm of cells (Inoue et
al., 1994). AS that are reduced to dihydrotestosterone can still illicit an androgenic or
anabolic effect on the cell via the AR (Kiernan, 2008). Androgen-receptor complexes
8
regulate the transcription of target genes that may control the accumulation of DNA
responsible for muscle growth. AS are relatively small molecules, thereby allowing
them to diffuse into cells and bind with the receptors present in the target cells.
Following activation of the AR, it is translocated into the nucleus and triggers the
formation of a transcription complex. Whilst it was previously thought that AR's
were saturated at physiological levels it is important to note that, despite previous
contradictory findings, AS concentrations have been shown to cause an up-
regulation of AR's (Carson et al., 2002). It is also believed that strength training can
increase the number of AR's (Bamman et al., 200 I) suggesting a possible
complimentary impact of AS use and strength training.
Whilst the direct anabolic effect of AS on skeletal muscle cells has been shown,
additional complimentary anabolic effects have been suggested. AS may also
stimulate the secretion of growth hormone (OH) or insulin-like growth factor (lOF-
1) both of which have documented anabolic effects (Kuhn, 2002). It has also been
postulated that behavioural effects of AS, such as increased aggression and
drive/determination, could influence training intensity thereby indirectly increasing
muscle size and strength (Yates, 2000).
1.3 Current AS Use: Practices and Side Effects
In order to maximise the positive effects of AS use, a number of techniques are
employed by users. Users often combine a series of 2 or more oral and/or injectable
AS preparations in a process referred to as 'stacking'. These combinations, with
9
varying ratios of different AS used at different time points, are administered in
'cycles' which typically last 4-12 weeks (Evans-Brown et al., 2008) although there is
large individual variation with some users continually using for extremely long
periods of time. Doses can vary substantially with anecdotal evidence suggesting
doses ranging between less than 500 mg per week up to 2000 mg per week with
additional anabolic agents also used. Evans (1997) reported doses ranging between
250 mg and 3200 mg per week of testosterone or its equivalent. Following an 'on'
cycle, users will often have a period of abstinence ranging from 2 to 6 weeks,
although, as with 'on' cycle lengths, there is large variation. This period of
abstinence is used to "clear the system" and allow the body to normalise ready for
another period of usage. 'Stacks' and 'cycles' are 'designed' in order to maximise
the effect of each AS on skeletal muscle growth, based on the different
pharmacokinetics and pharmacodynamics that each steroid can exert, despite having
little scientific underpinning (Evans-Brown et al., 2008). In addition to AS, a number
of other drugs are often taking in combination. These drugs include anabolic agents
such as insulin and IGF -1, stimulant and fat loss agents such as ephedrine and
clenbuterol as well as drugs to limit and prevent issues of aromatisation such as
tamoxifen. Further to this, many AS users undertake a post-cycle therapy in order to
help stimulate the natural production of testosterone, using substances such as
tamoxifen and clomid to help stimulate the production of follicle stimulating
hormone and luteinizing hormone to in turn increase production of testosterone from
the testes.
Not surprisingly, given the supraphysiological or supraclinical doses that are used,
case studies and case-series research has indicated a number of negative side effects
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associated with AS use/abuse. Some of the negative side-effects that are associated
with AS abuse include acne, gynaecomastia and testicular atrophy (Evans-Brown et
aI., 2008) and have also been associated with certain psychological disturbances such
as mania, hypomania and depression (Pope Jr and Katz, 1994). The abuse of
anabolic steroids (AS), outside of therapeutic use, has raised significant concerns
about negative CV health consequences (Melchert and Welder, 1995). Despite the
commonly held belief that AS are detrimental to CV health the scientific data
detailing CV disease presence, morbidity, mortality as well as risk are controversial
(Korkia and Stimson, 1997). If AS use has a direct impact on cardiovascular risk it
may then precipitate cardiovascular disease and events (e.g. heart attack).
Alterations in CV risk factors such as lipid profiles (Lane et al., 2006, Hartgens et
aI., 2004). and cardiac events (Bispo et aI., 2009, Santamarina et aI., 2008) have been
reported with AS use but are often contradictory (Hartgens and Kuipers, 2004).
There has been conflicting research regarding the effects of AS on both structural
and functional parameters of the heart. Whilst there has been evidence of increases in
left ventricular mass and wall thicknesses in AS users (Sachtleben et al., 1993,
Kasikcioglu et aI., 2009) there have also been findings that have observed no
differences (Hartgens et aI., 2003, Baggish et aI., 2010). Research concerning
alterations in cardiac function in AS users, and more specifically the relaxation
capabilities of the ventricle, have also had conflicting outcomes (Dickerman et al.,
1998, Kasikcioglu et aI., 2009, Baggish et aI., 2010). Despite this, reductions in the
relaxation capacity of the ventricles in AS users would imply a consistent increased
cardiac workload that may signify an increased CV risk.
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In order to develop our knowledge further, this thesis will focus on the
cardiovascular consequences of AS use/abuse. Specifically, it will first present a
review of previous case study and case series research related to a number of
cardiovascular risk factors. The thesis will then progress to 4 empirical studies
detailing; 1) the effects of AS use on cardiac structure and function using novel,
state-of-the-art regional deformation analysis, 2) the impact of AS use on both left
and right ventricular structure and global function using the gold standard technique
of magnetic resonance imaging (MRI) which will also facilitate the assessment of
perfusion defects or interstitial fibrosis in the hearts of AS users, 3) the impact of AS
use on the dynamic response to resistance exercise either in the form of the
integrated cardiovascular response to a single set of exercise, or 4) the cardiac
functional and biomarker response to a single training session. These latter 2 studies
will move the assessment of the cardiovascular consequences of AS use away from
resting studies to dynamic scenarios where the heart of the AS user will be placed
under greater stress.
Aims
The aims of this Thesis are:
1. To examine the effect of AS upon global and regional cardiac structure and
function using new "state-of-the-art" echocardiographic technologies.
2. To determine the impact of AS use on both left and right ventricular global
structure and function as well as perfusion and fibrosis using the "gold
standard" MRI technique.
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3. To explore the effect of AS use on the integrated cardiovascular response to a
single set of dynamic resistance exercise.
4. To explore the effect of AS use on cardiac function and markers of
cardiomyocyte damage following a full body resistance exercise workout.
13
Chapter 2. Literature Review
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2.1 Introduction
The use and abuse of anabolic steroids (AS) gains popular and media attention when
elite athletes fail "doping" tests. Although significant, in some respects, these cases
underplay the pervasive nature of AS use in Western societies. Whilst official figures
from the British Crime Survey (2008) suggested a decrease in anabolic steroid (AS)
use, reports from needle exchange programmes and other public health initiative's
have pointed towards a growing use of AS in the UK (McVeigh et al., 2003). The
clandestine nature of AS use makes an accurate assessment of the prevalence of use
difficult. Despite this, some studies have attempted to quantify the level of use in
specific groups. Yesalis et al. (2000) found that between 4 and 6% of high school
males and 1-2% of high school females had tried AS. Bahrke and Yesalis (Bahrke
and Yesalis, 2004) remarked that studies from countries including Canada, Sweden,
England, Australia and South Africa suggest 1-3% of high school students had tried
AS at some time. The widespread use of AS has been documented in professionals
working in emergency services, casual fitness enthusiasts, as well as sportsmen and
women from a wide variety of different sports (Korkia and Stimson, 1997).
Although the exact health consequences of AS use are largely undefined, AS use
represents a growing public health concern.
The therapeutic use of testosterone is somewhat controversial with conflicting data,
although some studies have indicated limited positive effects on isolated
cardiovascular (CV) risk factors in CV disease states (Ong et aI., 2000). The use of
AS outside of therapeutic prescription has raised significant concerns about negative
CV health consequences (Melchert and Welder, 1995). Despite the commonly held
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belief that AS are detrimental to CV health, scientific data detailing CV disease
prevalence, morbidity and mortality are limited and controversial (Korkia and
Stimson, 1997).
This review considers the current evidence-base regarding AS use in humans and the
presence of CV disease or elevated risk of developing CV disease. We seek to
present the latest data as well as limitations and future directions for work in this
area. For the purposes of this review, data has been delimited to available human
studies. Whilst much can be learned from animal models (LeGros et al., 2000) and
recent data suggests a direct link between AS use and coronary lesion formation
(Belhani et al., 2009), such studies rarely reflect the reality of human AS use for
performance or image enhancement. Throughout the review we will seek to critique
available evidence, discuss potential mechanism(s) where relevant human and/or
animal data provide insight.
Search Strategies
In order to locate relevant studies for this review, a literature search was performed
through the Liverpool John Moores University electronic library which covers a
number of databases including Sport Discus, Web of Science, Science Direct,
Emerald, Cinahl Plus, PubMed and Academic Search. The search terms used were
'anabolic steroids', 'anabolic androgenic steroids', with additional operators of
'cardiovascular effects', 'cardiac' and 'vascular' with the search period being set
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between 1970-2010. Inclusion of studies was delimited to human and cellular
studies, with animal studies only being used to infer possible mechanisms of action.
2.2 Anabolic Steroid Use and the Presence of cv disease
Assessment of the presence of CV disease in any population can be made In a
number of ways. Epidemiological approaches, which follow large cohorts over
prolonged follow-up periods, assess specific end-points including cardiac-related
death, acute myocardial infarction, cardiac failure and presence of coronary disease
on coronary angiography. Such studies have been performed to assess the impact of
various risk factors on CV disease presentation (e.g. physical [in]activity; (Morris et
al., 1953, Paffenbarger and Hale, 1975)). In many sporting sub-cultures AS use is
banned, partially because of concerns over adverse health effects as well as the fact
that it constitutes "cheating" and a breakdown of the "Olympic-ideal" (Pipe and
Hebert, 2008). These issues would make many users, some of whom are involved in
competitive sport, reluctant to admit their use.
Alternative ways to determine the presence of cardiovascular disease include the
assessment of the presence and nature of any atherosclerotic load or burden within
an individual. Assessments can be made before a significant CV event occurs,
providing another option in the assessment of the effects of AS on CV health. The
National Institute for Clinical Excellence (NICE) guidelines for assessment of chest
pain use an algorithm starting with the assessment of the presence of CV risk factors
(smoking, diabetes, hyperlipidaemia) coupled with sex and age. This is then
followed by non-invasive and invasive testing as required, depending on the
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perceived degree of risk. Of the tools available, invasive coronary angiography
remains the gold-standard for assessment of coronary atherosclerosis. However, the
use of an invasive test in AS users without a history of chest pain, coupled with the
use of radiation, cost and complexity in addition to the semi-invasive nature of
angiography are why this is not routinely performed outside of a clinical setting and
why there appears to be no controlled human trials of AS use using these techniques.
Non-invasive computerised tomography (CT) coronary angiography is an alternative
technique, but again cost, radiation and limited resolution available until recently
has led to its use being limited. Other assessments exist including CT coronary
calcium scores, which indicate the overall atherosclerotic burden without indicating
the degree of stenosis in the coronary arteries, but again we are unaware of any such
data in AS users. This would be a useful technique given the rapid acquisition time,
but also requires low dose radiation. Another option is the assessment of the carotid
artery intima-media thickness (cIMT), which measures the width or depth of the wall
of a conduit artery, most often the carotid artery. The sub-intimal space is where
plaque formation typically occurs in arterial disease and assessment of cIMT is
easily and accurately performed using ultrasound technology which thus provides a
non-invasive assessment of atherosclerotic burden (Salonen and Salonen, 1993).
Despite being assessed in a peripheral artery, the measurement of cIMT has been
shown to reflect atherosclerotic burden in the coronary arteries (Bots et al., 2002).
Sader et al. (2001) reported no difference in the cIMT of AS using and non-AS using
subjects, despite a greater cIMT observed in both bodybuilding groups compared to
the sedentary control cohort.
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The only substantial and growing database related to the association between AS use
and the presence of CV disease is provided by case study reports (Hartgens and
Kuipers, 2004) (see Table 2.1). Case studies can present CV events or disease end-
points (e.g. sudden cardiac death, acute myocardial infarction etc.) as well as autopsy
data that directly determine atherosclerotic burden. The developing list of case
studies provides evidence of the possible significant, and maybe fatal, association
between AS and CV disease (Lau et al., 2007, Murai et al.). Although not completely
exhaustive, Table 2.1 documents the occurrence of a number of significant CV
disease end-points, such as strokes, myocardial infarctions and thrombo-embolism.
Often these events are fatal, and even if not, can lead to significant disability and
functional impairment. The physical, psychological and sociological ramifications
are likely significant in those who survive an initial "event".
Few common themes emerge from consideration of the case studies presented in
Table 2.1. A broad spectrum of specific events is observed in a range of individuals.
A noticeable pattern of disease presence and/or risk is hard to deduce. It is also
difficult to be sure of accurate reporting of a broad spectrum of physiological or
behavioural risk factors for CV disease for each subject.
Whilst case studies provide a useful initial insight into the effects of AS that may
help drive case-series or case-control studies, they are by no means conclusive and
cannot be considered strong evidence of causal relationships. Case studies are also
reliant on self-reporting of substance use, which can often be unreliable, with a lack
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of independent confirmation of what the person believes they are taking, as well as
ignoring the co-abuse of other substances.
Table 2.1 Case study events in AS users and reported presence of risk factors.
Event Case Studies [CV Disease Risk Factors Present]
Stroke FrankIe et at. (1988) [ + HDL, t Liver enzymes], Mochizuki et at. (1988),
Kennedy et at. .( 1993), Sahraian et al. (2004), Santamarina et at. (2008) [ t
Apo B].
Myocardial
Infarction
McNutt et al. (1988) [jLDL, ~HDL], Bowman (1990) [jTC, ~HDLj,
Ferenchick and Adelman (1992) [Family History], Kennedy (1993) [jTC,
~HDL, Smoker], Appleby et al. (1994) [Smoker, jBP], Huie (1994) [Family
History, j ALT, lASP, jCK], Fisher et al. (1996), Goldstein et at. (1998),
Fineschi et at. (2001), Gunes et al. (2004) UHDLj, Angelilli et al. (2005)
[jTrig, history of hypertension], Wysozcanski et al. (2008) [jBP, jCK, ~HDL],
Lunghetti et al. (Lunghetti et al., 2009).
Sudden Death Luke et al. (1990), Campbell et al. (1993), Hausmann et al. (Hausmann et al.,
1998), Madea and Grellner (1998) [jBP, jTC & LDL, ~HDL jTrigj, Fineschi
et al. (2007) Laroche (1990) [Smoker], Gaede & Montine (1992), Jaillard et at.
(1994), Mewis et at. (1996) [ t LDL], N ieminen et at. (1996) (Patient 4), Palfi
et at. (1997), Falkenberg et al. (1997) [Patient 2: Smoker], Hourigan et al.
(1998), McCarthy et al. (2000), Ment & Ludman (2002) [Smoker, t TC],
A1hadad et al. (20 10) [Protein C deficiency], Liljeqvist et at. (2008), Frogel et
at. (2009).
Cardiac
Hypertrophy
Nieminen et al. (1996) (Patient 2), Mark et al. (2005)
Cardiomyopathy Ahlgrim & Guglin (2009), Bispo et at. (2009) [ t ALT & AST].
Endocarditis Nierninen et al. (1996), [Patient 1: + HDL], Fineschi et al. (2007) (Patients I &
2), Frogel et al. (2009).
Atrial Fibrillation Sullivan et al. (1999) [Tachycardia, t CK].
Heart Failure Clark & Schofield (2005) [Sinus tachycardia, tALT, AST]
Subdural
Haematoma
Alaraj et al. (2005), Alhadad et al. (2010) [Protein C deficiency].
BP= Blood Pressure, TC= Total Cholesterol, LDL= Low-density lipoprotein, HDL= High-density
lipoprotein, Trig= Triglycerides, CK= Creatine Kinase, ALT= Alanine Transaminase AST= Aspartate
Transaminase, Apo B= Apolipoprotein B. Case Studies where no cause of death is reported or
ascertained are grouped under 'sudden death' whereas those case studies where death is attributed to a
myocardial infarction are grouped accordingly.
20
2.3 Anabolic Steroid Use and Cardiovascular Disease Risk Factors
Independent risk factors for CV disease include hypertension, hyperlipidemia,
diabetes, obesity and a family history of premature coronary disease. High levels of
homocysteine and high sensitivity C-reactive protein [hsCRP] have also been used as
surrogate markers for the development of CV disease (Ridker et al., 2002). In the
absence of data from epidemiological or coronary imaging studies assessing CV
disease presence or prevalence in AS users, studies have assessed the prevalence of
known risk factors, with or without comparison to matched controls. The link
between each of these factors and the development/progression of atherosclerosis,
combined with case reports of the presence of risk factors in AS users who have had
significant CV events (see Table 2.1), has prompted their assessment as a potential
measure of future CV disease risk. Not surprisingly these data are somewhat
contradictory and thus inconclusive (see Table 2.2).
Hypertension has been identified as an important CV disease risk factor (Dawber et
al., 1957). Freed et al. (1975) and Riebe et al. (1992) reported significantly higher
systolic blood pressure in bodybuilders using AS compared to non-AS using
bodybuilding controls. Conversely, Sader et al. (2001) and Lane et al. (2006)
reported no elevation of blood pressures in AS users. The disparity between studies
may reflect significant variance in the inclusion of smokers and the lack of control of
diet across the groups. Of interest is that only Riebe et al. (1992) assessed blood
pressure during exercise and this was elevated in AS users. The importance of an
exaggerated blood pressure response to exercise for CV risk has been postulated
(Chaney and Eyman, 1988) but not fully assessed in AS users. Another factor
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associated with elevated arterial blood pressure is aortic stiffness (lowered aortic
compliance). Stiffer arteries tend to augment pulse-pressure and alter SBP and/or
DBP. Interestingly, large artery stiffness may be increased with resistance training
(Kawano et al., 2008). The impact of AS use on central or large artery stiffness has
received some attention recently. For example Kasikcioglu et al. (2007) found that
AS use could be associated with a reduction in aortic elastic properties (increased
stiffness), which could directly increase risk of a CV event. The authors suggested
that AS directly affect nitric oxide-mediated relaxation through the inhibition of
guanylate cyclase, a second messenger that carries the signal for smooth muscle to
relax.
Elevated total cholesterol (TC) and low-density lipoproteins (LDL) and low high-
density lipoproteins (HDL) cholesterol have been shown to increase CV risk
(Robinson et al., 2009). Studies of TC, LDL and HDL levels in AS users have
produced contradictory outcomes. Although most studies report little difference in
'I'C, most demonstrate a decrease in HDL with some observing an increase in LDL
(Hartgens et al., 2004, Lane et al., 2006, Sader et al., 2001). Lane et al. (2006),
observed little difference in total cholesterol levels between AS users, (4, 0 ± O·83
mmol/l), and non-users, (3'8 ± 0·38 mmol/l), whilst LDL (2'9 ± 0·7 vs. 2·1 ± 0·3
mmolll), was significantly elevated and HDL (0' 7 ± O'4 vs 1·3 ± O'3 mmolll)
significantly decreased in the AS group. A rise in LDL cholesterol often leads to
increased arterial fat deposition and this change in lipoprotein profile is therefore
associated with an increased atherosclerotic risk (Robinson et al., 2009).
Apolipoprotein, a component of HDL cholesterol, has also been studied in AS users.
Studies, by Hartgens et al. (2004) and Hartgens & Kuipers (2004) reported
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conflicting data, possibly due to issues of drug dosage and comparisons of single to
poly-drug regimens. Whilst the exact mechanisms for the effect of AS on lipid
profiles is yet to be fully established, some mechanisms have been postulated.
Applebaum-Bowden et al. (1987) suggested that after administration of stanozolol
for 7 days there was a decrease in HDL levels with a concomitant increase in hepatic
triglyceride lipase (HTGL). HTGL is partly responsible for the production of LDL
but these results would also suggest a possible catabolic effect of HTGL on HDL,
thereby leading to negatively affected lipid profiles.
High sensitivity C-reactive protein (hsCRP) is a marker of inflammation and has
been associated with CV events including myocardial infarctions and stroke (Ridker
et al., 2002). Measurement of hsCRP is not routinely performed by doctors in the
evaluation of CV risk in the general population. As such, limited attention has been
paid to hsCRP in AS users. Grace and Davies (2004) reported that hsCRP was
elevated in AS-using bodybuilders compared to both non AS-using bodybuilders and
sedentary controls. Although the mechanism(s) for this observation is not known,
and such findings require replication, the data highlights the possibility that AS use
could result in local or systemic inflammation that has the potential to damage
cardiomyocytes and/or the vascular endothelium.
Elevated levels of the amino acid homocysteine (HCY) have also been associated
with increased CV disease risk (Boushey et al., 1995) as a consequence of
endothelial damage (McCully, 2005). As with many CV disease risk factors, the data
regarding HCY and AS use are conflicting. Zmuda et al. (1997) reported no change
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in HCY in AS users whereas Graham et al. (2006) observed high HCY levels even in
those subjects who had abstained from AS use for 3 months. The disparity in
outcomes is difficult to explain but maybe related to subject-specific issues such as
diet. A possible explanation for an increase in HCY in AS users is that the AS could
affect the absorption of certain B vitamins (in particular B6 and BI2), a deficiency
that can lead to an increase in HCY levels. Other medical conditions which cause
elevated haemoglobin levels (polycythaemia) are associated with increased CV risk
and this therefore may be an additional cause in AS users.
Finally, Alen (Alen, 1985) and Lane et al. (Lane et aI., 2006) reported significantly
elevated haematocrit (Hct)/haemoglobin (Hb) levels in AS users. In addition, Lane
et al. (Lane et aI., 2006) observed Hb levels were not different to controls after a 3
month abstinence from AS. In contrast, Hartgens et al. (Hartgens et al., 1995)
reported that Het and Hb remained unaffected.
In summary, whilst it has become quite apparent that AS use can have a significantly
negative effect on HDL levels (Applebaum-Bowden et aI., 1987, Hartgens et aI.,
2004, Lane et aI., 2006), and therefore increase CV risk (Robinson et aI., 2009),
much of the research that has assessed the association of AS use with alterations in
CV disease risk factors is limited, contradictory and may be multifactorial. It is ,
therefore, worthwhile reflecting on case study data in Table 2.1 where there are no
clear patterns of measurable CV disease risk in cases with "hard" CV event end-
points. Scope for on-going work reflecting long-term poly-drug users with attention
paid to variations with cycle-phase is apparent. Further, when available data for CV
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disease risk factors in AS users is combined with case study reports, one could
surmise that factors additional to traditional CV disease risk factors may be
responsible for any association between AS use and CV disease occurrence. It is for
this reason that other research groups have assessed the link between AS use and
cardiac electrical, structural and functional parameters as well as any impact of AS
use on vascular health.
Table 2.2 Anabolic Steroids and associated risk factors.
Risk Factor Studies Subjects In) Findings
Blood Pressure Freed et al. (1975) ASU vs P ASU t SBP*
[n=13]
Kuipers et al. (1991) ASU vs P ASU JDBP*
[n=14]
Riebe et al. (1992) ASU vs BC ASU j SBP* @ rest
[ASU=10, BC=10] and exercise
ASU j DBP* during
exercise.
Sader et al. (2001) ASU vs BC No significant
[ASU=10, BC=10] difference between
groups.
Lane et al. (2006) ASU vs BC No sig. Difference.
[ASU=10,Off-AS=8,
BC=10]
Cholesterol Baldo-Enzi et al. ASU vsBC& ASU FC**
( 1990) AS On vs Off ASU !HDL***
treatment. On !HDL***
[ASU=!4, On/Off
AS=lO, BC=!7]
Zmuda et al. (1993) T vs TL vs T & TL T l HDL*
(3 weeks T & TL lHDL*
administration) No significant change
in LDL in all groups
Sader et al. (2001) ASU vs BC. TC No sig. Difference
[ASU=!O, BC=10] ASU !HDL ***
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Hartgens et al. (2004) ASU vs BC
[ASU=19, BC=16] TC No sig. Difference
ASU jLDL*
ASU lHDL*
Lane et al. (2006) ASU vs ASA vs BC vs
SC TC No sig. Difference
[ASU=10,Off-AS=8, ASU jLDL*
BC=IO] ASU lHDL***
C-Reactive Protein Grace & Davies ASU vs BC vs Se. ASU t CRP * vs BC
(CRP) (2004) [ASU=IO, BC=IO, &SC
SC=8]
Homocysteine (HCY) Zmuda et al. (1997) T vs TL vs T & TL No change in all
(3 weeks groups
administration)
[n=14]
Graham et al.
(Graham et al., 2006) ASU vs ASA vs BC & ASU** & ASA*
Se. JHCY vs BC & Se.
[ASU=lO, ASA=IO,
BC=10, SC=IO]
Apolipoproteins Hartgens et al.
(APO) (Hartgens et al., 2004)
Study 1. ASU vs BC ASU 1 APO (A-l &
[ASU=19, BC=16] B) ***.
No significant
Study 2. AS (200mg/week of difference between
Nandrolone Decanoate) groups.
vs P
[n=16]
Haemoglobin (Db) Alen (Alen, 1985) ASU vs BC Tendency for Hb to be
[ASU=5, BC=6] higher in ASU group.
SBP= systolic blood pressure, DBP= diastolic blood pressure, TC= total cholesterol, HDL=High-
density lipoprotein, LDL= Low-density lipoprotein, T=Testosterone, TL= Testolactone, BC=
bodybuilding controls, SC= sedentary controls, ASU= anabolic steroid users, ASA= abstinent from
steroids for 3 months, P = placebo. * p<O.05, **p<O.Ol. *** p<O.OOI
2.4 Anabolic Steroid Use and Cardiac Electrical Activity, Structure and
Function
The assessment of cardiac electrical activity, structure and function are commonly
used in the determination of the presence or risk of CV disease. An example is the
association of increasing left ventricular (LV) mass and prognostic CV disease
relevance (Savage et al., 1990, Yeboah et al., 2007).
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2.4.1 Cardiac Electrical Activity
Case reports have shown a possible effect of AS use on cardiac electrical activity
with some finding an association between AS use and atrial fibrillation and cardiac
failure precipitated by sinus tachycardia (Sullivan et al., 1999, Clark and Schofield,
2005). Human (and animal) studies have shown an association between testosterone
and an increase in the rate of cardiac repolarisation (Bidoggia et al., 2000, Fulop et
al., 2006). Consequently the potential for AS use to alter cardiac electrical activity
would seem a valuable line of enquiry. However, there is limited research on the
effect of AS abuse on cardiac de/repolarisation or any other aspect of the ECG in
humans. Whilst previous findings have suggested prolonged QT interval may be
present in some athletes as a result of training (Stolt et al., 1999), one study has
suggested that AS use may be associated with a shortening of the QT interval (Bigi
and Aslani, 2009). It has been suggested that the androgenic component of AS
impacts on cardiac electrical activity via facilitation of the expression of two
potassium channel proteins, Kir2.1 and Kir4.3, which are responsible for mediation
of hI and Ito respectively (Fulop et al., 2006). The relevance of the effect on Ikl
becomes clear as it has been cited as an important current involved in ventricular
repolarisation which may cause the shortening of the QT interval (Liu et al., 2003).
To further understand the role that AS may have on cardiac electrical activity, as
well as the mechanism through which they act, it is clear more research is necessary.
A number of measures of cardiac structure and function have been investigated in
order to ascertain the effects of AS use on the heart (Tables 2.3-2.5). However, it is
clear that the deployment of novel non-invasive imaging techniques in the study of
AS users is limited to only a few recent studies. New imaging tools provide both
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global and regional assessments of cardiac structure and function (Langeland et al.,
2005) that may provide extra insight in regard to the impact of AS upon myocardial
tissue.
2.4.2 Cardiac Structure
A number of morphological adaptations of the heart have been observed in AS users.
In a group of top-level bodybuilders, Urhausen et al. (1989) reported AS users had
an increased LV posterior and septal wall thickness compared to a group of non-
using bodybuilders. This resulted in an increased LV wall thickness:diameter ratio as
well as an increased LV muscle mass:volume ratio. These findings were supported
by Sachtleben et al. (1993) who noted AS users had greater LV mass, inter-
ventricular septal wall thicknesses and LV diameter in diastole compared to non-AS
using bodybuilding controls. It was also observed that when the users were "on"
cycle they had a greater LV mass, septal wall thickness, and LV diameter compared
to when "off' cycle. Some other studies have reported differences in cardiac
structure between AS using and non-AS using athletes (D'Andrea et al., 2007,
Dickerman et al., 1998). Both D'Andrea et al. (2007) and Dickerman et al. (1998)
reported cardiac dimensions in AS users that were either greater than sedentary
controls or outside of normal ranges, despite no significant difference to non-AS
using athletes. These studies would suggest that training may be as potent a stimulus
for cardiac adaptation as AS use. At odds with most previous literature, Nottin et al.
(2006) observed no differences in LV wall thickness but significantly greater LV
cavity size and mass in AS using body-builders compared to non-using athletes. This
supports an eccentric as opposed to a concentric LV remodelling in AS users. The
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reason for this contradiction is unclear, however significant differences in training
between groups could offer an explanation.
Marsh, et al. (Marsh et al., 1998) observed AS can directly alter cardiac muscle
protein metabolism, following activation of cell surface androgen receptors, through
possible modulation of gene transcription in animal and human cardiac tissue. This
theory offers an explanation for how AS use could cause structural and functional
changes to the cardiac tissue of regular AS users.
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Table 2.3. Studies showing effects of anabolic steroids on cardiac structure.
Study Findings
Urhausen et al.
(1989)
Subjects [nJ
ASU vs BC
[ASU=14,
BC=7]
Parameters Measured
Total Heart Vol., LVM,
LVDd, LVPW, IVS,
LVWT:D, LVM:LVV.
Total Heart Vol. & LVM: No
difference
LVDd:
ASU! ** vs BC
LVPW, IVS, LVWT:D &
LVM:LVV:
ASUj** vs BC
Sachtleben et al.
( 1993)
ASU (On&
Off Cycle) vs
BC
[ASU=11,
BC=13]
LVM, LV and IVS wall
thicknesses, LVD(s&d)
LVM and IVS thickness:
ASU (On)j* vs ASU (Off)
LVM, IVS & LV posterior
wall thickness:
ASU (ON)j* vs BC
Dickerman et al.
(1998)
ASU vs BC
[ASU=6,
BC=7]
LV wall thickness, LV wall thickness:
6/6 ASU >llmm
317 BC > Ilmm
Hartgens et al.
(2003)
No significant differences
observed.
ASU vs BC
[ASU=17,
BC=15]
LVEDd, LVM, LVMI, IVS,
RVD, PWEDWT, LVET.
Nottin et al.
(2006)
ASUvs BC vs
SC
[ASU=6,
BC=9,
SC=16]
LVD(s&d), LVM,
LVV(s&d), LV wall
thicknesses.
LVM& LVDd:
ASUj* vs BC & SC
LVV(s&d):
ASUj** vs SC
LV wall thicknesses:
No sig. difference between
group
D'Andrea et
al.(2007)
ASU vs BC vs
SC
[ASU=20,
BC=25,
SC=25]
LVM, LVDd LVM&LVDd:
No sig. difference between
groups
Kasikcioglu et
al. (2009)
ASU vs BC
[ASU=12,
BC=14]
LV and RV. LVM:
ASUj* vs BC
RVD:
ASU!* vs BC
Baggish et al.
(2010)
ASUvs BC
[ASU=12,
BC=7]
IVS, LVPWd, LVIDd, LVM No significant differences
observed.
ASU= Anabolic steroid user, BC=Bodybuilding control, SC= Sedentary control, LV=Left ventricle,
RV=Right ventricle, IVS=Inter-ventricular septum, LVM=Left ventricular mass, LVD=Left
ventricular diameter, PWEDWT= Posterior wall end diastolic wall thickness
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2.4.3 Systolic Function
Whilst gross changes in cardiac structure provide one focus for studies of AS use, it
is also pertinent to assess if AS use has any impact upon LV function. Both LV
systolic (Table 2.4) and diastolic (Table 2.5) function have been assessed in AS users
and controls in cross-sectional studies. Earlier studies, such as those by Nottin et al.
(2006) and Hartgens et al. (2003) observed no difference in ejection fraction (EF)
between strength trained athletes who did and did not use AS. The assessment of
global LV systolic function may mask subtle or regional changes in function.
Consequently, most recent research has adopted new imaging tools that can assess
tissue velocities or strain in localised segments of LV wall tissue. Nottin et al. (2006)
observed no significant differences between AS users and non-users in peak systolic
myocardial veolicty at the mitral annulus (Sm) in the left ventricular posterior wall
(LVPW), inter-ventricular septum (IVS), inferior wall or anterior wall despite
slightly elevated values seen in the AS group. D'Andrea et al. (2007) found reduced
peak strain and strain rates at both the mid and basal levels in the LVPW and IVS in
AS users versus non-AS users and a control group of sedentary men. Kasikcioglu et
al. (2009) measured the LV septal and RV free wall Sm in AS users, bodybuilding
controls and sedentary controls. No difference was observed in Sm between the two
bodybuilding groups and sedentary controls in either the LV or RV. Conversely, in a
recent study Baggish et al. (20 I0) observed a reduced EF in an AS group compared
to non-AS users, that was also clinically relevant in many individuals (i.e. <55%).
They also reported significantly reduced longitudinal and radial strain in AS users
when compared to non-AS users. The reason for the contradictions in the research
mentioned previous is not entirely clear. Baggish et al. (2010) has suggested that
participant differences between studies, such as older AS users as well as the lower
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level of competitive individuals used in their study, could have been the cause of the
differences observed. This is because possible reductions in cardiac function with
age in addition to previous studies using high level competitors which could have
favoured 'healthier' AS users. A reduction in ejection fraction could possibly be
caused by a reduction in myocardial elastance. As LeGros et a1. (2000) have
suggested, an increase in collagen cross-links within the myocardium through up-
regulation of lysyl oxidase, an enzyme responsible for initiating cross-links between
adjacent collagen molecules. Further in vitro studies of the direct mechanistic
pathway that may be responsible for this change are required to develop our
understanding of the direct effects of AS on myocardial cells.
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Table 2.4. Studies showing effects of anabolic steroids on systolic cardiac function.
Study Subjects Parameters Measured Findings
Hartgens et al.
(2003)
No significant differences
observed.
ASU vs BC EF
[ASU=17,
BC=1S]
Nottin et al.
(2006)
No significant difference
observed.
ASU vs BC vs Sm
SC
[ASU=6, BC=9,
SC=16]
0'Andrea et al.
(2007)
ASU vs BC vs E and SR @ LV lateral
SC wall and IVS, Srn
[ASU=20,
BC=2S, SC=2S]
Srn:
No significant differences
observed.
Peak systolic LV strain rate
and strain:
IVS:
ASUt *** vs BC & SC
LV lateral wall:
ASUt ** vs BC & SC
Kasikcioglu et al.
(2009)
ASU vs BC vs
SC
LV and RV. LV:
Srn:
No significant differences
observed.
RV:
Srn:
No significant differences
observed.
[ASU=12,
BC=14]
Baggish et al.
(2010) Radial E
ASU vsBC
[ASU=12,
BC=7]
EF, Longitudinal E, EF:
ASUt * vs BC
Longitudinal E:
ASUl * vs BC
Radial E:
ASUl * vs BC
.ASU= Anabolic steroid user, BC=Bodybuilding control, SC= Sedentary control, LV=Left ventricle,
RV=Right ventricle, IVS=Inter-ventricular septum, LVM=Left ventricular mass, LVD=Left
ventricular diameter, PWEDWT= Posterior wall end diastolic wall thickness, EF=Ejection Fraction,
E=peak strain, SR=Peak Strain Rate. *p<0.05, **p<O.Ol, ***p<O.OOI
2.4.4 Diastolic Function
There has, to some extent, been greater attention paid to whether AS use might alter
LV diastolic function, possibly because of a potential link to AS-induced concentric
hypertrophy. Dickerman et al. (1998) did not observe any differences in Doppler-
derived early (E) and late (A) diastolic filling velocities as well as the E:A ratio in
bodybuilders who did or did not use AS. Krieg et al. (Krieg et al., 2007) found no
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significant difference in E:A ratios of AS using and non-using strength trained
athletes, although they did find a significant reduction in early to late diastolic tissue
velocities (Em/Am) in the AS group. Nottin et al. (2006) reported a greater
isovolumic relaxation time and a smaller peak early diastolic (E) filling velocity in
AS users, showing a reduced contribution of early relaxation to LV filling. This
observation was supported by Baggish et al. (2010) who also commented that the
lower E:A ratio in AS users was clinically significant in 10 out of the 12 athletes
assessed. Nottin et al. (2006) also recorded tissue Doppler measurements of early
(Em) and late diastolic (Am) myocardial wall velocities at the mitral annulus (in
septal, lateral, inferior and anterior wall segments) as an adjunct to diastolic filling
blood flow velocities. In the AS using bodybuilders peak Em and the peak Em/Am
ratio were significantly smaller than the bodybuilding and sedentary controls.
D' Andrea et al. (2007) and Kasikcioglu et al. (2009) also reported significantly
lower Em:Am ratios in AS using bodybuilders compared to non-AS using
bodybuilders and sedentary controls. A recent study by Baggish et al. (2010) also
found a significantly lower Em in the AS users but interestingly didn't report strain
rate measurements in diastole.
A reduction in early diastolic filling parameters (whether assessed regionally or
globally) suggests AS use has a negative effect on early relaxation and thus the
suction that is exerted on LV inflow by the rapid decline in LV pressure compared to
left atrial pressure. A reduction in early relaxation in AS users could be explained by
a reduction in myocardial elastance (LeGros et aI., 2000) reflecting a stiffer LV.
Despite evidence of a direct effect of AS use on cardiac structure and function being,
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at times, contradictory, some effort has been directed to try and ascertain potential
mechanism(s) using animal models. The androgenic component of AS has received
some attention with research showing that AS can affect extracellular calcium
channels as well as calcium mobilisation from the endoplasmic reticulum (Lieberherr
and Grosse, 1994). It has been suggested that this effect on calcium channels can, in
tum, affect mitochondrial permeability which may allow the release of apoptogenic
factors. This is supported by the findings of Zaugg et al. (2001) that found dose-
dependent apoptotic cell death in rat myocytes.
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Table 2.S Studies showing effects of anabolic steroids on diastolic cardiac function.
Study FindingsSubjects Parameters Measured
Dickerman et al.
(1998)
ASU vs BC
[ASU=8,
BC=8]
E, A, E:A ratio No significant differences
observed.
Hartgens et al.
(2003)
No significant differences
observed.
ASU vs BC
[ASU=17,
BC=15]
E, A, E:A ratio
Nottin et al. (2006) ASU vs BC vs
SC
[ASU=6,
BC=9, SC=16]
Em:
ASU~ ......vs BC & SC
Am:
No significant difference
observed.
Em: Am:
ASUt vs BC"'· vs SC·
0'Andrea et al.
(2007)
Em: Am ratio:
ASU~·· vs BC & SC
ASU vs BC vs
SC
[ASU=20,
BC=25,
SC=25]
Em:Amratio, strain rate
and strain @ LV lateral
wall and IVS, Srn
Krieg et al. (2007) ASU vs BC vs
SC
[ASU=14,
BC=ll,
SC=15]
Em: Am ratio:
ASU~ vs BC & SC
E:A:
No significant differences
observed.
Kasikcioglu et al.
(2009)
ASU vsBC vs
SC
[ASU=12,
BC=14]
LV and RV. LV:
E:A, Em, Am, & Em:Am:
ASU~· vs BC
RV:
Em:
ASU~'" vs BC
Baggish et al.
(2010)
ASU vs BC
[ASU=12,
BC=7]
E, A, E:A, E', A' E, E:A& E':
ASU~ vs BC
A:
ASUf· vs BC
A':
No significant differences
observed.
ASU= Anabolic steroid user, BC=Bodybuilding control, SC= Sedentary control, E=Early diastolic
filling velocities, A=Atrial diastolic filling velocities, E:A=Early:Atrial filling ratio, E'=Early
diastolic tissue velocity, A'=Atrial diastolic tissue velocity.
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2.5 Anabolic Steroids and Vascular Health
Limited positive effects of therapeutic doses of testosterone on vascular function
have been described (Ong et al., 2000). The impact upon vascular health of AS use at
higher concentrations has received less attention. This is somewhat surprising given
the potential negative CV consequences of AS use reported in the literature (Grace
and Davies, 2004, Hartgens and Kuipers, 2004, Baldo-Enzi et aI., 1990, Appleby et
al., 1994, Baggish et al., 2010). The progression from endothelial dysfunction to
significant clinical atherosclerosis in coronary arteries is important in underpinning
and predicting CV events.
The assessment of peripheral conduit arteries, using a number of techniques,
facilitates the assessment of the CV risk and atherosclerotic burden of the circulatory
system (Takase et al., 1998, Takase et al., 2005). As atherosclerosis is a progressive
disease in which endothelial dysfunction is an early and integral feature, assessment
of the function of endothelium may provide an "early-window" on the negative
effects of AS use. In a case study by Green et al. (1993), an individual taking part in
a study assessing forearm blood flow in response to methacholine (MCh) and
sodium nitroprusside (SNP), potent NO-mediated vasodilators, had values that were
dramatically decreased on the second testing session. The investigators ascertained
that the participant had been self-administering AS for four months. He agreed to
abstain from AS before the final testing session. Values had returned to the level of
the first testing session following the period of abstinence. This suggests that AS
have an acute effect on the NO dilator system that is somewhat reversible following
a short period of abstinence.
37
Flow-mediated dilation (FMD) is a non-invasive method used to assess conduit
artery function and abnormal FMD values can predict future CV event rates (Gokce
et aI., 2003). Ebenbichler et al. (2001) and Sader et al. (2001) reported that FMD and
glyceryl trinitrate (GTN)-induced vasodilation of the brachial artery were reduced in
AS users compared to healthy sedentary controls, indicating that some effect of AS
on vascular smooth muscle function may be evident. In support of this contention,
Lane et al. (2006) reported that endothelial-independent dilatation was impaired in
those currently using AS, compared to those who had abstained from AS use for 3
months and a group of bodybuilding controls. Interestingly, Sader et al. (2001)
reported a similar reduction in FMD in both AS-using and non-AS using
bodybuilders, suggesting that prolonged and intense resistance training alone may be
responsible for negative impacts on vascular health. This conclusion is endorsed by
studies of the effect of resistance training on vascular function in otherwise healthy
subjects (Miyachi et aI., 2004, Rakobowchuk et aI., 2005). Whilst not investigating
the effects of AS use in strength-trained athletes, McCredie et al. (1998), examined
the effect of testosterone implants on vascular reactivity in a group of female-to-male
transsexuals against a group of female controls. They found that GTN values were
significantly reduced in the transsexual group, whilst there was a mean difference of
1.8% in FMD scores between groups with the transsexual group having a lower
mean FMD score. Whilst the authors did state that the high number of smokers
within both groups is a likely confounding factor, the results imply a reduced
relaxation capability within the vasculature due to high androgen exposure.
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A number of mechanisms for an AS mediated reduction in vascular function as a
consequence of AS use have been proposed. These include suggestions that AS may
have a direct, negative effect on the NO dilator system. Kasikcioglu et al. (2007)
proposed that down-regulation of the nitric-oxide dilator system could underpin an
AS-related increase in arterial stiffness and reduction in FMD. AS use has been
shown to have a negative effect on endothelial growth (D'Ascenzo et al., 2007). It is
also possible that AS have a detrimental effect of endothelial cell turnover and
renewal, implying that AS could cause stiffening within the heart and vasculature
through affecting endothelial proliferation and propagation. However, no direct
studies of endothelial progenitor cells currently exist. In addition, it has also been
suggested that AS not only attenuate the effect of vasodilators, demonstrated in
rabbits, but also enhance the effects of vasoconstrictors (Ammar et al., 2004).
McCrohon et al. (1999) investigated the effect of AS on monocyte adhesion to
endothelial cell in vitro and they found that androgens caused a dose-related increase
in monocyte adhesion to endothelial cells. This increase in cell adhesion was
mediated by an up-regulation in vascular cell adhesion molecule-l (VCAM-l).
Whilst this study was performed in vitro, it does give an indication of another
possible mechanism through which AS might negatively impact atherosclerotic risk.
The effects of AS use on vascular health is inconclusive, yet significant negative
effects of AS on endothelial and vascular smooth muscle function have been
demonstrated (Sader et al., 2001, Ebenbichler et al., 2001). Whilst resistance training
alone could cause a reduction in endothelial function, AS could further confound this
effect by significantly impairing vascular smooth muscle relaxation (Sader et al.,
2001). Despite conflicting evidence with regards to the effect of endothelial
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dependent relaxation as a result of AS, it is noteworthy to show that a mechanism for
endothelial vascular relaxation impairment has been demonstrated that could help to
explain the propensity of CV events in AS users. Although this was demonstrated
using very large relative doses (D'Ascenzo et al., 2007).
Summary
The current data regarding the effects of AS use/abuse on CV health is largely
contradictory and inconclusive. Whilst causal relationships for negative CV effects
have been suggested from case-study data, cross-sectional studies have been less
definitive and there is an absence of longitudinal studies detailing effects within
individuals. To date the most consistent data reflects a significant negative effect of
AS use on lipid profiles and in particular a reduction in HDL levels (Lane et aI.,
2006, Baldo-Enzi et al., 1990). A common theme appearing in recent data is the
suggestion that a decrease occurs in the relaxation properties of both the myocardium
and the vascular wall. An increased stiffness within the ventricles of the heart and
vasculature could mean a reduced ability of AS users to cope with physiological
stressors.
Despite this, the data reviewed, mainly in the form of a burgeoning body of case
study reports of CV events and disease end-points, raises significant concerns about
the CV health consequences of AS use. This may be particularly relevant in specific
individuals, but predicting those at greater risk among the AS using community is
beyond our capacity at present. Current evidence, allied to an appreciation of many
technical and design limitations when studying AS use, should prompt on-going
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research into numerous aspects of CV health, risk factors as well as CV structure and
function in those who choose to use AS for promoting performance and/or image
enhancement.
As has been demonstrated through this literature review, it is apparent that there are
significant gaps in the literature that require greater investigation. Despite research
into cardiac structure and function, including the use of novel techniques such as
strain and strain rate, there is a lack of diastolic data using this technique. Further to
this, whilst cardiac magnetic resonance imaging provides the most comprehensive
non-invasive assessment of cardiac structure and function, this technique has yet to
be utilised in a group of AS users. Finally, the effects of exercise on cardiovascular
function can provide a useful insight into the ability of the CV system to adapt to
physiological stress. Due to the lack of data in AS users that utilise these techniques,
this thesis will employ assessment of diastolic function using speckle-tracking, strain
and strain rate, as well assessing CV function using cardiac MRI in addition to
assessing the CV response during and after exercise in AS users.
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Chapter 3. Anabolic steroid use and longitudinal, radial and
circumferential cardiac motion
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3.1 Introduction
Anabolic steroids (AS) are synthetic derivatives of the male hormone testosterone. It
has long been established that AS increase skeletal muscular size and strength
through an up-regulation of protein synthesis. These effects have led to the
increasing trend of AS use for both performance and image enhancement (Bahrke
and Yesalis, 2004). The exact number of current AS users in the UK and worldwide
is difficult to gauge due to the legal issues surrounding their possession and use.
Despite this, reports from needle and syringe programmes (NEP's) have pointed to a
large and continual growth of AS use in the UK, with the number of AS-injecting
individuals attending the NEP's increasing 2000% from 1991-2006 (MeVeigh et aI.,
2003).
Due to this trend for increasing AS use, there is growmg concern about the
cardiovascular (CV) health consequences of AS use. This is despite the fact that
empirical evidence of increased CV risk is often equivocal. Concerns about the CV
health risks have been prompted by substantial case study data that has linked AS
use with CV end-points such as myocardial infarction, (Lunghetti et al., 2009) stroke
(Santamarina et al., 2008) and cardiomyopathies (Bispo et al., 2009). Establishing a
causal relationship from case studies is difficult and thus a number of traditional and
new CV risk factors, such as blood pressure, blood lipid profiles as well as
homocysteine and C-reactive protein (CRP) have been studied in case-control studies
of AS users (Riebe et al., 1992, Graham et al., 2006, Grace and Davies, 2004), again
with equivocal results. Other tools have been used to assess CV health including
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ECG, but data is limited even though a recent study linked AS use to shortened
ventricular repolarisation (Bigi and Aslani, 2009).
Some studies have suggested that left ventricular (LV) morphology and function
may be negatively altered with AS use but data is not consistent (De Piccoli et al.,
1991, Nottin et al., 2006). With continuing developments in non-invasive imaging,
recent studies have assessed LV function at a regional level as well as measuring
global function (D'Andrea et al., 2007, Baggish et al., 2010). Using tissue-Doppler
and cardiac strain (l) assessment both D'Andrea et al. (2007) and Baggish et al.
(2010) observed reduced LV function in AS users. D'Andrea et at. (2007) reported
only longitudinal E and Baggish et al. (2010) presented data only for longitudinal and
radial E in a small number of AS users. A comprehensive evaluation of cardiac E in
all three planes of motion (longitudinal, radial and circumferential), as well as
assessment of rotation and torsion, would provide a significant addition to our
understanding of the CV consequences of AS use. The determination of strain rate
(SR) to provide peak SR in both systole and diastole provides added subtlety to
functional cardiac measures.
The aim of the current study, therefore, was to assess traditional CV risk factors as
well as to develop a more comprehensive assessment of LV structure and function
using state-of-the-art non-invasive imaging tools. We hypothesised that there would
be a significant effect of AS use on traditional risk factors as well as LV systolic and
diastolic cardiac function at global and regional levels. We also investigated the
44
short-term impact of a small number of case studies following brief removal from
AS.
3.2 Method
Subjects
Strength training individuals (n=47, male=46, female=I(AS)) were recruited through
local gyms, personal contacts and local syringe exchange programmes. Posters and
information sheets were placed in various locations and also distributed by hand to
individuals. The posters stated that there was a study investigating the effects of
strength/resistance training, either with or without the use of AS on cardiovascular
health. Inclusion criteria were; participants aged between 18 and 50 years of age;
resistance training history of minimum of 3 years with 3-4 training sessions per
week. Exclusion criteria for the study were the presence of known respiratory, CV
or musculoskeletal disease. Specific inclusion criteria for the AS using group (AS:
n=28, age=31±7 yr) included a documented self-report history of AS use for at least
2 years (including on and off-cycles). Inclusion criteria for the non-AS (NAS) group
(n=19, age=28±8 yr) included self reported history of never taking AS. Prior to
taking part in the study, details of each part of the testing were described to each of
the participants. The study was granted ethics approval from the Liverpool John
Moores Ethics Committee and participants provided written informed consent.
Design
A cross-sectional cohort design was utilised for the study with participants required
to make a single visit to our laboratory. Initially, subjects completed self report
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questionnaires related to general health, training status and history as well as detailed
accounts of AS use. This was followed by assessment of body composition, a venous
blood sample and a comprehensive CV evaluation including brachial artery blood
pressure, a resting 12-lead ECG and an echocardiogram. All tests were conducted on
the participants following an overnight fast, as well as a 24 hr abstention from
resistance training.
Protocols
Participant History and AS use
Training history included data on years of training, the average number and length of
sessions per week, as well as self-reported one repetition maximums for the bench
press and squat (Table 3.1). Those in the AS group provided a detailed history of AS
use including names, dosage and cycling information and none of the participants
self-reported co-abuse of any other illicit substances. For simplicity we provide a list
of exemplar AS used but note that all subjects used multiple AS in various stacking
procedures with varied periods of abstinence or "off-cycles". The types of AS
currently being used by some of the AS participants included, Trenbolone (15),
Testosterone (13), Sustanon (9), Boldenone (7), Nandrolone (10),
Meathandrostenolone (8), Drostanolone Propionate (3), Oxandrolone (4) and
Stanozolol (3). Of those in the AS group that provided sufficient information to
perform an analysis of their daily usage (n=14), we found that the mean AS dose was
232 mg/day with a standard deviation of 208 mg (range 35 - 707 mg/day). To give
an indication of an AS regimen we include a case exemplar of a participants AS use,
Testosterone Propionate = 800mg/wk, Testosterone Cypionate = 500 mg/wk,
Stanozolol = 350 mg/wk, Nandrolone Decanoate = 600 mg/wk. This was broken
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down into three injections of Testosterone Propionate (1= 400 mg, 2= 200 mg), two
of Cypionate (250 mg/injection) and two of Nandrolone Decanoate (300
mg/injection) per week and 25mg of oral Stanozolol twice a day. This was repeated
for 8 weeks.
Table 3.1 Body Composition Data and Training history in AS and NAS groups (data
are mean ± SD).
AS (n=28) NAS (n=19) P value
Height (cm) 178± 8 178 ± 7 0.98
Weight (kg) 96 ± 15 81 ± 9 0.01
BSA (m') 2.18±0.21 1.99± 0.14 0.01
BMI 30.23 ± 4.23 25.32 ± 2.92 0.01
Lean body mass 81.1 ± 13.3 70.7 ± 6.5 0.01
(n=22) (n=15)
Fat mass 14.4 ± 7.7 9.9 ± 7.7 0.04
(n=22) (n=15)
Body Fat % 14.6± 6.5 11.9 ± 3.3 0.15
(n=22) (n=15)
Training duration 7±5 11± 9 0.16
(years)
SessionslWeek 5 ± 1 4±1 0.03
(n)
Avg. Session Length 75 ± 26 64 ±16 0.12
(min)
Bench Press lRM 143± 36 113 ± 26 0.01
(kg)
47
Squat lRM
(kg)
194± 39 145± 59 0.01
BSA = Body Surface Area, BMI = Body Mass Index, 1RM = One Repetition Maximum
Body-Compos ilion
Height and body mass were recorded using standard scales allowing the calculation
of BMI and BSA (Du BoisD, 1916). In a sub-sample from both groups, body-
composition, including lean mass, fat mass and body fat percentage, was measured
using dual energy x-ray absorptiometry (DXA, QDR Discovery A, Hologic, MA)
(AS n=22, NAS= 15).
Lipid Profile
Venous blood samples were taken from the antecubital vein directly into serum gel
(serum) and lithium heparin vacutainers (plasma) (BD, Oxford, UK). Samples were
centrifuged for 10 min at 3000 rpm, after which, plasma and serum was placed into
aliquots for immediate assessment of total cholesterol (AS n= 19, NAS n=9), high-
density lipoprotein (HDL) (AS n=20, NAS n=12), low-density lipoprotein (LDL)
(AS n=6, NAS n=4), triglycerides (AS n=15, NAS n=6) using the Daytona RS Blood
Analysis machine (Randox, Co. Antrim, N. Ireland).
Blood Pressure and ECG
At the end of a 10 minute resting supine period repeated resting brachial artery blood
pressures were recorded from the left arm via an automated blood pressure monitor
(AS n=27, NAS n=18) (Dinamap; GE Pro 300V2, GE Healthcare). A resting 12-lead
ECG was performed (Mac 1200, GE Healthcare Systems, WI, USA) after this supine
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rest (AS n=28, NAS n= 19). Key parameters assessed included rate, QRS complex
voltages and QTc duration (Bazett correction).
Echocardiography
For assessment of global and segmental cardiac structure and function ultrasound
echocardiography (Vivid Q, GE Healthcare, Norway) was used to gather images of
the left ventricle (LV) in multiple planes from parasternal and apical acoustic
windows (AS n=37, NAS=19). A single experienced echocardiographer performed
all imaging with the subject in the left lateral decubitus position. Intra-observer
reliability was assessed through intra-class correlations for 2D, Doppler, TDI, and
£/SR data (Chan-Dewar et al., 201Oa, 2010b) with a range ofO.693-0.993 (P<0.05).
Parasternal long axis views allowed the collection of M-mode images at the tips of
the mitral valve leaflets perpendicular to septal and posterior walls taking care to
ensure clear endocardial definition. From M-mode traces septal (lVSd) and LV
posterior wall thickness (LVPW d) in diastole as well as LVchamber dimensions at
end-diastole and systole (LVIDd, LVIDs) were assessed following American Society
of Echoardiography guidelines (Lang et al., 2005). We estimated LV mass using a
regression corrected cube formula (Devereux et al., 1986). A LV mass index was
constructed by scaling allometrically for height raised to the power 2.7 as this is the
technique most often used in a clinical setting. (de Simone et al., 1995). In a sub
sample (n=37, AS=22, NAS=15) we scaled LV mass for individual differences in
lean body mass derived from DEXA.
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Apical 2 and 4-chamber views were digitised to asses LV end-diastolic (LVEDV)
and end-systolic (LVESV) volumes which then allowed the estimation of stroke
volume (SV) and ejection fraction (EF) using Simpsons' bi-plane method. From the
4-chamber view, colour Doppler and pulsed wave Doppler were used to assess peak
flow velocities across the mitral valve. Using a 4 mm sample volume in the area of
peak flow LV early (E) and late (A) diastolic in-flow velocities were recorded. In
combination with LV outflow spectral Doppler envelopes we also measured the
isovolumetric relaxation time (IVRT) from closure of the aortic valve to opening of
the mitral valve. From the same view tissue-Doppler measures of myocardial wall
velocities were recorded. Taking care to adjust filters and scale and with the septal
wall parallel to the ultrasound beam we interrogated the mitral annulus at the septal
wall, recording peak systolic (S') as well as early (E') and atrial (A') diastolic tissue
velocities. This also allowed the production of the E/E' ratio that has been shown to
estimate left atrial pressure (Nagueh et al., 1997).
Segmental and global E and SR data were obtained from parasternal short axis views
at the base (just below mitral valve) and apex (1-2 cm above LV cavity obliteration)
as well as via a 4-chamber apical view. Cine loops of LV motion were captured for
off-line analysis (Echopac, GE Heathcare, Norway). Specific speckle-tracking
software that tracks natural acoustic markers or "kernals" facilitated the estimation
of E and strain rate in six wall segments in all views. In short axis views the LV was
split into septal, anteroseptal, inferior, posterior, anterior and lateral wall segments.
Radial, circumferential and rotational data from these segments were averaged to
provide global E, SR, rotation (Rot) and rotation rate (RotR) data. Comparison of
basal and apical rotation facilitated the calculation of LV torsion (Oxborough et al.,
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2010, Oxborough et al., 2009, George et al., 2009). In the long axis view the LV was
split into basal, mid-wall and apical septal wall segments as well as basal, mid-wall
and apical lateral wall segments. Again these were averaged to provide global
measures of longitudinal E and SR. SR data were recorded in systole (S SR) and
early diastole (ESR). Two-dimensional image optimisation was performed including
maintaining frame rate between 40 and 90 fps. For all measurements images were
analysed off-line by a single experienced technician with no knowledge of group
allocation. Data reflect the average of 3-5 continuous cardiac cycles.
Figure 3.1 Longitudinal E and SR image derived from myocardial speckle tracking.
Case Studies of "On" and "Off" Cycle Assessments
A sub-group of AS users (n=4, male=3, female=l) were tested during both a period
of AS use ('On' Cycle) and a period of abstinence ('Off' Cycle). The same
experimental measures were taken at both testing points. In order to make the study
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as relevant to 'real-world' scenario's, we aimed to test participants at the end of an
'On' and an 'Off cycle. The 'On/Off cycle durations ranged from 8-12 weeks.
Statistical Analysis
Statistical analysis of data was performed using statistical software package SPSS
Version 17 (IBM inc., Armonk, NY, USA). All data were subjected to tests of
normality. Differences between AS and NAS participants were analysed using paired
T-Tests if normally distributed or the Mann-Whitney U-Test if not normally
distributed (e.g. ElA ratio data). A P value <0.05 was considered significant.
3.3 Results
Participant History and AS use
The AS group performed on average one more training session per week than the
NAS group whilst the NAS had a longer (yr) history of training. There was little
difference in the average session length between the two groups. Maximal bench
press and squat were also significantly higher in the AS group (Table 3.1).
Body Composition
Whilst height did not differ between groups, the AS group were significantly
heavier, which resulted in a significantly elevated BSA and BMI (Table 3.1). Lean
mass and fat mass (81.1 ± 13.3 vs. 70.7 ± 6.5; 14.4 ± 7.7 vs. 9.9 ± 7.7, respectively,
P<0.05) were both significantly elevated in the AS users, whilst body fat percentage
(14.6 ± 6.5 vs. 11.9 ± 3.3) was elevated in the AS group, this was not significantly
different between groups.
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Lipid Profile
LOL and HOL were significantly elevated and reduced, respectively, in the AS
group, which led to a significantly greater total cholesterol to HOL ratio in the AS
group (Table 3.2). Total cholesterol was elevated in the AS group, although this was
not statistically significant. There was little difference in triglyceride levels between
groups (0.84 ± 0.28 vs. 0.82 ± 0.28).
Blood Pressure and ECG
Mean systolic pressures were elevated but not significantly higher, whilst mean
diastolic pressures were lower in AS users, they did not reach statistical significance
(systolic blood pressure: 133±15 vs. 126±12 mmHg; P=O.ll; diastolic blood
pressure: 67±7 vs. 73±10 mmHg; P=0.07). Resting heart rate was significantly
higher in AS users (79±12 vs. 64±13 beats.min"; P=O.OI). Fourteen AS users and
eight NAS met the voltage criteria for LV hypertrophy but and voltage data for R
waves in V5 and V6, as well as S waves in VI And V2, were not different between
groups. R-R corrected QT interval (QTc) was also not significantly different
between AS users (409±20 ms) and NAS (401±23 ms). Three members of each
group had a QTc marginally below the 380 ms cut off for short QT.
Cardiac Structure and Function
Thickness of the IVSd, LVPW d, as well as LV mass were significantly higher in the
AS group (Table 3.2). LV mass index, when scaled for height remained significantly
higher in the AS group, however when scaled for lean body mass in a sub sample, it
was no longer significant (P=0.13). There was no significant difference between
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groups for LV internal dimensions or volumes in systole or diastole yet there was
significantly reduced ejection fraction in the AS group. In diastole, significant
reductions in ElA, E', A' and E' lA' were observed in the AS group. A was
significantly elevated in the AS group. There was no significant difference between
groups in isovolumetric relaxation time (103 ± 14 vs. 103 ± 15 ms) and E wave
deceleration time (182 ± 37 vs. 202 ± 40 ms).
Table 3.2 Structural and functional data for the LV, and lipid profiles in AS and NAS groups
(data are mean ± SD).
AS (0=28) NAS (0=19) P value
IVSd (mm) 13± 2 12± 2 0.01
LVPWd(mm) 12± 2 11± 1 0.01
LVIDd (mm) 53 ± 5 52±4 0.49
LV Mass (g) 280 ± 60 231 ±44 0.01
LVMI (glHe·') 59 ± 13 49 ± 11 0.01
LVMI (glffm 1.0) 3.57 ± 0.53 3.27 ± 0.66 0.13
(n=22) (n=15)
EF(%) 59± 8 63 ± 6 0.04
E (cm.s") 72 ± 14 77 ± 15 0.27
A (cm.s") 54 ± 11 39 ± 12 0.01
E/A 1.36± 0.29 2.04 ± 0.59 0.01
S' (cm.s") 9±3 9±2 0.79
E' (cm.s") 10± 2 12± 2 0.01
A' (cm.s') 9±2 7±2 0.01
E'/A' 1.16± 0.35 l.91 ± 0.56 0.01
E/E' 7.44 ± l.67 6.05 ± 1.20 0.01
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Total Cholesterol
(TC) (mmollL)
LDL (mmoIlL)
HDL (mmollL)
TC:HDL
4.78 ± 1.53 4.04 ± 0.69
(n=19) (n=10)
3.68 ± 0.47 2.41 ± 0.49
(n=6) (0=4)
0.69 ± 0.26 1.21± 0.31
(0=20) (0=12 )
8.21 ±4.72 3.11±0.47
(n= 19) (n=8 )
0.18
0.01
0.01
0.01
LV - Left Ventricle, LVMI = Left Ventricular Mass Index (glhe'). LVMi=Left Ventricular Mass
index (g/ffm':"), EF = Ejection Fraction, E = Early Diastolic Flow, A = Late Diastolic Flow, IVRT =
Isovolumetric Relaxation Time, E Dec = Early Diastole Deceleration, E' = Early Diastolic Tissue
Velocity, A' = Late Diastolic Tissue Velocity, LDL = Low-Density Lipoprotein, HDL = High-
Density Lipoprotein.
Myocardial E and SR (longitudinal, circumferential and radial)
In the longitudinal plane peak E was significantly reduced in the AS group (Table
3.3). There was no significant difference in peak S SR, whilst peak E SR was
significantly reduced and peak A SR significantly elevated, in the AS group. This led
to a significantly reduced ElA SR ratio in the AS users.
Table 3.3. Longitudinal E and SR data for AS and NAS groups (data are mean ± SD
unless otherwise stated).
AS (0=25) NAS (0=19) P value
[(%) -14.6 ± 2.3 -16.9 ± 2.2 0.01
Peak S SR (.S-I) -1.09 ± 0.23 -1.09±0.18 0.97
Peak E SR (.S-I) 1.45± 0.31 1.65± 0.23 0.02
Peak A SR (.S·I) 1.12± 0.60 0.80 ± 0.25 0.04
ElA SR Ratio+ 1.63 2.41 0.02
[= Peak Strain, SR = Strain Rate, t =Data given as Median.
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In the circumferential plane peak E and S SR did not differ between groups at the
basal level (P>O.05) whilst peak E was significantly reduced in the AS group at the
apical level (P<O.05, Table 2.4). Peak E SR was significantly reduced in the AS
users at the apical level and ElA SR was significantly reduced in the AS group at
both basal and apical levels. At the apical level Peak E RotR was significantly
elevated and peak rotation was significantly reduced in the AS group. Peak A SR
was significantly elevated in the AS users at the basal level. Peak A RotR was
significantly elevated in AS users at the basal level, which also lead to a significantly
reduced E/A RotR. All other data were similar between groups (Table 3.4). Torsion
was not different between the two groups.
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Table 3.4. Circumferential E, SR, rotation, rotation rate and torsion in AS and NAS groups
(data are mean ± SO unless otherwise stated).
AS (n=26) NAS (n=18) P Value
Basal Level E(%) -11.8 ± 7.2 -13.2 ± 8.5 0.57
Peak S SR (.S-I) -1.49 ± 0.42 -1.20 ± 0.81 0.13
Peak E SR (.S-I) 1.52 ± 0.47 1.39 ± 0.81 0.49
Peak A SR (.S-I) 0.90 ± 0.41 0.59 ± 0.60 0.05
ElA SR Ratiot 1.99 3.37 0.03
Rotation (j -3.52 ± 5.42 -3.75 ± 4.12 0.88
Peak S RotR (.S-I) -69.3 ± 35.2 -63.8 ± 19.6 0.55
Peak E RotR (.S-I) 64.5 ± 27.5 64.43 ± 28.7 0.99
Peak A RotR (.S-I) 47.9±21.1 34.0± 15.3 0.02
ElA RotR Ratiot 1.52 2.25 0.03
Apical Level E(%) -20.6 ± 5.8 -24.6 ± 6.0 0.04
Peak S SR (.S-I) -1.82 ± 0.58 -1.62 ± 0.45 0.28
Peak E SR (.S-I) 1.99 ± 0.64 2.71 ± 1.04 0.01
Peak A SR (.S-I) 1.12 ± 0.54 0.83 ± 0.38 0.08
ElA SR Ratio+ 2.19 3.94 0.01
Rotation (j 3.62 ± 4.31 6.84 ± 4.57 0.04
Peak S RotR (.S-I) -49.6 ± 19.3 -52.8 ± 36.7 0.74
Peak E RotR (.S-I) 58.3 ± 34.6 30.2 ± 32.5 0.02
Peak A RotR (.S-I) 34.6± 14.1 22.5 ± 25.0 0.08
ElA RotR Ratlo+ 1.66 1.74 0.79
Torsion 6.30 ± 5.27 9.86 ± 6.44 0.07
(n=21 ) (n=15)
E - Circumferential Strain, SR = Circumferential Strain Rate, RotR = Rotation Rate, S = Systole, E =
Early Diastole, A = Late Diastole. t= Data given as Median.
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In the radial plane, there was no difference in peak E and S SR at the basal levels
whilst peak E and S SR were significantly elevated in the AS group at the apical
level (Table 3.5). Peak E SR were similar in AS and NAS groups at both levels, but
A SR was significantly elevated in the AS group at the basal level which led to a
significant depression in the basal ElA radial SR ratio.
Table 3.5. Radial plane E and SR in AS and NAS groups (data are mean ± SD unless
otherwise stated)
AS (0=26) NAS (0=18) P Value
Basal Level E(%) 25.5 ± 11.6 30.7 ± 14.5 0.20
Peak S SR (oS-I) 2.13 ± 0.96 1.99± 1.41 0.69
Peak E SR (oS-I) -1.72 ± 0.66 -1.64 ± 0.49 0.66
Peak A SR (oS-I) -1.34 ± 0.57 -0.88 ± 0.54 0.01
ElA SR Ratiot 1.48 2.99 0.01
Apical Level E(%) 34.3 ± 14.5 22.2 ± 12.8 0.01
Peak S SR (oS-I) 2.00 ± 0.53 1.40 ± 0.76 0.01
Peak E SR (oS-I) -2.48 ± 1.06 -2.45 ± 1.17 0.94
Peak A SR (oS-I) -1.06 ± 0.57 -0.79 ± -0.48 0.14
ElA SR Ratiot 2.78 3.23 0.22
E= radial strain, SR = Radial Strain Rate, S = Systole, E = Early Diastole, A = Late Diastole. t =
Data given as Median.
Case Studies of AS users "On" and "Off" Cycle
Moderate changes were seen in mass from 'On' to 'Off cycle with only a significant
change seen in one subject (Table 3.6). HDL levels increased in all the three subjects
when 'Off' cycle where data were available. Minimal differences in structure were
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seen at the different points of the AS cycles, with the greatest changes seen in
diastolic function with two subjects showing improved ElA values when 'Off cycle
and all those tested at both time points exhibiting improved ElA SR values.
Table 3.6. Cardiac structure, function and HDL Data from AS users when 'On' and
'Off Cycle.
Subject & Mass HR HDL LVMi EtA LongE EtASR
On/Off (g) (bpm") (mmolll) (g/ffm') (%)
1 On 80.4 68 0.64 3.77 1.39 -14.03 0.93
Off 79.4 63 1.05 3.58 1.22 -14.03 1.69
2 On 126 73 0.44 3.35 1.83 -12.57 0.69
Off 118.3 56 0.58 3.60 1.85 -12.24 1.57
3 On 105.3 70 3.64 1.49 -18.39 1.29
Off 106.6 70 3.68 1.76 -19.29 1.45
4* On 69.4 60 1.04 2.88 1.85 -15.72 1.60
Off 70.3 59 1.56 3.03 2.1 -21.02 4.28
HR=Heart Rate, LVMi=Left Ventricular Mass (g/ffm 1.0), ElA=Early:Atrial Diastolic filling ratio,
E'/A'= Early:Atrial Diastolic tissue velocity ratio, TC=Total Cholesterol, LDL=Low-Density
Lipoprotein, HDL=High-Density Lipoprotein, E = Peak Strain, SR = Strain Rate, * female subject
3.4 Discussion
The umque contribution of this study is that it builds on the recent work of
D'Andrea, Caso, Salerno et al. (2007) and Baggish, Weiner, Kanayama et al. (2010)
by providing a comprehensive profile of cardiac E and SR data in multiple planes of
LV motion. Specifically, the current study observed decreased longitudinal peak [' as
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well as well as some evidence of decreased diastolic SR in the circumferential
(apical) and radial planes (basal). Further we provide data consistent with previous
findings that AS use is associated with significant alterations in lipid profiles
(Hartgens and Kuipers, 2004, Lane et al., 2006) as well as left ventricular concentric
hypertrophy and diastolic impairment (Nottin et al., 2006, Kasikcioglu et aI., 2009).
Taken together this data suggest that an increased CV risk profile exists in AS users.
Initially we observed alterations in body composition, lipid parameters and resting
heart rate in AS users. The significant increases in weight, BSA and BMI seen in the
AS users were somewhat predictable (Bhasin et al., 1996) as AS have been shown to
up-regulate protein synthesis, thereby increasing the amount of lean muscle that can
be developed when used in conjunction with intense resistance training (Payne et al.,
2004). It is unlikely that the significant differences in body size and composition can
be explained solely by small differences in the training exposure of the two groups.
In addition we observed an altered lipid profile in AS users. Whilst mean total
cholesterol was higher in AS users, the difference between groups was not
statistically significant which supports data from Sader et al. (2001) but contradicts
Baldo-Enzi et al. (Baldo-Enzi et al., 1990). It can be argued that lipid profiles are
more important than overall cholesterol when determining CV and atherosclerotic
risk (Robinson et al., 2009). The decrease in HDL in AS users in the present study
agrees with past research (Sader et al., 2001, Baldo-Enzi et al., 1990, Hartgens et al.,
2003, Lane et aI., 2006). Likewise, an increase in LDL in the current study also
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supports previous data (Hartgens et al., 2003). Supraphysiological doses of AS lead
to high hepatic androgen exposure and high androgen levels can alter levels of
lipoprotein (a), which directly effects the formation ofHDL (Hartgens et al., 2004).
The AS user group had a significantly elevated resting heart rate compared to NAS
users. Whilst increased heart rates in AS users have been shown in previous studies
(D'Andrea et al., 2007) these differences have not been significant. Case studies have
observed increased heart rates in AS users (Sullivan et al., 1999) but the present
study is the first to report a significant difference in resting HR in a cohort study. An
elevated resting HR in AS users could be due to a number of mechanism(s)
including; a relative lack of aerobic/endurance training in AS users, an indirect effect
of the increased atherosclerotic risk, through alterations in risk factors such as lipid
profiles, or a direct effect of steroids on cardiac pacemaking. Whilst resting systolic
and diastolic blood pressures observed in the present study did not differ
significantly between the two groups, systolic BP was elevated whilst diastolic BP
was reduced in the AS group (7 and 6 mmHg). Blood pressure data were highly
variable between individuals and a lack of between group significance may be due to
low power with respect to this data.
Larger LV wall thicknesses observed in the AS users in the present study confirms
data reported in previous studies (Nottin et al., 2006, Sachtleben et al., 1993,
Baggish et al., 2010). It is also important to note that these data contradict other
studies. Specifically, D'Andrea et al. (2007) and Hartgens et al (2003) reported no
increased wall thickness in AS users. Comparisons between AS-user studies can be
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complicated by between-subject differences in training history, AS use history etc
that may explain variable outcomes. The increase in LV wall thickness and LV mass
may be expected as the receptor mechanisms that result in an increase in skeletal
muscle protein up-regulation with AS use, are present within the myocardium
(Marsh et al., 1998). In the current study the increased LV wall thickness contributed
to an elevated LV mass that remained even after scaling for between-subjects
differences in height (Dewey et al., 2008). When LV mass was scaled for lean mass
in a sub-sample (n=37, AS=22, NAS=15), the difference between groups was no
longer statistically significant (P=0.13). This suggests that some, but likely not all, of
the LV hypertrophy could be explained by an increase in whole body lean tissue.
Whether there is cardiac tissue hypertrophy in excess of body size, suggesting a
possible increased anabolic effect of AS in cardiac tissue over skeletal muscle
requires verification. Whilst we cannot exclude small between-group differences in
training stimulus as a potential mediator of LV morphology, it is unlikely to
underpin all of the observed variation between groups.
The increased LV morphology in AS users was also associated with significant
between group differences in LV function. Notably the AS users had a reduced EF.
The EF, however, remained within the normal range which contradicts a recent
report (Baggish et al., 2010) but confirms other studies (Hartgens et al., 2003). The
lack of difference in S' between groups also supports previous studies (Kasikcioglu
et al., 2009, Nottin et al., 2006). Whilst myocardial E and S SR assessment have
become increasingly useful in quantifying regional myocardial function in
individuals, from both a clinical (Abraham et aI., 2007) and research perspective
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(Langeland et al., 2005) its application in AS-users has to this point been incomplete
(Baggish et al., 2010, D'Andrea et al., 2007). We observed a significant reduction in
peak longitudinal E in AS users, similar to that reported previously (D'Andrea et al.,
2007, Baggish et al., 2010), as well as a significant reduction in circumferential E at
the apical level. A small non-significant reduction in radial E at the basal level along
with an increase in radial E at the apical level in AS users was observed in the
current study, yet greater, and significant, decreases in AS users were reported by
Baggish et al. (2010). The absolute values of radial strain were lower in the AS users
in the current study compared with the AS users assessed by Baggish et al. (20 I0).
Circumferential E as well as S SR in both apical and basal LV levels has not been
reported in previous literature. Our observations of these parameters in AS users
suggests that there is no consistent change in indices of LV motion/contraction
between planes of motion and further that these data should be confirmed in on-
going studies. Similarly, peak rotation and peak systolic rotation rates have not been
reported previously in AS users and in the current study, excluding peak rotation at
the apical level, were largely unaltered by a history of AS use. Consequently, LV
torsion whilst reduced in AS users was not significantly different between groups.
Whilst evidence of impairment of global diastolic function was observed in AS
users, it is interesting to note that E and IVRT were not altered in the AS group. A
lengthened IVRT has been reported before in AS users (Nottin et al., 2006). Other
alterations observed in the AS users were a decreased E', suggestive of early
relaxation impairment and increased A and A' suggesting altered atrial contraction
or LV compliance. Both ElA and E'lA' ratios were reduced in AS users, which is
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suggestive of an overall reduction in "efficiency" of LV motion/filling and again
these changes parallel published data (Kasikcioglu et al., 2009). The lack of
significant difference in E in the current study is somewhat surprising but given a
reduction in E', this may reflect pseudo-normalisation (Khouri et al., 2004) which is
supported by an increase in left atrial driving pressure as estimated by EIE'. An
increased E/E' has also been noted in past studies and was present in the present
findings (Krieg et al., 2007, Kasikcioglu et al., 2009).
Previous studies employing E and SR analysis have not assessed diastolic function
(D'Andrea et al., 2007, Baggish et al., 20 I0). Although not consistent in all planes,
levels and segments, evidence of significant alterations in E SR, A SR, as well as E
and A rotation rates provide new evidence for altered diastolic function in AS users.
A reduction in E SR likely reflect alterations in early relaxation/elastic recoil of LV
wall segments and any alteration in A SR or A rotation rate likely reflect changes in
atrial contraction or LV compliance. Overall changes in filling or tissue movement
during atrial diastole probably represent an increased reliance on atrial filling in the
AS users as the LV adjusts to a reduction in early filling. The diastolic impairment
observed in AS users could occur through possible impaired LV relaxation,
increased LV diastolic pressure and/or elevated left atrial pressure (Little and Oh,
2009). However, the specific mechanisms underpinning altered early or atrial
diastolic function cannot be directly determined from the current non-invasive study.
Altered loading and rate may be considered but the heart rate difference is small and
available data suggests that parameters such as E, E', E and SR would increase with
heart rate, not decline. Altered preload is difficult to assess in a cross-sectional
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design and whilst some differences in blood pressure were apparent it is problematic
to link this to LV function in the current research design. The mechanism( s) by
which AS could have a direct effect on LV diastolic relaxation and/or compliance
are not fully understood but some pathways have been postulated. D' Ascenzo et al.
(2007) speculated that AS negatively alter endothelial cell growth, promote
apoptosis and increase collagen cross-links in LV walls. Human data to support this
speculation is currently limited but worth pursuing. Whether the changes in LV
function are a direct consequence of long term AS use, or an indirect effect of AS,
via altered lipid profiles or blood pressure, is worthy of further study.
Despite only a small number of AS subjects being tested when both 'On' and 'Off'
cycle, the results start to give an indication of changes in CV parameters that can
occur after a relatively short period, 8-12 weeks, of abstinence from AS use. This
data also prompts on-going studies in this area. Our data suggest some improvement
in the lipid profiles of those tested, with decreases in overall total cholesterol and
also LDL and increases in HDL levels thereby showing an improvement in perceived
CV risk. Whilst strain and strain rate data from the different cycles was somewhat
inconclusive, the increase in ElA SR in the radial plane seen in all users when 'Off'
cycle, in conjunction with an increase in ElA ratios in three of the subjects, gives an
indication of a potential improvement in ventricular relaxation following cessation of
AS use for a relatively short period of time. It is important to note, however, that
despite an improvement in ventricular filling ratios in three of the subjects, the
values seen were still below the average of the NAS group, indicating some
restriction in ventricular relaxation remained. Nonetheless, these values were still
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well within normal clinical ranges. These findings do, however, indicate a possible
short-term effect of AS use on cardiac function outside of a possible role of
apoptosis or increased collagen cross-links, or at least a reversibility in any increase
in these cross-links associated with AS use.
The implications of the data presented in this and other studies is that AS use is
associated with multiple changes in CV structure, function, health and thus risk. This
provides some potential links to case studies reporting significant CV events in AS
users. Large epidemiological studies, although difficult in this type of cohort, should
provide further insights into the "real" risk of AS use. What implications the current
data have at an individual level is hard to discern. Overall the increase in ventricular
mass, decreased cardiac function (in particular diastolic impairment) as well as
marginal changes in blood pressure and alterations in blood lipid profiles point to an
increased CV disease risk associated with AS use. The small sample of data from
'On' and 'Off cycle in AS users points to a possible, if limited, reversal of some of
the negative CV effects seen in AS users.
As with any study of AS use there are some inherent limitations that are important to
note. Investigating AS use is complicated by the heterogeneity in subject specific
details (age, training status, diet etc) that were either not controlled or not assessed in
the current study. Obviously inter and intra-individual differences in AS dose
(volume, drug type, veracity or authenticity), self-report details of history as well as
variations in "stacking" and "cycling" approach can occur within the AS using
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population. We made no a-priori attempt to control these parameters in order to
reflect the reality of AS use. Further to this, the differing types of AS use which are
used for differing outcome, i.e. for bulking or for 'cutting' in order to potentiate lean
mass, could have a confounding effect on the results but, we did not account for this
in our analysis. We present some case-studies of the impact of "cycling" of AS use
but this should be addressed in a larger study.
It is also pertinent to mention that all of the LV structural and functional measures in
the present study were obtained through non-invasive techniques, thereby limiting
the ability of the researchers to confirm the mechanistic reasons for any changes
observed. Whilst we present what we consider is a comprehensive look at AS and
their CV effects, the addition of radial and circumferential data at the mid-LV level
may provide additional insight into global systolic functioning. Low participant
numbers in certain aspects of the data, such as aspects of the lipid profiles, we
present does limit their interpretation to a wider group. An important and often
overlooked area is the effect of AS on haematocrit levels. There is limited data
concerning this area of research but some results have demonstrated a negative
impact (Alen, 1985, Lane et aI., 2006). Further research could help to explain certain
CV events and changes to LV geometry and function (e.g. strain and strain rate) that
have been observed in AS users. Specifically, whilst we have confirmed an increase
in CV risk in AS users by adding new data in relation to cardiac function in AS users
at rest it would make sense to assess cardiac functional responses to exercise stress
as this may be an important adjunct to risk and the onset of events seen in case study
reports in AS users. Whilst we document gross structural alterations in the LV of AS
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user's limited data is available for the right ventricle and the left atria. Further study
using MRI techniques may interrogate the impact of AS use on LV perfusion and/or
the potential presence of fibrosis.
In conclusion, the present study has reported a range of negative CV consequence of
AS use in conjunction with resistance training that is in agreement with recent
findings (Baggish et al., 2010, Kasikcioglu et al., 2009). We have developed the
available database by indicating an association between AS use and some evidence
of impaired E and SR data, largely reflecting altered diastolic cardiac motion.
Combined with altered LV mass, lipid profile changes in cardiac function with AS
use likely increase the CV risk in AS using subjects.
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Chapter 4: MRI determination of global left and right ventricular
structure, function, perfusion and fibrosis in anabolic steroid users
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4.1 Introduction
The use of anabolic steroids (AS) has been associated with significant cardiac events
including acute myocardial infarction (Lunghetti et al., 2009, Wysoczanski et al.,
2008) and sudden cardiac death (Fines chi et al., 2007, Luke et al., 1990). An
increased cardiovascular risk is assumed with the abuse of AS but the possible
mechanisms remain unclear or controversial. Previous research has shown
significant effects of AS on cardiovascular risk factors (CV) such as BP (Riebe et al.,
1992) and total cholesterol (Baldo-Enzi et al., 1990) however these findings were
inconclusive and have been contradicted in subsequent studies (Sader et al., 200 I).
Whether direct alterations m ventricular structure and function may mediate an
increased cardiovascular risk in AS users is unclear. There is some
echocardiographic evidence of increased cardiac muscle mass in AS users (Baggish
et al., 2010, Angell et al., 2011) but this is not entirely consistent (Urhausen et al.,
1989, D'Andrea et al., 2007). Recent studies, using ultrasound echocardiography,
have suggested negative alterations in cardiac function are associated with AS use
(Hartgens et al., 2003, Baggish et al., 2010, Angell et al., 2011). Using novel
deformation assessment techniques these studies have documented, in AS users,
reduced longitudinal strain (l) (D'Andrea et al., 2007), reduced radial and
longitudinal E (Baggish et al., 2010), and alterations in diastolic strain rates (Angell
et al., 2011). The consequences or causes of these functional changes are not known.
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Some areas of study have received less attention in AS users. Specifically, there is
very little data related to right ventricular (RV) structure and function in AS users.
This is partially understandable because of the historic difficulties related to non-
invasive imaging of the RV. Recent studies from Belgium give renewed impetus to
study the RV as both Heidbuchel et al. (2003) and Ector et al. (2007) reported
complex ventricular arrhythmias in well-trained athletes were largely of right
ventricular origin and in some precipitated sudden cardiac death. Other potential
mechanisms that could link cardiac structure/function and cardiovascular events in
AS users may relate to atherosclerosis and perfusion defects and/or the presence of
intemstitial fibrosis within the myocardium that could act as an arrhythmic substrate.
To the best of our knowledge no data is available describing the presence of
perfusion defects or interstitial fibrosis in the myocardium of AS users.
Limitations in echocardiography, including operator variability, poor spatial
resolution and the use of mathematical models to predict 3D structures or function
likely limit the interpretation of global data derived using this technique (Kuhl et al.,
2003). Cardiac magnetic resonance imaging (cMRI) is now considered the gold-
standard for non-invasive assessment of global cardiac structure and function due to
its increased spatial resolution and its lack of reliance on geometric assumptions
(Kerber and Pesek-Bird, 2002). Unlike echocardiography, cMRI is not limited by
poor acoustic windows. This allows an accurate assessment of right ventricular
structure and function. Importantly, cMRI can be used to assess cardiac perfusion
defects (Cury et aI., 2008) and the presence of interstitial fibrosis (Jellis et al., 20 I0)
both of which may increase the risk of a cardiovascular event. It has been speculated,
but never empirically supported, that cardiac fibrosis as a consequence of AS use
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may provide a mechanistic link to a substantial number of case reports of acute
myocardial infarctions in AS users (Angell et al., 2011).
To the best of our knowledge cMRI has not been employed in a comprehensive
assessment of cardiac structure and function in AS users. Consequently, the aim of
the current study was to assess the cardiac morphology, function, perfusion and
presence of interstitial fibrosis in regular AS users using cMRI. We hypothesised
that AS users would have increased RV and LV dimensions in the presence of
reduced systolic and diastolic function. Further, there may be case evidence of
significant perfusion defects and interstitial fibrosis.
4.2 Method
Subjects
Strength trained individuals (n=22, 1 female) were recruited through local gyms, and
personal contacts. Inclusion criteria were; participants aged between 18 and 50 years
of age; resistance training history of a minimum of 3 years with 3-4 training sessions
per week. Exclusion criteria for the study were the presence of known respiratory,
cardiovascular or musculoskeletal disease. Specific inclusion criteria for the AS
using group (AS: n=14, 1 female; age=30 ± 5 yrs) included a documented self-report
history of AS use for at least 2 years (including on and off-cycles). Inclusion criteria
for the non-AS (NAS) group (n=8, age=28 ± 6 yrs) included self reported history of
never taking AS. Participants were matched for age and training history. Prior to
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taking part in the study, details of each part of the testing were described to each of
the participants. The study was granted approval from the Royal Brompton and
Harefield Research and Development Committee as well ethics approval from the
LJMU Ethics Committee. All participants provided written informed consent.
Design
A cross-sectional cohort design was utilised for the study with participants required
to make a single visit to the Royal Brompton MRI laboratory. Initially, subjects
completed self-report questionnaires related to general health, training status and
history as well as detailed accounts of AS use. This was followed by assessment of
body composition, a venous blood sample and a comprehensive CV evaluation
including brachial artery blood pressure, an echocardiogram and a cardiac MRI. All
tests were conducted on the participants following an overnight fast, as well as a 24
hr abstention from caffeine consumption and resistance training.
Protocols: Participant History and AS use
Training history data recorded included; years of resistance/strength training, the
average number and length of sessions per week, as well as self-report one repetition
maximums for the bench press and squat. Participants in the AS group provided a
detailed history of AS use including names, dosage and cycling information.
Insufficient data regarding aerobic training was provided by the AS participants,
limiting a comparison between groups.
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Body-Composition
Height and body mass were recorded using standard scales allowing the calculation
of BMI and BSA (Du BoisD, 1916). Assessment of body-composition was made
using bio-electrical impedance (InBody 230 Body Composition Analyser, Biospace
Co Ltd) to estimate total fat mass and fat free mass.
Blood Pressure
At the end of a 10 minute resting supine period repeated resting brachial artery blood
pressures were recorded from the left arm via an automated blood pressure monitor
(VIOODinamap, GE Medical Systems).
CMR Image Acquisition Protocol
All participants were asked to abstain from caffeine-containing beverages or drugs
for 24 hours prior to imaging. All images were acquired using a dedicated I.ST
scanner (Siemens Avanto, Siemens Healthcare, Erlangen, Germany) with an eight-
element phased-array receiver coil. Using scout images for planning, expiratory
breath-hold, ECG-gated, balanced steady-state free precession cine images were
acquired in the vertical long axis (VLA), horizontal long axis (HLA) and left
ventricular outflow tract (LVOT) planes. Using the VLA and HLA images for
planning ensure imaging was parallel to the atrioventricular groove. A contiguous
short-axis stack was obtained from base to apex ensuring full LV and RV ventricular
myocardial coverage (Kramer et al., 2008). Global LV and RV parameters (end-
diastolic volume, end-systolic volume, stroke volume, and ejection fraction) and LV
mass were determined using a semi-automated threshold-based algorithm after
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manual tracing of epicardial and endocardial borders using commercially available
software (CMRtools, Cardiovascular Imaging Solutions, London, UK). Ventricular
volumes and mass were reported as absolute data and then normalised for individual
differences in fat free mass (Batterham et al., 1999).
After initial acquisition of cine images at rest, adenosine was infused at 140
mcg/kg/min through a 20G cannula in the left antecubital fossa for a minimum of 3
minutes according to response (Kramer et al., 2008). Active shimming was used to
ensure magnetic field homogeneity over the regions of interest, and manual
frequency adjustments were carried out to ensure maximum fat-water separation
with the selected radiofrequency excitation pulse. The imaging planes were planned
using end-systolic frames of the long-axis cine images to ensure that the LVOT was
excluded from the basal slice and that each slide was parallel to the atrioventricular
groove. At peak stress, gadolinium contrast (Gadovist, Bayer-Schering, Berlin,
Germany, 0.1 mmollkg) was injected at a rate of 3.5 ml/s followed by a 15 ml saline
bolus at 7 mils via an 180 cannula in the right antecubital fossa using a power
injector (Medrad UK, Ely, Cambridgeshire, UK). Short axis perfusion images were
then acquired at the base, mid-ventricle and apex together with the arterial input,
function, which is the concentration of contrast in the left ventricle as a function of
time during its first pass, over 50 cardiac cycles using a breath-hold hybrid echo-
planar imaging (EPI) dual sequence approach. The imaging parameters were as
follows: repetition time (TR), 5.1 ms; TE for first echo, 1.02 ms; flip angle, 30°
degrees; base resolution, 128x128 pixels; voxel size 2.8x2.8x8 mm; bandwidth, 1860
Hz/pixel; inversion time (II), 90 ms; parallel imaging T-SENSE R=2; and EPI-
factor of 4.
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Ten minutes after contrast injection for stress perfusion imaging late gadolinium
enhancement images (LGE) were obtained using an ECG-gated expiratory breath-
hold segmented turbo Fast Low Angle Shot (FLASH) gradient echo sequence
(Simonetti et aI., 2001). Images were obtained in all long-axis planes and in the same
short-axis stack as for cine images with the TI optimised to null the normal
myocardium. This was then repeated in an orthogonal phase encoding direction to
exclude artifact. After a minimum of 30 minutes to allow for washout of gadolinium,
rest perfusion images were acquired using the same protocol used at stress.
CMR Image Analysis
All data were analysed by single experienced blinded observer. Global left and right
ventricular parameters (end-diastolic volume, end-systolic volume, stroke volume,
and ejection fraction) and LV mass were determined using a semi-automated
threshold-based algorithm after manual tracing of epicardial and endocardial borders
using commercially available software (CMRtools, Cardiovascular Imaging
Solutions, London, UK). Ventricular volumes and mass were as absolute data and
normalised for individual differences in fat free mass (Batterham et aI., 1999). Late
enhancement and perfusion images were assessed qualitatively to determine the
presence or absence of LGE or inducible perfusion defects respectively.
76
Figure 4.1 LGE images from CMRI
Echocardiography
For assessment of global diastolic filling and segmental cardiac velocity and
deformation characteristics, ultrasound echocardiography (Vivid Q, GE Healthcare,
Norway) was used to gather images of the left ventricle (LV) in the apical 4-chamber
view. A single experienced echocardiographer performed all imaging with the
subject in the left lateral decubitus position.
Doppler was used to assess early (E) and atrial (A) peak diastolic filling velocities
allowing E:A filling ratio's to be equated. Tissue-Doppler imaging (TDI) was
performed to determine peak systolic (S') as well as early (E') and atrial (A')
diastolic tissue velocities in the basal septum. The ratios E':A' and E:E' were
calculated. 2D cine loops of an apical 4 chamber view were stored for off-line
assessment of segmental and global longitudinal E and strain rate (SR) data
(Echopac, GE Heathcare, Norway). Specific speckle-tracking software that tracks
natural acoustic markers or "kernals" facilitated the estimation of £ and SR in six
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wall segments (basal, mid-wall and apical septum as well as basal, mid-wall and
apical lateral wall). These were averaged to provide global measures of longitudinal
E and SR. SR data were recorded in systole (SSR) and early (ESR) and atrial diastole
(ASR). Two-dimensional image optimisation was performed including maintaining
frame rate between 40 and 90 fps. All measurements were made by a single
experienced technician and reflected the average of 3 to 5 continuous cardiac cycles.
Data Analysis
Statistical analysis of data was performed using statistical software package SPSS
Version 17 (IBM Inc., USA). Categorical variables are presented as frequencies and
percentages. All continuous data were subjected to tests of normality and are
presented as mean±standard deviation (SO) for normally distributed variables or as
medians with interquartile ranges for non-parametric variables. Differences between
AS and NAS participants were analysed using independent T-Tests with Levene's
test for uniformity of variance if normally distributed or the Mann-Whitney U-Test if
not normally distributed (e.g. ElA ratio data). Two-tailed values of p<0.05 were
considered significant Correlation analyse'S were run to examine the relationship
between the number of years of AS use or the amount of active AS currently being
taken and LV mass, end-diastolic volume (EDV), end-systolic volume (ESV), peak
wall thickness, and RV EDV and ESV, scaled for fat-free mass as well as for LV and
RV ejection fraction, E:A, E':A', E:E' and longitudinal E. A P value <0.05 was
considered significant.
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4.3 Results
AS Use and Training History
For simplicity we provide a list of exemplar AS used, as well as a mean total AS
weekly dose, but note that all subjects used multiple AS in various stacking
procedures with varied periods of abstinence or "off-cycles". The types of AS
currently being used by the AS group included, Trenbolone (7), Testosterone (6),
Meathandrostenolone (5), Boldenone (4), Nandrolone [Deca Durabolin] (4)
Drostanolone Propionate (3), Stanozolol (3), Sustanon (3) and Oxandrolone (2).
There were large individual variation in the dosages used by participants with a
mean weekly dose of active ingredient being 1201 ± 698 mg (range 250 - 2000 mg).
The number of different AS used in a cycle per participant also varied with a mean
AS per cycle being 3 (range 1-4). An example cycle for one of the participants was
1000 mg per week of Deca-Durabolin with 1000 mg per week of Sustanon. Whilst
training history and regimes did not differ between groups, the AS group had
significantly greater 1 RM for both bench press and squat (see Table 4.1).
Insufficient data regarding aerobic training was provided by the AS participants to
make a comparison between groups. The AS group also provided limited
information regarding their overall length of AS use.
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Table 4.1 Training and performance data for AS and NAS groups (data are mean ±
SD).
AS Non-AS
Years Training 9 ± 4.05 10 ± 6
SessionslWk 4 ± 1 4 ± 1
Avg.Session (min) 74 ± 26 69 ± 8
1RM Bench (kg) 150 ± 36 III ± 18*
lRM Squat (kg) 189 ± 36 132 ± 52*
*= P<O.05,
Anthropometry
There was no significant difference in height, body fat percentage or fat mass
between groups. The AS group were, however, significantly heavier and had
significantly greater, fat free mass, BSA and BMI.
Table 4.2 Anthropometric measures for AS and NAS groups (data are mean ± SD).
AS Non-AS
Height (cm) 178 ± 9 180 ± 7
Weight (kg) 98.2 ± 16.2 80.3 ± 9.0*
BSA (mz) 2.20 ± 0.22 2.00 ± 0.15·
BMI (kg/mi) 30.9 ± 4.2 24.8 ± 1.7*
Fat Free Mass (kg) 83.68 ± 11.95 71.46 ± 7.71*
Fat Mass (kg) 14.44 ± 9.01 8.84±3.10
Body Fat %t 14.1 ± 7.0 10.9 ± 3.3
BSA- Body surface area, BMI= Body mass index, lRM= 1repetition maximum, *= P<O.05,
**= P<0.005
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Blood Pressure
Whilst resting heart rate was significantly lower in the AS users both systolic and
diastolic BP were not different between groups (Table 4.3).
Table 4.3 Blood pressure measures for AS and NAS groups. (data are mean ± SD).
AS Non-AS
Systolic BP (mmlHg) 130 ± 16 125 ± 7
Diastolic BP (mmlHg) 70± 10 66 ± 10
Resting HR(beats.min·l) 74± 8 60 ± 7**
BP= Blood pressure, HR= Heart rate. "''''= P<O.005
CMRl
Peak wall thickness, LVEDV and LV mass were increased in AS users but this was
largely due to an increased FFM as scaled data were not different between groups
(Table 4.4). A similar pattern was observed for RVEDV. LV SV and EF were
similar between groups but RV EF was significantly reduced in AS users because of
a significantly elevated RVESV. There were no positive perfusion defect scans or
positive LGE scans for the presence of interstitial fibrosis in either group.
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Table 4.4 Cardiac MRI structural and functional measures in AS and NAS groups.
(data are mean ± SD).
AS Non-AS
PeakWT(mm) 12.8 ± 2.2 9.4 ± 1.3**
Peak WT/ffm*O.33 0.51 ± 0.12 0.44 ± 0.10
LV EDV (ml) 201.2 ± 27.6 187.5 ± 28.4
LV EDV/FFM (ml/ffm·l) 2.47 ± 0.57 2.65 ± 0.47
LV ESV (ml) 79.3 ± 15.3 70.6 ± 14.7
LV ESV/FFM (mllffm-I) 0.97 ± 0.25 0.99 ± 0.22
LVM (g) 215±47 163 ± 27*
LVM/FFM (g/ffm-I) 2.64 ± 0.76 2.32 ± 0.48
RV EDV(ml) 225.9 ± 40.8 199.8 ± 39.6
RV EDV/FFM (mllffm-I) 2.55 ± 1.04 2.81 ± 0.59
RV ESV (ml) 110.4 ± 24.7 83.1 ± 23.0*
RV ESV/FFM (ml/ffm") 1.25 ± 0.54 1.17 ± 0.35
LV SV(ml) 122 ± 13 117 ± 16
LV EF (%) 61 ± 3 63 ± 3
RV SV (ml) 115±19 117± 18
RV EF(%) 51 ± 4 59 ± 5**
Perfusion defect All Negative All Negative
Late Gad All Negative All Negative
LV-Left ventricle, EDV= End-diastolic volume, ESV= End-systolic volume, SV= Stroke
Volume, EF= Ejection Fraction, LVM= Left ventricular mass, RV= Right ventricle, WT=
Wall thickness, FFM= Fat free mass, Gad= Gadolinium. *= P<O.05, **= P<O.005
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Echocardiography
There was no significant difference in early (E) diastolic filling velocities between
groups (Table 4.5). Atrial (A) diastolic filling velocities were significantly elevated
in the AS group, leading to a significant reduction in E:A. Peak E' and E'/A' were
significantly reduced and A' significantly elevated in the AS group. In addition, E:E'
was significantly higher in the AS group. Longitudinal E was significantly reduced in
the AS group whilst the mean longitudinal SR data and peak S' tissue velocities
were not different between groups.
Table 4.5 Echocardiographic data for AS and NAS groups (data are mean ± SO).
Measure AS Non-AS
E (cm.s") 66 ± 0.11 77 ± 0.20
A (cm.s") 52 ± 0.08 38 ± 0.61 **
E:At 1.29 1.88**
S' (cm.s") 9± 0.01 10 ± 0.02
E' (cm.s-I) 9 ± 0.02 13 ± 0.23**
A' (cm.s-') 10 ± 0.02 7±0.01**
E':A't 1.14 1.78**
E:E't 7.32 5.66*
Longitudinal E (%) -14.15 ± 2.58 -16.58 ± 1.87*
Peak S SR (.s-I) -0.99 ± 0.22 -1.14 ± 0.11 **
Peak E SR (.s-') 1.40 ± 0.36 1.65 ± 0.28
Peak A SR (.s-') 1.01 ± 0.34 0.72 ± 0.25
E:ASR 1.44 2.86
E= Early Diastolic Filling, A= Late Diastolic Filling, E:A= Early:Late Diastole Ratio
S'=Systolic tissue velocity, E'= Early Diastolic tissue velocity,
A'= Late Diastolic tissue velocity, E':A'= Early:Late Diastolic tissue velocity ratio. [=
Strain, SR= Strain Rate, *= P<O.05, **= P<O.005, t= Data given as Median.
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Correlation analyses produced only small and non-significant associations between
years of AS use or the amount of current active AS used by the AS participants with
cardiac morphology or functional parameters. The ratio E:E' was moderately but
significantly correlated with years of AS use.
Table 4.6 Correlation Coefficients of MRI and Echocardiography measures to years
of AS use and amount of current AS use.
Measure Years of AS Use
LVM/FFM (g/ffm-I) -.257
LV-EDV/FFM (mllffm-I) -.306
LV-ESV/FFM (ml/ffm-I) -.336
LV-EF (%) .265
RV-EDV/FFM (ml/ffm") -.271
RV-ESV/FFM (mllffm-I) -.320
RV-EF (%) .296
Peak WT (mm) .043
E:A -.430
E':A' -.339
E:E' -.586*
Longitudinal E (%) -.111
Current Active AS Use
-.491
-.362
-.282
-.190
-.407
-.338
-.392
-.212
-.254
-.175
-.170
-.548
LV-Left ventricle, EDV= End-diastolic volume, ESV= End-systolic volume, SV= Stroke
Volume, EF= Ejection Fraction, LVM= Left ventricular mass, RV= Right ventricle, WT=
Wall thickness, FFM= Fat free mass, E:A= Early:Late Diastole Ratio, E':A'= Early:Late
Diastolic tissue velocity ratio, [= Strain. *= P<O.05,
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4.4 Discussion
This study contributes significantly to previous research in this area by offering a
unique insight into the effects of AS use/abuse on cardiac structure and function, by
using gold-standard imaging techniques. To the authors knowledge this is the first
time that cardiac MRI has been used in this population and the novel data produced
from this study adds to the extant literature regarding the cardiac effects of anabolic
steroid use/abuse. Specifically, the use of MRI demonstrated bi-ventricular
enlargement in AS users (largely in line with lean mass changes), a reduction in RV
EF and a decline in indices of LV tissue velocity and deformation. Despite this, we
observed no perfusion defects or the presence of interstitial fibrosis in any resistance
trained athlete using AS.
In the first instance, this study has confirmed the association of AS use with
significant morphological changes in the LV. The significantly greater peak LV wall
thickness and LV mass observed in the AS users in the present study is in agreement
with previous echocardiographic findings (Urhausen et al., 1989, Sachtleben et al.,
1993). It is also of interest that the quantitative differences in wall thickness and LV
mass observed in the present study are comparable to the findings of previous
echocardiographic studies (Sachtleben et al., 1993, Urhausen et al., 1989). Other
studies have reported greater wall thickness and LV mass in AS users and controls
(Baggish et al., 2010). Whilst research has shown a good correlation between
echocardiographic assessment of LV mass compared to necropsy (Devereux et al.,
1986), more recent data has shown significant discrepancies between
echocardiography and MRI (Stewart et al., 1999). The differing geometric
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assumptions and equations used in the echocardiographic assessment of LV mass
also have a significant effect on the outcome values when compared to MRI, with a
propensity to significantly overestimate LV mass (Missouris et al., 1996, Pluim et
al., 1997). Consequently, a question may be placed over some
echocardiographically-derived data reporting more substantial increases in LV mass
in AS users. The increase in LV mass in AS users persisted when indexed to BSA,
which is the "classical" clinical approach to scaling and is supported by professional
guidelines (Lang et al., 2005). When indexing was performed by scaling to an
estimate of fat free mass, as is currently supported by empirical data and reviews
(Batterham et al., 1999, Dewey et al., 2008), the between group difference in LV
mass largely disappeared. The AS users had a significantly greater fat free mass,
which can be explained by findings that show an up-regulation of protein synthesis
associated with AS use when used in conjunction with resistance training (Ferrando
et al., 1998). This would suggest that cardiac morphological changes occur together,
both qualitatively and quantitatively, with changes in skeletal muscle mass. There is
some common sense to this as both cardiac and skeletal muscle tissue have androgen
receptors to which AS may bind and promote protein anabolism (McGill et al.,
1980). It is also possible that an increase in fat-free mass could have an indirect
effect on cardiac morphology, due to an increased demand for blood placed on the
heart through an increase in muscle mass, requiring an increase in cardiac muscle to
cope with demand.
The increase in LV mass and wall thickness in AS users in the current study was also
accompanied by a significant impact on function. Whilst global measures such as
LV EF were not different between groups, supporting other data (Angell et al.,
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2011), there was a significant reduction in longitudinal [' as well as alterations in
diastolic function in AS users. This is in agreement with the findings of 8aggish et
al. (2010) and D'Andrea (2007) who also reported significant reductions in
longitudinal [' in a group of AS users. In addition, we demonstrated a significant
reduction in diastolic function in AS users through Doppler and Tissue Doppler
measures which has been shown in previous studies (Kasikcioglu et al., 2009, Nottin
et al., 2006, Krieg et al., 2007). When combined, these functional data highlight that
AS use could be associated with reduced cardiac functional capacity.
We have also demonstrated, for the first time, significant effects of AS on RV
structure and function. An increase in RV EDV is commensurate with a global effect
of AS use on cardiac morphology and again these changes appear to be in line with
group differences in estimates of fat free mass. Interestingly, and at odds with the
effect on the LV, there was a significantly lower RV EF in AS users. RV EF is a
global measure of systolic function and contractility in the RV and when assessed
via MRI is highly accurate (REF). The lower RV EF in the AS users is a
consequence of an increase in RVESV as opposed to a relative change in RV EDV.
The increased RV ESV points to an intrinsic alteration in RV contractility although
measures of pulmonary pressure, and thus RV afterload, are not available. The
cause(s) and consequences(s) of this change in RV function are difficult to deduce
from this cross-sectional, cohort descriptive study. However, a role of changes in
pulmonary pressure, possibly due to polycythaemia cannot be discounted. It may
also reflect the fact that the RV is more susceptible to the acute impact of exercise
sessions. There is recent data (La Gerche et al., 2011) that has documented that the
relative increase in afterload in the pulmonary circulation is greater than that in the
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systemic circulation when exercise IS imposed. La Gerche and others have
speculated that there may be a link between the impact of acute, prolonged exercise
on the RV and the development of an ARVC-like RV phenotype, that may also
explain the increased risk, in some, of significant arrhythmias of RV origin
(Heidbuchel et al., 2003, Ector et al., 2007). Most of this recent data has been
described in endurance athletes performing prolonged but submaximal exercise.
Whether this hypothesis transfers to intermittent resistance-type exercise, that may
be further complicated by the use of AS is highly speculative but worthy of on-going
research. We do know that heavy resistance exercise (MacDougall et al., 1985) can
induce massive alterations in blood pressure and afterload in the systemic
circulation. It would be a fair assumption that these changes also occur in the
pulmonary circuit, especially in the presence of a valsalva manoeuvre, and this could
be more significant in a lower pressure system.
Doppler-derived reductions in RV diastolic function have been observed in AS users
(Kasikcioglu et al., 2009) but these require substantiation with newer techniques
such as myocardial speckle tracking that has been used in the interrogation of RV
function in an athletic setting recently (Oxborough et al., 20 I0). This would provide
another important avenue of on-going research.
The reduced LV and RV functional data associated with AS use would imply that
AS use and concomitant resistance strength/training could impair both the
contractility and relaxation of the myocardium. The reasons for this impairment are
still somewhat unclear, however, a number of mechanisms have been postulated.
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Research by D' Ascenzo et al. (2007) suggested that AS can cause an increase in
collagen cross-links across cells. This would imply that the myocardium would
become more rigid and have reduced compliance, which would be in agreement with
previous research which found reduced diastolic function in AS users indicated by
reductions in early ventricular filling with concomitant increases in late atrial filling
(Angell et al., 2011). In addition, work by Zaugg et al. (2001) found that AS induced
apoptosis in rat myocardial cells, however this was seen using very high doses of
AS. This suggests that AS could impair individual myocardial cell function by
altering its development. Confirming such processes in a human model is very
problematic. Although alterations in electrical conduction capabilities and
repolarisation of myocytes have also been suggested as a possible mechanism for
alterations in cardiac function, recent data has been contradictory at best (Maior et
al., 2010, Bigi and Aslani, 2009).
Resting heart rates were significantly elevated in the AS group, which agrees with
Angell et al. (Angell et al., 2011). Whilst it has been suggested that AS use can
interfere with cardiac electrical signalling (Bigi and Aslani, 2009), it is unclear if this
is a direct effect of anabolic steroids or a coincidental finding. It is also interesting to
note that, in the present findings, mean systolic and diastolic blood pressure
measures were higher in the AS group, although these did not reach a statistically
significant level.
Despite significant changes in morphology and function of the LV and RV of AS
users, as well as known alterations in lipid profiles of AS users suggestive of
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significant atherosclerotic risk (Angell et al., 2011), we observed no perfusion
defects in any of the AS users or the resistance-trained athletes. This would suggest
that these AS using athletes were not at an elevated risk for any overt ischemic event,
associated with exercise stress that could be related to a blood flow limitation.
Alternatively, we hypothesised that there may be case evidence of interstitial fibrosis
in some of the AS users that may provide an arrhythmic trigger and could link AS
use to case studies of cardiac events such as MI or sudden cardiac death. Again we
found no evidence of fibrosis in the AS users, or indeed in the non-using resistance
trained athletes. In this cohort, at least, these mechanistic pathways are not apparent.
Future work may wish to re-evaluate the issue of perfusion defects or fibrosis in a
larger sample of resistance-trained athletes using AS. It may be pertinent to place an
emphasis on those that have used the highest AS doses for the longest periods of
time (and may have significant elevations in other cardiovascular risk factors such as
altered lipids and elevated CRP).
The implications of the current data are that they add weight to the belief that AS use
places the cardiovascular system under singificant strain and likely increases the risk
of future cardiovascular events. When we add RV morphology and function to
previous data from this thesis and others; for example a mal-adjustment in lipid
profiles (Hartgens et al., 2004, Lane et al., 2006) concerns are raised about the long
term cardiovascular health of AS users.
Whilst we feel that this study offers a unique insight in to the effect of AS on cardiac
structure and function, it is limited by methodological issues that are inherent within
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the area of research related to elicit AS use. Variations in drug stacks, dosages and,
cycle composition lengths make a definitive statement regarding the effect of AS
dose somewhat problematic. Whilst we attempted to address this through
correlational analysis, only modest correlations were noted between cardiac
measures and the number of years of AS use or the amount of AS currently being
taken. This does, however, highlight the possible short-term, as well as reversibility,
of the negative effects of AS. An important factor that is extremely difficult to
control for however, is the volume of AS used throughout the users lives as well as
the quality of AS used and the actual amount of active ingredient that is present in
any of the substances that they have ever used. In addition, despite little difference in
time spent training, it is difficult to account for the individual differences in the
volume and intensity of training regimes used both between and within groups.
Future research should focus on the role of the RV and the novel use of speckle
tracking in the RV in this group would further develop a knowledge of the global
cardiac effect of AS use. Further to this, the vast majority of research into the effects
of AS use has been conducted at rest. The ability of the body to cope with the
stresses of exercise is an important issue that is not well understood in AS users.
In summary, the unique application of MRI in this study confirms that AS use is
associated with an LV hypertrophy and changes in LV function, primarily in
diastole. Further this study presents new data on RV enlargement and a reduction in
RV EF in AS users. Whilst this study documents further evidence of cardiac
structural and functional adaptation to AS use we did not observe any evidence of
perfusion defects or the presence of interstitial fibrosis in AS users. Based on this
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and other previous data we speculate that AS results in a significant increase in the
risk of CV disease progression and events.
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Chapter 5. Cardiovascular responses to resistance exercise: A
pilot/feasibility study of two concepts.
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5.1. Introduction
Despite the complex nature of research associated with AS use, a pattern of
potentially negative cardiovascular consequences, such as altered lipid profiles and
changes to cardiac morphology and function are beginning to emerge (Hartgens and
Kuipers, 2004). This is supported by empirical data presented in this thesis using
state-of-the-art technology. A reduction in the capacity for the myocardium to relax,
coupled with altered vascular function in AS users (Lane et aI., 2006, Ebenbichler et
al., 200 I, Sader et al., 200 I) suggests an increased CV risk. Despite this we found no
evidence of perfusion defects or the presence of any interstitial fibrosis in AS users
in the previous chapter and thus the link between AS use and a mechanism that may
promote specific cardiac events, as observed in many case studies, is still lacking.
When the literature base associated with the consequence of AS use for
cardiovascular health is viewed in its entirety, a striking observation is that most
studies are completed at rest. Whilst the logistics of that are understandable,
especially given problems associated with non-invasive imaging during exercise, this
represents a weakness when linking AS use to cardiovascular risk. When anyone
exercises the cardiac workload and stress are increased and it is more likely that
cardiac health problems maybe "unmasked". We know that exercise per se increases
the risk of cardiac events and sudden cardiac death in virtually all groups, from
healthy through to pathology (Thompson et al., 2007). As a consequence, the focus
of this exploratory chapter is cardiovascular responses to exercise and recovery in
AS users.
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The study of cardiovascular function during exercise and recovery is pertinent for
other specific reasons. AS users engage in predominantly resistance exercise
training and previous research has suggested that resistance exercise causes a marked
acute increase in both systolic and diastolic pressure in both healthy (Sale et al.,
1994, Greer et al., 1984, Palatini et al., 1989) and diseased patients (Hung et al.,
1982). Classic work by MacDougall et al. (1985) reported significant increases in
both systolic and diastolic blood pressures to a mean of 320 and 250 mmHg during
double leg-press exercise to failure, with one subject recording pressures exceeding
480/350 mmHg. The authors speculated that this extremely large increase in
pressures is caused by; an increase in cardiac output, sympathetic drive,
intramuscular pressure and the valsalva manoeuvre (MacDougall et al., 1985). There
is very limited data in AS users with respect to the blood pressure response to
exercise with some saying it is augmented (Riebe et al., 1992) with others
disagreeing (Sader et al., 2001). The nature of any blood pressure response to
exercise in AS users should also pertain to activities commonly undertaken during
training. The consequence( s) of the significant blood pressure response to resistance
exercise for cardiovascular function and control during exercise have not been fully
described in either users or non-users of AS. Specifically, it may be pertinent to
understand the role of heavy resistance exercise (acute double leg press), with and
without valsalva, on cardiac electrical activity, cardiac function and arterial blood
pressure in AS users and resistance-trained controls. This provides the rationale for
the first part of the exploratory data collection reported in this chapter.
Cardiovascular function during recovery IS a research topic that has multiple
applications. Rapid recovery of HR is often regarded as a key measure of
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cardiovascular fitness and the concept of post-exertional hypotension has been
assessed in endurance and resistance exercise settings as a potential process by
which exercise can promote healthy blood pressure regulation (Jones et aI., 2007).
Of specific interest in the chapter is the concept that acute exercise may result in a
transient cardiac fatigue as well as the appearance of biomarkers of cardiac cell
damage (Shave et al., 2010b). There is a growing evidence base that acute but
prolonged endurance exercise may be followed by a transient reduction in cardiac
systolic and diastolic function during recovery (Oxborough et aI., 2010).
The combination of exercise-related circumstances (mode, intensity, duration,
volume etc.) that promote "cardiac fatigue" is not broadly described as most
available evidence is restricted to endurance-based field studies (George et al.,
2008). The impact of other exercise modes is important to determine but to date we
are aware of only one study that has assessed the cardiovascular response to acute
resistance training (Carranza-Garcia et al., 2011, Stephenson et al., 2005).
Stephenson et al. (2005) study suggested that cardiac function was unaltered during
recovery from resistance exercise but intensity was only moderate and relatively
insensitive cardiac techniques were employed. The second study proposed in this
chapter aims to build on this work.
The mechanism(s) underpinning exercise-induced cardiac fatigue are largely
unknown. Despite this many have promoted the idea that cardiac fatigue is
consequent to small pockets of cardiomyocyte damage (Scharhag et al., 2008). This
is based upon the description, in many studies, that cardiac fatigue occurs at the same
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time as an elevation in serum biomarkers of cardiac cell damage (Shave et al.,
2010a). The most common biomarker used is cardiac troponin (either cTnI or cTnT)
that are regulatory proteins present in cardiac muscle. They are cardiac-specific and
commonly used as a marker of cardiac damage following myocardial infarctions and
acute coronary events (Ammann et al., 2004). Whilst cTnI and cTnT are widely
reported to be elevated after endurance exercise (WHYTE et al., 2000, Shave et al.,
2010a) a recent study by Shave et al. (201Oa) noted that cTnI was increased after as
little as 30 min of fatiguing, high intensity running exercise. The response of c'Tnl to
high intensity resistance exercise is not known. Neither are we aware of whether the
use of AS will mediate cardiac biomarker release, or indeed the development of
cardiac fatigue.
NT -pro B-natriuretic peptides (NT -proBNP) is another cardiac biomarker often
reported to be elevated after prolonged exercise that is used clinically to provide
evidence of chronic cardiomyocytes stretch that underpins poor LV function (Bhalla
et al., 2004, Atisha et al., 2004). As with cTnI, little is known about the response of
NT -proBNP to resistance exercise. This drives the specific rationale for the second
exploratory trial reported in this chapter.
As this final empirical study is exploratory in nature we make no a-priori statement
of hypotheses and we have recruited small numbers, in the first instance, to pilot the
feasibility of this work.
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5.2 Methods
Subjects
Strength trained individuals (n=12) were recruited for both studies through local
gyms, personal contacts and local syringe exchange programmes. Posters and
information sheets were placed in various locations and also distributed by hand to
individuals. The posters stated that there was a study investigating the acute effects
of resistance exercise, either with or without the use of AS, on cardiovascular
function. Inclusion criteria were; participants aged between 18 and 50 years of age;
resistance training history of minimum of 2 years with 3-4 training sessions per
week. Exclusion criteria for the study were the presence of known respiratory, CV
or musculoskeletal disease. Specific inclusion criteria for the AS using group
included a documented self-report history of AS use for at least 2 years (including on
and off-cycles). Inclusion criteria for the non-AS (NAS) group included self reported
history of never taking AS. Prior to taking part in the study, details of each part of
the testing were described to each of the participants. The study was granted ethics
approval from the Liverpool John Moores Ethics Committee and participants
provided written informed consent. Training history included data on years of
training, the average number and length of sessions per week, as well as self-
reported one repetition maximums for the bench press and squat (Table 5.2). Those
in the AS group provided a detailed history of AS use including names, dosage and
cycling information and none of the participants self-reported co-abuse of any other
illicit substances. For simplicity we provide a list of exemplar AS used but note that
all subjects used multiple AS in various stacking procedures with varied periods of
abstinence or "off-cycles". The types of AS currently being used by the AS
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participants included Sustanon, testosterone, deca durabolin, Boldebolin and
Proviron. Of those in the AS group that provided sufficient information to perform
an analysis of their daily usage (n=4), we found that the mean AS dose was 1600 ±
692 mg/day (range 800-2000 mg/day).
Design
In both instance a mixed model design was employed. A between groups analysis
was utilised to compare AS users with non-AS users and repeated measures were
observed as various aspects of cardiovascular function and biomarkers were recorded
at different time points.
In both trials participants were required to make two visits to our laboratory and
gym. Initially, subjects completed self-report questionnaires related to general health,
training status and history as well as detailed accounts of AS use. After this a main
testing session was conducted on the participants following an overnight fast, as well
as a 24hr abstention from resistance training. Specific trial details will now be
confinned.
Trial}
In this study participants (AS n=4, Age= 31 ± 6; NAS n=8, Age=23 ± 2) were
assessed at rest, at multiple points during acute leg press exercise at 90% 1 RM
(concentric, isometric and eccentric phases) as well as during recovery. Trials were
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undertaken with and without the performance of a valsalva. Participants were asked
to cycle at 60 rpm on a bicycle ergometer (Recline Exercise Bike 500, Technogym,
Italy) for 5 min prior to testing and were then seated in a semi-recumbent leg press
machine. Following a warm-up of 3-5 repetitions, at 3 different, but increasing
weights, participants performed 4 leg-press repetitions (2 valsalva and 2 without
valsalva). During each repetition, participants were required to take the weight and
perform a leg press until the knee was at approximately 90 degrees. Each repetition
lasted a total of 9 seconds with a 3 second descent, a 3 second hold at the bottom of
the lift followed by a 3 second extension, returning the bar to its starting position.
This was to allow for peak measurements during concentric, isometric and eccentric
contraction phases. Due to limitations in data collection, the highest peak of a
measure was taken irrespective of where it occurred. There was a one minute rest
between each repetition.
Blood Pressure and ECG
After a standardised warm-up noted above subjects had blood pressure and a single
lead ECG recorded continuously during a 10 min seated resting period. Arterial
blood pressures were recorded from the right forefinger via an automated blood
pressure monitor (Finometer PRO, Finapress, Amsterdam, The Netherlands).
Comparisons of finger arterial blood pressure measures and intra-arterial BP have
shown that finger areterial BP gives a satisfactory representation of arterial BP
(Imholz et al., 1998). A single-lead ECG (VS) was also monitored and recorded
continuously at 200 Hz using an analogue-to-digital converter (Powerlab/16SP
ML795, AD Instruments) and displayed on a PC computer with commercially
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available software (Chart version 7, AOInstruments), in order to infer stroke volume
and cardiac output.
Echocardiography
A commercially available ultrasound echocardiography system (Vivid Q, GE
Healthcare, Norway) was used to gather images of the left ventricle (LV) in the four-
chamber long-axis apical acoustic window. Because of the repeated measures data
capture during these trials over short time periods (3 s for each portion of the lift),
we were limited to one acoustic view and one imaging mode. To capture LV systolic
and diastolic functional indices we utilised pulsed-wave tissue-Doppler imaging
(TOI) with a 2 mm sample volume placed in the mid-wall of the septum at the level
of the mitral annulus. Care was taken to image the septal wall parallel to the
ultrasound beam. We continuously recorded tissue velocities that included in each
cardiac cycle; peak systolic (S ') as well as early (E ') and atrial (A') diastolic tissue
velocities. A single experienced echocardiographer performed all imaging with the
subject in a reclined position on the leg press machine. Intra-observer reliability for
TOI data has been assessed and published within our laboratory (Chan-Dewar et al.,
201Ob, Chan-Dewar et al., 2010a)
As this was a feasibility or exploratory trial with low numbers, data analysis was
completed descriptively.
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Trial2
In this study measurements of cardiac function, blood pressure and biomarkers of
cardiac cell damage and stress (serum samples) were taken at rest and following a
full body resistance exercise session (AS n=5, age=29 ± 5yr; NAS n=6, age= 25 ± 1
yr). The exercise protocol consisted of a warm-up on the stationary bike for 10
minutes, followed by the full body resistance exercise routine. The exercises
performed included the back squat, bench press, bent-over row, behind-neck press,
preacher curls and triceps extensions. Each exercise was performed for 8-12 reps for
3 sets with one minute rest between each set. Each participant had a I RM assessed
a-priori and resistance was then assigned for each activity (Table 5.1). The total
resistance exercise session duration was c. 60 minutes and repeat assessment of
cardiac function, blood pressure and biomarkers were made at 15 min of recovery.
Relative exercise intensity for each exercise was determined according practice trials
in a small group of regular resistance trainers.
Table 5.1. Relative exercise intensity per exercise.
Exercise % lRM (relative to what exercise)
Squat
Bench Press
Bent-Over Row
Behind-Neck Press
Preacher Curl
Triceps Extension
70% (Squat)
70% (Bench Press)
50% (Bench Press)
50% (Bench Press)
20% (Bench Press)
15% (Bench Press)
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Blood Pressure
Duplicate brachial artery blood pressures were recorded from the left arm via an
automated blood pressure monitor (Dinamap; GE Pro 300V2, GE Healthcare).
Blood Samples
Venous blood (5 ml) was collected from the brachial antecubital vein directly into
serum gel (serum) vacutainers (BD, Oxford, UK). Blood was allowed to clot (-45
min), centrifuged for 10 min at 3000 rpm and stored at -80°C for later analysis. cTnI
was determined using the TnI-Ultra assay for Advia Centaur XP immunoassay
system (Siemens Medical Solutions Diagnostics, Frimley, Surrey). Assay detection
limit was 0.006 ug/L with a linear calibration range up to 50 ug/L (Apple et al.,
2008). Assay precision in our laboratory was estimated as 10% CV at 0.045 ug/L
(Collinson et al., 2009). NT-proBNP was determined using the NT-proBNP assay
for Immulite 2500 (Siemens Medical Solutions Diagnostics, Frimley, Surrey). The
assay detection limit was 20 pg/ml with a linear calibration range up to 35,000 pg/ml
(Gardner et al., 2003).
Echocardiography
Global and segmental cardiac function were assessed using ultrasound
echocardiography (Vivid Q, GE Healthcare, Norway). A single experienced
echocardiographer performed all imaging with the participant in the left lateral
decubitus position. In our laboratory intra-observer reliability has been assessed
through intra-class correlations for 2D, Doppler, TO!, and £/SR data (Chan-Dewar et
al., 2010a, Chan-Dewar et al., 2010b), with a range ofO.693-0.993 (P<0.05).
103
Specifically, parasternal long axis views allowed the collection ofM-mode images of
the LV at the tips of the mitral valve leaflets perpendicular to septal and posterior
walls taking care to ensure clear endocardial definition. From M-mode traces septal
(IVSd) and LV posterior wall thickness (LVPW d) in diastole as well as the LV
chamber dimension at end-diastole and systole (LVIDd, LVIDs) were assessed
following American Society of Echoardiography guidelines (Lang et al., 2005). We
estimated LV mass using a regression corrected cube formula (Devereux et al.,
1986). Apical 2 and 4-chamber views were digitised to asses LV end-diastolic
(LVEDV) and end-systolic (LVESV) volumes which then allowed the estimation of
stroke volume (SV) and ejection fraction (EF) using Simpsons' bi-plane method.
From the 4-chamber colour Doppler and then pulsed wave Doppler were used to
assess peak flow velocities across the mitral valve. Using a 4 mm sample volume in
the area of peak flow LV early (E) and late (A) diastolic in-flow inflow velocities
were recorded. From the same view tissue-Doppler measures of myocardial wall
velocities were recorded. Taking care to adjust filters and scale and with the septal
wall parallel to the ultrasound beam we interrogated the mitral annulus at the septal
wall, recording peak systolic (S ') as well as early (E') and atrial (A') diastolic tissue
velocities. This also allowed the production of the E/E' ratio that has been shown to
estimate left atrial pressure (Nagueh et al., 1997).
Segmental and global E and SR data were obtained from parasternal short axis views
at the base (just below mitral valve) and apex (1-2 cm above LV cavity obliteration)
as well as via a 4-chamber apical view. Cine loops of LV motion were captured for
off-line analysis (Echopac, GE Heathcare, Norway). Specific speckle-tracking
software that tracks natural acoustic markers, or "kernals", facilitated the estimation
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of E and strain rate (SR) in six wall segments in all views. In short axis views the LV
was split into septal, anteroseptal, inferior, posterior, anterior and lateral wall
segments. Radial and circumferential data from these segments were averaged to
provide global E and SR data. SR data were compiled during systole (S SR), early
diastole (E SR) and atrial diastole (A SR). In the apical 4-chamber axis view the LV
was split into basal, mid-wall and apical septal wall segments as well as basal, mid-
wall and apical lateral wall segments. Again these were averaged to provide global
measures of longitudinal E and SR. Two-dimensional image optimisation was
performed including maintaining frame rate between 40 and 90 fps. Data reflect the
average of 3-5 continuous cardiac cycles.
Data analysis was descriptive on the basis of this being a pilot or feasibility study.
5.3 Results
Trial]
Body Composition and Performance
There was no substantial difference in height or weight between the two groups and
the weight lifted during the leg press was similar between the two groups, although a
higher mean was observed in the NAS group.
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Table 5.2 Anthropometric and Exercise Data
AS NAS
Height (cm)
Weight (kg)
Weight Lifted (kg)
180 ± 7
85 ± 11
210 ± 69
161 ± 38
91 ± 34
225 ± 36
Heart rate, stroke volume systolic and diastolic blood pressure were different
following exercise compared to baseline, whilst there was no meaningful difference
between the valsalva to non-valsalva exercise conditions. Systolic blood pressure
was higher in the AS group at rest and had a greater peak during both exercise
conditions.
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Table 5.3 Peak heart rate, BP's, cardiac output and stroke volume at rest and during
valsalva and non-valsalva exercise bouts (data are mean ± SD).
Cardiac Output (1/
min)
AS NAS
Rest 75 ± 9 65 ± 17
Valsalva 95 ± 17 85 ± 16
Non-Valsalva 101 ± 15 90 ± 15
Rest 141 ± 22 131 ± 24
Valsalva 205 ± 83 184 ± 28
Non-Valsalva 200 ± 67 160 ± 29
Rest 62 ± 17 59 ± 14
Valsalva 114 ± 14 100 ± 14
Non-Valsalva 101 ± 18 93 ± 6
Rest 8.95 ± 1.82 10.63 ± 2.30
Valsalva 10.37 ± 2.57 10.96± 2.78
Non-Valsalva 9.66 ± 2.92 10.82 ± 2.24
Rest 73 ± 9 71 ± 24
Valsalva 100 ± 13 96 ± 25
Non-Valsalva 91 ± 16 96.± 26
BP=B1ood Pressure.
Heart Rate (bpm'l)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Stroke Volume (ml)
Both S' and A'measures were higher in the AS group. The difference in A' then
resulted in a lower E':A' in the AS group. E' did not differ significantly between
groups. In both groups E' and A', but less so for S', were increased during exercise
with often higher values during valsalva.
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Table 5.4 Tissue Doppler Measures at rest and during valsalva and no-valsalva
exercise bouts (data are mean ± SD).
E':A'
AS NAS
Rest 0.12 ± 0.02 0.09 ± 0.01
Valsalva 0.16 ± 0.03 0.11 ± 0.01
Non-Valsalva 0.16 ± 0.05 0.12 ± 0.01
Rest 0.12±0.01 0.13 ± 0.01
Valsalva 0.15±0.01 0.16±0.01
Non-Valsalva 0.16 ± 0.03 0.17 ± 0.02
Rest 0.08 ± 0.01 0.06 ± 0.01
Valsalva 0.12 ± 0.02 0.08 ± 0.01
Non-Valsalva 0.12 ± 0.02 0.08.± 0.01
Rest 1.54 2.15
Valsalva 1.31 2.03
Non-Valsalva 1.37 2.10
S'-Systolic tissue velocity, E'=Early Diastolic tissue velocity, A'=Late Diastolic tissue velocity,
E':A'=Earyl:Late Diastolic tissue velocity ratio.
Trial2
Body Composition and Performance
There was no substantial difference between groups for height or weight. A trend in
both of these data resulted in a higher BSA in the AS group. The number of training
sessions per week, average session length and IRM data for both bench press and
squat were similar between groups (Table 5.5). Insufficient data regarding aerobic
training was provided by the AS participants, limiting a comparison between groups.
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Table 5.5 Anthropometric and Training Data (data are mean ± SD).
AS NAS
Height (cm) 181 ± 10 176 ± 5
Weight (kg) 96 ± 21 76 ± 12
BSA (ml) 2.16±0.27 1.91 ± 0.13
SessionslWk 5 ± I 4 ± I
Avg. Session Length (min) 75 ± 15 67 ± 23
1RM Bench (kg) 110±21 105 ± 37
1RM Squat (kg) 105 ± 41 137 ± 48
BSA= Body surface area, IRM= One repetition maximum.
Heart Rate and BP
There was no difference between groups at rest for heart rate, systolic and diastolic
blood pressure. Heart rates increased in both groups, in a similar fashion, following
exercise. Post-exercise systolic blood pressure was unchanged but diastolic blood
pressure dropped in both groups.
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Table 5.6 HR and BP Pre and Post Exercise (data are mean ± SD unless otherwise
stated).
AS NAS
Pre Post Pre Post
HR(bpm- )
Systolic BP
(mm/Hg)
Diastolic BP
(mmlHg)
55± 8
130 ± 10
81 ± ID
131±14
58± 7
122 ±II
84 ± 1
125 ± 7
75 ± 11 67 ± 7 68 ±6 58 ± 2
HR= Heart Rate, BP= Blood Pressure.
Echocardiography
Cardiac structural data were generally higher in the AS group but in both groups this
data did not change after exercise. LV volumes were similar between groups and in
both AS and NAS both LVEDV and LVESV decreased post-exercise. As a
consequence EF did not change in either group after a bout of resistance training.
Data for E, A and E:A were similar at rest in both groups. Post-exercise E declined
marginally, A increased and E:A declined to a similar extent in both groups. The
same pattern was obvious in the TDI data except for the fact that A' data did not
alter post-exercise. E:E' data were slightly elevated in AS users only.
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Table 5.7 Cardiac structural and functional measures pre and post exercise (data are
mean ± SD unless otherwise stated).
AS NAS
Pre Post Pre Post
IVS (mm) 11.2 ± 1.0 10.8 ± 2.0 9.9 ± 1.2 10.9 ± 1.1
LVPW (mm) 11.3 ± 0.9 11.3 ± 0.8 8.4 ± 1.1 9.1 ± 1.6
LVD(mm) 50.1 ± 4.2 48.2 ± 4.5 50.2 ± 2.6 49.21: 2.9
LVM (g) 216±47 198 ± 58 158 ± 27 182 ± 17
LVEDV (ml) 120 ± 22 III ± 25 119 ± 15 110 ± 25
LVESV (ml) 48 ± 16 45 ± 12 51 ± 9 43 ± II
EF(%) 61 ± 6 60 ±4 57 ± 4 63 ± 6
E (cm.s') 84 ± 8 78 ± 22 81 ± 7 74 ± II
A (cm.s") 53 ± 8 65 ± 11 51 ± 3 57 ± 9
E:A 1.60 ± 0.23 1.20 ± 0.33 1.61±O.12 1.32 ± 0.21
S' (cm.s") 10 ± 1 11 ± 1 9 ± I 10 ± I
E' (cm.s") 13 ± 1 11 ± 3 13 ± 2 12 ± I
A' (cm.s'] 9±2 8 ± 1 8 ± I 8 ± I
E':A' 1.63 1.21 1.71 1.58
E:E' 6.55 6.76 6.24 5.85
LV - Left Ventricle, LVD= Left Ventricular Diameter, LVM = Left Ventricular Mass, LVEDV-Left
Ventriculad End-Diastolic Volume, LVESV= Left Ventricular End-Systolic Volume, EF = Ejection
Fraction, E = Early diastolic Flow, A = Late diastolic Flow, E:A= Early: Late diastolic flow ratio,
S'=Systolic tissue velocity, E'=Early Diastolic tissue velocity, A'=Late Diastolic tissue velocity,
E':A'=Earyl:Late Diastolic tissue velocity ratio, E:E'= Early diastolic flow:Early diastolic tissue
velocity ratio.
Longitudinal [' and SR
Longitudinal E and peak SR did not differ markedly between groups and most data
was not altered after a resistance exercise training session. The one variable to
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change was an elevation in A SR in AS users only that resulted in a decline in the
E:A SR ratio in AS users only.
Table 5.8 Pre-Post Longitudinal Strain (data are mean ± SD unless otherwise stated)
AS NAS
Pre Post Pre Post
£(%) -14.8 ± 1.3 -14.1 ± 2.4 -15.0±4.5 -14.3 ± 5.2
SR(.s-t) -0.93 ± 0.06 -1.22 ± 0.30 -1.11 ±0.33 -1.13±0.3
E SR(.s-t) 1.56 ± 0.27 1.56 ± 0.31 1.60 ± 0.38 1.68 ± 0.38
A SR(.s-t) 0.68 ± 0.09 0.97±0.19 0.78 ± 0.20 0.82 ± 0.2
E:ASR 3.56 1.57 2.14 2.26
Circumferential and radial [ and Strain Rate
There was no large effect of exercise or group on circumferential or radial peak rat
basal or apical levels. In addition, no effect of group or exercise was also seen in
peak basal or apical circumferential S SR. A similar pattern was apparent for E SR,
A SR and E:A SR ratio. Generally E SR was slightly reduced post-exercise, A SR
was slightly increased and the ratio was further reduced, often to a greater extent in
the AS users.
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Table 5.9 Circumferential E and SR, in AS and NAS groups (data are mean ± SD
unless otherwise stated).
AS NAS
Pre Post Pre Post
Basal E(%) -15.7 ± 3.7 -14.4 ± 6.2 -15.6 ± 2.3 -14.3 ± 6.2
Level
Peak S SR (.S-I) -1.61 ± 0.34 -1.67 ± 0.21 -1.40 ± 0.25 -1.49 ± 0.24
Peak E SR (.S·I) 1.92 ± 0.27 1.64 ± 0.45 1.75±0.17 1.52 ± 0.46
Peak A SR (.S-I) 0.87 ± 0.33 0.97 ± 0.26 0.52 ± 0.25 0.73±0.15
ElA SR Ratto+ 2.45 1.63 3.35 2.96
Apical E(%) -25.2 ± 4.7 -22.1 ± 5.5 -22.5 ± 5.9 -21.7±9.4
Level
Peak S SR (.S-I) -2.42 ± 0.43 -2.02 ± 0.49 -1.48 ± 0.32 -4.50 ± 6.20
Peak E SR (.fl) 2.69 ± 0.51 2.35 ± l.l3 2.25 ± 0.86 2.00 ± 0.98
Peak A SR (.S-I) 0.87 ± 0.20 1.17 ± 0.27 0.59 ± 0.07 0.97 ± 0.37
ElA SR Ratio+ 4.02 2.40 3.47 2.20
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Table 5.10 Radial E and SR in AS and NAS groups (data are mean ± SO unless
otherwise stated).
AS NAS
Pre Post Pre Post
Basal E'(%) 27.1 ± 9.5 20.7 ± 28.5 23.7 ± 11.0 27.7 ± 12.9
Level
Peak S SR (.S·I) 1.70 ± 0.49 2.23 ± 0.93 1.43 ± 0.44 2.12±0.51
Peak E SR (.S·I) -1.68 ± 0.54 -1.43 ± 0.68 -1.30 ± 0.50 1.30 ± 0.33
Peak A SR (.s·') -1.36± 1.31 -1.71 ± 1.08 -0.64 ± 0.33 -0.98 ± 0.36
ElA SR Ratie+ 0.93 0.92 1.64 1.79
Apical E'(%) 36.6 ± 31.6 30.1 ± 17.2 20.9 ± 7.6 22.9 ± 16.1
Level
Peak S SR (.s·') 2.32 ± 0.96 2.69 ± 0.59 1.21 ± 0.48 1.45 ± 0.77
Peak E SR (.s·') -3.28 ± 0.99 -2.31 ± 0.41 -1.88 ± 0.83 -2.39 ± 1.02
Peak A SR (.s·') -0.81 ± 0.34 -1.69 ± 0.80 -0.78 ± 0.37 -0.81 ± 0.69
ElA SR Ratio+ 4.65 1.58 2.84 2.78
Bloods
Only one detectable cTnI sample was obtained at rest (AS) and only one detectable
cTnI value was observed post-exercise (AS, but different participant). Both these
detectable values were low and not clinically relevant. At rest NT -proBNP was
marginally higher in the AS group, but no change post-exercise was noted in either
group.
114
Table 5.11 Pre and Post-Exercise cTnI and NT-proBNP data in both groups (data are
mean ± SD; for cTnI the detection limit was 0.02).
AS NAS
cTnl (mg/L)
NT -proBNP (pg/mL)
Pre
Post
Pre
Post
0.024 ± 0.001
0.023 ± 0.007
33.28 ± 15.85
30.45 ± 9.32
0.02 ± 0
0.02 ± 0
24.38 ± 8.92
22.12 ± 3.28
c'I'nl= Cardiac Troponin I, NT-proBNP= N-terminal prohormone of brain natriuretic peptide.
5.4 Discussion
The key finding from this chapter is that the execution of a single resistance exercise
or the completion of a standard resistance exercise programme provides an increase
in stress upon the cardiovascular system and that this may be mediated by AS use.
As pilot, or feasibility, studies some valuable information was garnered that will
inform the progression to full studies. Specifically, the assessment of cardiovascular
function was possible within both protocols although some unique challenges were
encountered. In the leg press exercise we were limited to single window, single
imaging mode analysis (TDI) but the body position occasionally interrupted the
transducer position resulting in abandoned trials. Further, we initially were
interested in assessing blood pressure and cardiac function in short discrete sections
of the lift (3 s concentric lift, 3 s isometric hold, 3 s eccentric lowering). Whilst with
training we could maintain these timings even with a valsalva the current limitations
of data collection tools meant that the acquisition of cardiac functional data
throughout these periods was problematic, hence we simply report here peak blood
pressure and cardiac data. In the "training session" trial 2 the major concern was the
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consistency of post-training assessment time. Past literature has not identified a
single, and most relevant, time so we tried to control this at 15 min post. This
provided 2 challenges; firstly that a prolonged imaging protocol meant that all scans
could not be collected at the same time (scan time c. 10 min) and secondly that the
blood sample could not be taken concomitantly with the echocardiogram. Despite
these technical issues, we feel that advancing with these studies is feasible and
potentially very interesting with minor changes in study design and set-up. In terms
of the data collected, albeit in a small sample of AS and NAS participants, this
feasibility study adds novel data to the area of AS research both during and
immediately following high intensity resistance exercise. Specifically, in trial one a
very high systolic blood pressure was recorded during single repetitions of seated
double leg press that were augmented by AS use, although valsalva did not seem to
alter blood pressure to any meaningful extent. The second trial provides data
suggesting that resistance training can reduce aspects of diastolic function. There
was some sporadic evidence that this may also be mediated by AS use but obviously
requires further verification. Although exploratory, taken together the findings could
indicate a possible increase in CV event risk in AS users during or immediately
following exercise.
Trial1
Heart rate and systolic blood pressure increased in both groups during the acute
resistance exercise movements as would be expected (MacDougall et al., 1985).
Systolic blood pressure was, however, noticeably increased in the AS group in all
conditions compared to NAS. This contradicts some blood pressure data collected in
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AS users at rest including data presented in Chapter 3 and 4 of this thesis. However,
an elevated blood pressure in AS users has been reported before (Riebe et aI., 1992,
Freed et al., 1975). The greater systolic blood pressures observed in the AS
participants during exercise (as well as rest) may mediate and increased CV event
risk during exercises that are commonly employed in resistance training. The strain
of exercise has long been associated with an increased CV event risk in those with
elevated blood pressures (Kurl et aI., 2001). A decreased ability to regulate
haemodynamics (Kasikcioglu et al., 2007), in AS users could help to explain the
association between AS and adverse CV events. It is interesting to note that the peak
systolic blood pressures reported in all participants (AS or NAS) were less than those
reported in the classic paper by MacDougall et al. (1985). This could be explained
by the application of single repetitions in the current study compared to a cumulative
effect of sets at high intensity to failure used in the MacDougall study. This may also
explain the lack of difference (from rest to exercise, between groups and from non-
valsalva to valsalva) in diastolic blood pressure in the current study. Likewise it
seems a single leg-press with and without a valsalva manoeuvre did not alter blood
pressure response. Also, it is pertinent to note that whilst we used a validated non-
invasive blood pressure assessment tool, MacDougall had in-dwelling arterial
pressure catheters for direct blood pressure assessment.
The mechanism(s) behind an increased systolic blood pressure response to a single
leg press will likely include an increase in cardiac output, sympathetic stimulation
and increased afterload (via compression of major arteries in the lower limbs) as
suggested by MacDougall et al. (1985). The exact interplay and importance of each
of these processes is difficult to assess in the current design. Suffice it to say that a
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brief increase in intra-thoracic pressure due to a short-lived valsalva did not alter
these processes. This is despite the understanding that a valsalva will lead to a short-
term decrease in cardiac output from a reduction in preload, mediated by the
increases in pressures normally observed, but this was not necessarily the case in the
present data. The impact of AS in mediating a higher systolic blood pressure at rest
and during these brief exercise trials is also difficult to fully elucidate. An increased
systolic BP response in the AS users could suggest a decrease in arterial
compliance/increased arterial resistance (Franklin et al., 1997). An increase in
arterial resistance, amongst AS users, has been postulated from previous findings
(Kasikcioglu et al., 2007, Lane et al., 2006), although this may be expected to impact
both systolic and diastolic blood pressures. It could be that AS use augments the
rapid increase in cardiac output and/or sympathetic stimulation as this could
influence systolic pressure predominantly.
An augmented sympathetic stimulation may explain the increase in S' observed in
both groups during leg press exercise, which resulted in higher S' during lifts with
and without valsalva in the AS group. An increased afterload or exaggerated heart
rate response (both observed here in AS users) could explain this difference in
systolic tissue velocities. As has been observed in the previous chapters (3 and 4)
and other recent findings (Baggish et al., 2010), AS have been associated with
decreased diastolic cardiac function and ventricular compliance (Angell et al., 2011,
Baggish et al., 2010, D'Andrea et al., 2007, Kasikcioglu et al., 2009). Whilst both
groups had an increase in E' and A' during the exercise bouts; the increase in A',
was greater in the AS users and thus the E':A' was lower in AS users at rest and
during exercise, with or without valsalva. Whilst it is important to note that the
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figures seen in both groups were both within the expected clinical range for the age
group (Stohn et al, 1997), the results would indicate an increased reliance on atrial
diastolic filling both at rest and during exercise in the AS users. In addition, this
would suggest an increase in cardiac workload and stress in the AS users. When
combined with increased systolic blood pressures, during exercise and at rest, these
findings could indicate an increased CV event risk associated with AS use.
Clearly there are constraints and limitations to the design and data collected in Trial
I, not least the very low sample size for AS users. Added to some issues in data
collection it is likely that to move forward with this trial would require some minor
adjustments to data collection and study design. Specifically, we would like to
determine a way of data assimilation to specific aspects of the lift (isometric
components etc) as well as looking at a design that employed cumulative repetitions
to failure, in line with the MacDougall study. Consequently, stopping data collection
at this feasibility stage is sensible to reduce time and expense of staff and
participants. Despite this the current form of this study did detail some evidence of
elevated cardiovascular strain and risk in AS users and thus this is an important
avenue of study to continue with.
Trial2
Trial 2 progressed much more smoothly from the point of view of data collection
thus we collected slightly more data in this feasibility trial. Despite this we still
elected to describe data and outcomes here prior to movement to a more advanced
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study with bigger participant numbers and multiple assessment points during
recovery.
Predictably, both groups had an increase in heart rate following the full body
exercise bout but there was no change in systolic or diastolic blood pressures
following the exercise bout, with no difference between groups. This interestingly, is
at odds with the previous trial but likely suggests a rapid blood pressure recovery
before measurement at 15 min post-training (as well as the potential limitation of
low numbers in both trials). An increased heart rate would be expected to augment
some facets of cardiac function (Giannaki et aI., 2008) whereas the lack of an
increase in afterload would not complicate cardiac functional data interpretation
In both groups LVEDV and LVESV were reduced, to a similar extent, after the
resistance training session. This has been observed after endurance exercise and
competition (George et aI., 2004) and may reflect a hypovolemia associated with
sweat loss due to exercise. It cannot be explained by posture as both pre and post-
training assessments were undertaken in a supine position, which theoretically
maximises LVEDV at rest. With both LVEDV and LVESV decreasing post-exercise
there was no exercise-related drop in EF in either group. This global systolic
functional index has demonstrated a similar lack of effect in a prior study
(Stephenson et aI., 2005) as well as in multiple endurance exercise trials of a similar
duration (Middleton et aI., 2007). The lack of systolic "cardiac fatigue" is borne out
by data for systolic tissue velocities and E that were largely unchanged post-exercise
in both groups. It may be that the total exercise volume and thus stress placed upon
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the heart were not substantial enough in a single intermittent resistance exercise
training session to produce a noticeable fatiguing effect.
Post-exercise there was evidence of an alteration in aspects of LV diastolic function.
Specifically, a reduction in E:A and E':A', were also seen in both groups following
exercise, with a slightly larger drop in AS users. This seems to reflect an alteration in
E, A and E' post exercise. This suggests that both early diastolic filling (active
relaxation and suction) and atrial contraction (atrial contractility and ventricular
compliance) may be altered with such exercise. Data for diastolic SR are more
sporadic but again some support exists for a reduction in global and segmental
diastolic function after resistance training. Again, this maybe more apparent in AS
users, although confirmation is required in a bigger trial. Of interest, an isolated
diastolic cardiac fatigue has been reported after shorter duration/volume endurance
exercise studies (GEORGE et aI., 2004) and may reflect the fact that early diastolic
function is largely dependent on a small mass of longitudinally aligned sub-
endocardial LV cardio-myocytes. A smaller mass of myocytes may be more prone to
fatigue after exercise imposition (the same concept may apply in the RV;
(Oxborough et al., 2010)). Interestingly, Shave et al. (2007) suggested, in a meta-
analysis, that diastolic functional changes after acute exercise bouts were not as
influenced by exercise duration (total cardiac work) as systolic function.
The mechanism(s) underpinning a diastolic cardiac fatigue after a single resistance
exercise training session are currently unknown although a few ideas have been
proposed. Depressed function due to ischemia or cardiac damage has been proposed
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by many (Scharhag et al., 2008) but evidence of a direct link is lacking. Here we
saw no evidence of ischemia on the ECG and biomarkers of cell damage were
sporadic at best. Neither would this theory explain an isolated diastolic cardiac
fatigue. A desensitisation or down-regulation of B-adrenergic receptors in the heart
has been proposed as a mechanism to underpin a reduced chronotropic or ionotropic
drive post prolonged exercise. Some evidence exists to support this (Hart et al.,
2006) but this pertains to prolonged endurance exercise where catecholamine's are
chronically elevated for hours. Also the data of Hart et al. (2006) and others did not
explain changes in LV diastolic function which is what occurred in isolation here.
Others have postulated metabolic reasons for a cardiac fatigue (reduced substrate
availability and calcium handling issues; (Scott and Warburton, 2008)) although no
direct human evidence exists to support these mechanisms. With the current data a
reduced early diastolic filling likely reflects poor active relaxation and this could be
influenced by poor calcium sequestration and sensitivity. An effect of AS use on
cardiac myocytes has been demonstrated in vitro, highlighting a possible increase in
collagen cross-links between myocytes which could offer an explanation for possible
decreases in ventricular relaxation in the AS group (LeGros et al., 2000). It has also
been suggested that AS use could be associated with a negative effect on nitric-oxide
release from vascular endothelial cells, thereby reducing the vasodilatory capability
of the vasculature which could explain the increased afterload and could have a
knock on effect on cardiac function (D'Ascenzo et al., 2007). Irrespective of this
speculation further work is needed to attempt to address putative mechanisms.
The appearance of biomarkers of cardiac cell damage (cTnI) or stress (NT-proBNP)
were limited, small and likely of no clinical significance in the current study (Shave
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et al., 2010b). Detectable cTnI was observed in one AS participant at rest and one
AS user post-exercise. Although concentrations were low and not clinically relevant
the combination with a lack of detectable cTnI in any NAS participant, suggests that
this may be valuable to study in a bigger sample. Recent data from endurance
exercise trials and even short high intensity running suggested a much bigger and
more prevalent release of cTnI with acute exercise. It may be that the current study
reflects the intermittent nature of resistance exercise and that the cardiac stress is
insufficient to consistently activate pathways and mechanisms of cTnI release.
Technically, we are limited by the assessment of one single blood draw post-exercise
and thus on-going studies should develop the data collection in recovery (Middleton
et al., 2007). Although baseline NT -proBNP was slightly higher in AS users the
change with exercise was negligible and similar between groups. This provides more
support that the cardiac stress, stretch or workload associated with a single resistance
exercise training session is quite small (especially in comparison to ultra-endurance
exercise trails reported in previous studies; (Scott et al., 2009)). The higher baseline
NT -proBNP data in AS users are still within normal limits and thus have no clinical
relevance. Despite this, again, confirmation in a bigger study would be valuable.
Overall, the study of an acute resistance exercise training session in AS and NAS
was logistically easier to complete than trial 1. As a feasibility exercise the general
running of the study was successful and thus slightly more participants completed
successfully. Despite this there are important lessons for the development of the
study and specific research questions. Most important of these is the need to collect
post-exercise data (scanning and blood samples) at multiple time points during
recovery.
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General Limitations
It is worth noting that the present studies were based on either single high-intensity
exercise bouts or a single full-body resistance exercise workout and may not reflect a
'typical' AS user's normal exercise programme. Nevertheless, the studies were
designed in such a way so as to illicit the greatest CV response in participants.
Further to this, whilst groups were matched for volume of training, through number
of sessions per week and average length of session, significant variations in training
methods could affect the findings. Future studies could focus on participants through
a typical training period over a number of weeks to examine the cumulative effect of
exercise, as well as AS use on CV parameters. It would be valuable to add measures
of intra-thoracic pressure as well as estimates of LV afterload and wall stress in
future studies. As has been highlighted in previous chapters, there are some
limitations that are inherent within AS research. Individual differences between AS
users and non-users, as well as differences within groups, in training status and
methods can complicate analysis of findings in this area of research. Variations in
AS dose (volume, drug type, authenticity) as well as differences in 'stacking' and
'cycling' procedures between users can further confound the issues surrounding AS
research.
General Conclusions
Despite the limited numbers of participants and some specific design issues related
to these exploratory trials, the studies themselves represent feasible propositions for
on-going study. The findings themselves give some indication of 1) the elevation in
systolic blood pressure with acute resistance exercise that is seemingly augmented
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by AS use, and 2) the impact of an acute resistance exercise training session on a
reduction in LV diastolic function during early recovery, which again may be
partially mediated by AS use. On top of data assessed at rest (Chapter 3 and 4) this
extends the notion that AS could increase CV risk by augmenting CV work during
and after exercise.
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Chapter 6. General Discussion
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There are reports of increased AS use, largely in recreational users as a means of
performance and image enhancement (Lenehan et al., 1996, Korkia and Stimson,
1997). Consequently, the health effects of AS come into sharp focus. The impact of
AS use on the cardiovascular system represents an important public health issue.
This chapter draws together empirical data contained in this thesis. A brief synopsis
of findings is followed by an overarching discussion of developing issues across the
thesis. This section will then reflect on the implications of issues of relevance to AS
users, researchers and clinicians. Self-reflection on limitations related to the studies
in this thesis will serve as a backdrop for suggestions for future research. Finally a
conclusion section will reflect on the original aims and hypotheses stated at the
beginning of the thesis.
6.1 Synthesis of findings
In studies one and two the focus of the data collection was around novel methods for
the assessment of cardiac structure and function. We did view other CV risk data
(e.g. blood pressure, lipids) but these were secondary outcome variables. In both
studies we recruited self-report AS users with varying histories of both training and
AS use. These participants were compared to an age and training exposure-matched
group of non-AS users.
In the first study we reported that resistance training and AS use resulted in a higher
lean mass and significantly greater strength compared to the matched control group.
From a cardiac perspective, LV hypertrophy was apparent in AS users who also
127
demonstrated a reduction in diastolic function compared to controls. Diastolic
function was described using a range of standard and novel imaging procedures. Left
ventricular systolic function was preserved globally although there was some inter-
individual heterogeneity. Secondary findings included a negative alteration in lipid
profile in AS users and a significantly elevated resting heart rate. Blood pressure,
whilst slightly higher was not significantly different between groups. In a small
cohort of case studies from within the AS users we documented changes in cardiac,
blood and body composition data during periods of withdrawal (off-cycles).
Although limited by the sample size and case study approach there was some
suggestion that cardiovascular risk is reduced by periods of abstinence from AS.
In the second study we reported data derived from cMRI and speckle-tracking
echocardiography again in age and training-exposure matched AS users and non-
users. cMRI is the "gold-standard" method for assessing cardiac structure with high
resolution and no requirement for geometric model estimation. As with study one,
we documented LV hypertrophy in AS users that was associated with diastolic
dysfunction determined using a range of ultrasound imaging modes. Uniquely we
described a RV hypertrophy that was also associated with a decrease in RV ejection
fraction. Despite these changes in cardiac structure and function we found no
individual evidence of perfusion defects or interstitial fibrosis that were speculated
as potential links between AS use and cardiac events.
For the third study we adopted a developmental approach which focused on the
cardiac response to exercise in AS users (and matched controls). This pilot study was
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set up to assess the feasibility of two different approaches to assessing the impact of
resistance exercise upon cardiac function in AS users. In trial one, we adopted an
acute single repetition model using a double leg press, with and without valsalva, on
blood pressure regulation, heart rate and cardiac function (using TO! only). In trial
two we adopted the "cardiac fatigue" model of assessing cardiac function at rest and
then in early recovery from a standard resistance training session. Despite small
numbers due to technical issues and the nature of the feasibility approach, the AS
users demonstrated a much larger systolic blood pressure response to a double leg
press, with or without valsalva as well as subtle differences in the response of
cardiac function, notably in diastole. After a model resistance training session LV
systolic function was well maintained in both AS users and non-users. LV diastolic
function was altered during recovery in both groups but the effect may be more
pronounced in AS users. An elevation in cTnT above detection limits occurred only
in AS users (1 pre-exercise and 1 post-exercise) but these responses are too limited
to draw any conclusions. NT -proBNP was higher at rest in AS users but there was no
meaningful exercise response. All cTnT and NT -proBNP values were below clinical
cut-off levels.
6.2 Overarching Issues
Through the comprehensive approach taken in study one and study two as well as the
feasibility trials in study three some points related to the empirical data were raised
directly or in-directly on a number of occasions and this is the focus for this short
reflective section.
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Overall, the alterations in resting cardiac structure, function, CV risk factors as well
as exercise responses would suggest that AS could increase the risk of developing
occult CV disease or encountering a CV event. The magnitude of this increase in risk
is almost impossible to estimate and despite the possible reversibility of the negative
consequences of their use, one would assume that with continued AS use the risk
would continue to rise due to a cycle of increased stress and atherosclerotic risk
factors when using AS. Despite this it became apparent across studies that an
increase in CV disease risk was highly variable; person-to-person, and measurement-
to-measurement as well as study-to-study. Some data sets were more consistent, such
as diastolic function which will be discussed later. That said, classic CV risk factors
such as blood pressure were highly variable. In the resting studies these were
elevated but not significantly in AS users but in the exercise trials blood pressure
was elevated at rest and during an acute leg press but not before and after a
resistance training session, however low numbers in the exercise trials need to be
considered when comparing the conflicting results from the different studies. Whilst
study one and two found little difference in BP measures at rest, study three
demonstrated greater BP levels in AS users both at rest and during exercise. Elevated
blood pressures and increased arterial stiffness have been associated with significant
increases in cardiovascular disease/event risk (Dawber et al., 1957, Laurent et al.,
2001) but this could be as much to do with resistance training as with AS use
(Kawano et al., 2008). Whilst Kasikcioglu et al. (2007) reported that AS use was
associated with increased aortic stiffness, suggesting a reduction in nitric-oxide
mediated dilation through inhibition of second messengers to the smooth muscle
surrounding the arteries, this is not a consistent finding. Whilst the importance of an
exaggerated BP response to exercise for cardiovascular risk has been proposed
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(Chaney and Eyman, 1988), and is partially supported by the findings in study three,
this hypothesis is yet to be fully proven in AS users.
Measures on LV systolic function (EF, E) were altered in some studies but not in
others. It was also apparent that no perfusion defects or interstitial fibrosis was
observed by highly accurate cMRI. One simple way to evaluate these disparate
findings is that an increase in CV risk is not obligatory when taking AS. It may be
that some inter-individual differences in the physiological response to AS use, or
quite simply the AS use/dose history may have had a impact on the development of
CV risk. These facets cannot be deduced from the current study and are likely very
difficult to assess in any self-report based study of AS in humans. It may be possible
that some individuals are quite "resistant" to negative CV side-effects of AS use,
whereas others at potentially similar dosages maybe more "susceptible". An
individual approach to human studies within case series may try to unpick some of
these issues.
Some "negative" CV responses to AS use were more consistent and deserve more
attention. Significant alterations in lipid profiles were observed in study I and were
also apparent in the cohort in study 2 (this data was not reported here because of a
low n). Abnorrnallipid profiles would suggest an increased risk of the development
of arterial plaques, and has also been observed in previous findings (Hartgens et al.
1987). A mechanistic process responsible for the alteration of lipid-profiles in AS
users, has been postulated by Applebaum-Bowden (1987) who reported an increase
in LDL producing hepatic-triglyceride lipase (HTGL) following AS administration.
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Whilst suggesting an increased production rate of LDL, these findings could also
imply a catabolic effect of HTGL on HDL.
Another consistent outcome across studies was the presence of an LV (as well as RV
in study 2) hypertrophy. Wall thickness and LV mass were different in absolute
measures when compared with matched controls. This finding confirms and extends
previous data (Sachtleben et al., 1993, Dickerman et al., 1998, Nottin et al., 2006).
Despite significant cardiac structural changes in the AS groups, these differences
were no longer present once they were scaled according to fat free mass. This
highlights the importance of appropriate scaling (Batterham et al., 1999; Dewey et
al., 2008). Further it provides indirect support for whole body protein anabolism in
all muscular beds and thus suggests a mechanism for cardiac hypertrophy in AS
users. Whilst an up-regulation of protein metabolism has been demonstrated in
skeletal muscle beds following AS administration (Cellotti and Cesi, 1992), Marsh et
al. (1998) have also demonstrated a similar increase in cardiac tissue. Interestingly, it
would suggest that in the presence of normal function the development of LV mass
in line with whole body fat free mass may be less insidious. However, whilst systolic
function was largely normal in AS users the same cannot be said of diastolic
function.
The changes seen in RV function are certainly worthy of further investigation. A
drop in RV systolic function observed in study 2 as well as previous research
suggesting a drop in RV diastolic function, could implicate a change in pulmonary
pressure as well as reduction in RV compliance and elasticity, possibly greater than
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that seen in the LV (Kasikcioglu et al., 2007). A number of mechanistic processes
may be responsible for this negative effect of AS on pulmonary pressure outside of
myocardial changes affecting ventricular compliance. Hematocrit levels have
received limited attention in the area of AS research with the data suggesting a
possible role of AS in increasing haematocrit and haemoglobin (Lane et al., 2006).
By virtue of the fact that AS are indiscriminate in the androgen receptors they bind
to, an up-regulation of red blood cell production from the bone marrow would be a
legitimate assumption. An increase in haemotocrit levels would be indicative of an
increase in blood volume and viscosity, in tum leading to an increase in blood
pressure that would be most notable in the lower pressure ranges seen in the
pulmonary system. Combined with a possible effect of AS on vascular compliance,
it would therefore be reasonable to surmise that this possible change would have a
direct effect on RV function through both systole and diastole.
A consistent finding in study one, was the persistent reduction in diastolic cardiac
measures within the AS users, whether this was at rest (study I and 2) or during/after
resistance exercise (study 3). Although a reduction in LV diastolic function has been
observed by some parameters in recent studies (Baggish et al., 2010, D'Andrea et al.,
2007, Kasikcioglu et al., 2009, Nottin et al., 2006, Krieg et al., 2007), this study
extended this with new regional and global measures of LV diastolic function
(notably strain data in the longitudinal, circumferential and radial plane). Although
peak longitudinal and radial strain data has previously been shown to be negatively
affected with AS use (Baggish et al., 2010, D'Andrea et al., 2007), this study was the
first to demonstrate a negative association of AS use with depressed diastolic strain
rates. The fact that this depression in function may persist or extend when in an
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exercise setting provides further cause for concern. It may be that the major impact
of AS use is upon early diastolic relaxation (that is compensated for with augmented
atrial or late diastolic function). Again, the causes are speculative but a number of
mechanisms for a reduction in cardiac relaxation have been postulated. LeGros et al.
(2000) suggested in increase in collagen cross-links between myocytes with AS. In
addition to this an effect of AS on calcium cross-channels (Lieberherr and Grosse,
1994) as well as an increased rate of apoptosis (Zaugg et al., 200 I) have also been
suggested as possible mechanisms for a reduction in cardiac diastolic relaxation
capacity.
It is also important to consider the possible reversibility of some of the negative
consequences of AS use following a relatively short period of abstinence, observed
in study I. Whilst the data regarding 'On/Off' cycle comparisons is on a small
number of users, each of them showed improvements in measures of either
cardiovascular risk or cardiac function. The key areas of change observed were
increases in HDL as well increases in E:A ratios. Despite difficulty in extrapolating
these findings to a wider group, they could suggest that any proposed increase in CV
risk may be exaggerated when the findings occur when users are 'On' cycle. It is,
however, difficult to assess the long-term effects of repeatedly increasing CV stress
through negative effects on atherosclerotic risk factors as well as decreases in
diastolic function. The acute changes seen following cessation of AS use may be
precipitated by an acute drop in enzymes such as hepatic triglyceride lipase as well
as an increase in lysyl oxidase inhibitors, causing down-regulation in LDL and
collagen cross-link formation respectively. Whilst the reversibility of the effects of
AS use on cardiac function has received some attention, they contradict the present
134
findings somewhat as they suggest that function may not completely recover
following cessation for several years (Urhausen et al., 2004).
6.3 Implications
The findings from the studies included in this thesis can have a number of
implications for AS users and researchers/clinicians. Whilst noting the discussion
above there is some clear evidence that AS use has the potential for negative CV
health side effects and in some this could be fatal. It is important that this message is
delivered clearly and honestly to this sub-culture, alongside the data that an increase
in CV risk factors or specific facets of proposed mechanisms of CV events are not
obligatory in response to AS use that mirrors the specific cohorts recruited within
this thesis. Such honesty of effect may actually have a more profound effect on AS
users who are often immune to the "tub-thumping" medic or public health specialist.
It is important to note that the present findings were all performed in young to
middle aged AS users who demonstrated a broad range of AS dose and use history
(years, cycle-specific data). There was no correlation between amount and time of
use and major cardiac variables in study 2 that limits conclusions about the
accumulative effect of AS use in this cohort. Whether decades of use would produce
different results is not known but is pertinent for clinicians as we are now
approaching 40yr of AS availability to resistance athletes. Another point for
clinicians to consider is that the secretive nature of AS use often means that users are
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reluctant to divulge their use to a medical practitioner and so it can be difficult for
practitioners to be aware of any increased risk that patients might be under.
Whilst the findings could not be said to be completely conclusive, they do suggest
that AS use can be associated with a number of negative CV side effects that may
not be apparent to the user or clinician/scientist for some time. Of particular interest
to the present AS user is the effect of AS on lipid profiles that were observed. The
role of AS in negatively altering lipid profiles has developed to become one of the
few quite well established consequence of AS use (Angell et al., 2011). This is an
important consideration for any current or potential user to consider, as the role of
LOL and HDL levels in CV disease progression is well established one and although
perfusion defects were not noted in the current cohort some manifestation of
coronary artery disease or coronary artery spasm is likely implicated in many case
studies of significant CV events.
From a scientific/research perspective, the present findings illustrate the need for
more comprehensive and detailed research studies that can apply the latest
technological advancements to improve accuracy within the area of CV assessment.
Whilst not being definitive, the findings from this thesis do highlight themes (such as
negative alterations of lipid profiles; diastolic dysfunction) that are starting to
become an established consequence of continual AS use and a greater understanding
of the role AS play in causing this effect is required.
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6.4 Limitations
O'Sullivan et al. (2000) stated that limitations of, and barriers to, research in the field
of AS use are substantial. Because of issues of legality and the consequent
clandestine use of AS, large population-based epidemiological data detailing CV
disease presence in AS users are unavailable. Open self-reporting on a large scale
over a long time period is hard to obtain. Simply gaining access to this group is a
difficult task. Many users are suspicious of 'outsiders' asking questions and this can
lead to a failure to reach many imbedded in the culture. That being said, different
methods have been employed to achieve greater access to users. Employing a cross-
departmental/profession approach between those working in clinical sciences and
public health (e.g. needle-exchange settings) can greatly improve the access of data.
The immersion of a researcher into the culture, in order to gain the trust of AS users
is still likely to be the most effective way to get open and honest accounts of AS use.
Randomised-control (placebo) trials of AS use are "few and far between" and are
limited by ethical concerns in respect of the AS dose used. In "real-life", the dose of
AS is often large and complex. Multiple steroids (stacking) are taken together, often
with other substances, in increasing and decreasing dosage profiles. Another
consideration is that the "true" dose of AS is also difficult to verify, even in honest
self-report cases, because of the black -market system of purchase and the widespread
distribution of counterfeit drugs (Thevis et al., 2008). Whilst we made some
attempts to verify data and we could not account for all drug-related limitations and
we did not even contemplate a randomised control trial for ethical reasons.
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It is quite clear that the use of AS may be suspended (off-cycle) for short periods
before resumption (on-cycle) but all of these practices differ significantly between
individuals. We made a brief, case-by-case attempt to assess the impact of AS
withdrawal in study 1. This was limited by current practice, was highly variable
between athletes and as such conclusions were significantly constrained.
Limitations to the direct impact of AS use on cardiovascular disease presence or end-
point are apparent. As a consequence of these limitations, the direct CV health
impacts of AS use are still to be fully determined. What data exists in humans has
largely been derived from case studies or case-series/case-control studies (Evans-
Brown et al., 2008). Whilst we employed case series data with variables that
attempted to reflect CV disease and event risk, these approaches are open to error of
association. Despite some attempts to assess homogenous and matched groups we
acknowledge; 1) the use of diverse subject groups with variable training exposure
and dietary practices, 2) the lack of urine assessment to verify drug load, 3) the wide
spectrum of AS dosage (quantitatively), drug type or source (e.g. veterinary), drug
quality (e.g potency and 'homemade' AS), and stacking or poly-drug regimens that
are often associated with the use of AS, and 4) the limitations of accuracy in self-
report AS use.
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6.5 Future Research
On the basis of (de)limitations noted above and in the specific empirical chapters we
would make the following suggestions as to productive lines of on-going enquiry
related to AS use.
In the first instance, the small subject numbers in most cross-sectional studies is a
limiting factor to this area of research alongside the inter and intra-individual drug
dosages. More longitudinal studies of "real-life" AS use, from as early in the AS use
history, as is reasonably possible, would be illuminating. This could also factor in
multiple withdrawals from AS use (off cycles) along with the differing cycles that
are used for 'bulking' or 'cutting'. The specific issue of reversibility of any CV
effects of AS is also an issue that requires attention. This could assess short-term
withdrawal as well as assessing long-term users who have ceased use.
Of what limited data there is regarding AS use, a vast majority of the focus has been
of their effects in men. Despite the majority of non-medicinal users being male, there
are still a number of competitive female body builders and athletes that use AS. It
could also be argued that due to the very nature of AS being derived from male
hormones, the risk posed to women could potentially be greater than those seen in
men. In order to further understand the potential negative consequences of AS use,
the inclusion of female participants in any longitudinal studies is necessary.
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Integral to future studies, alongside longitudinal designs (etc), is the need to utilise
state-of-the-art techniques to assess CV health and generate new data and insights.
For example, with a greater spatial resolution and the ability to tissue track as well as
assess fibrosis and perfusion, using cardiac magnetic resonance imaging would allow
for a much more comprehensive assessment of cardiac structure and function as well
as determine if perfusion defects, inflammation and/or fibrosis existed within the
cardiac muscle of AS users. Of specific interest would be to develop the database
associated with RV adaptations to AS use. Whilst we demonstrated a RV
hypertrophy and a reduced RV EF we did not assess RV diastolic function or indeed
assess regional and global deformation using speckle-tracking echocardiography.
The cellular mechanisms responsible for any negative CV changes that occur from
AS use/abuse also require further attention. Whilst previous research has examined
the effects of AS on hepatic (Welder et al., 1995b) and endothelial cells (Welder et
aI., 1995a), work on myocardial cells has been limited to animal studies (Zaugg et
aI., 2001). Future animal in vitro work should aim to replicate doses to that which
occurs in human users with a particular focus on proteomics and the area of sub-
cellular enquiry.
6.6 Conclusions
This thesis has provided a significant insight in to the effect of AS use on CV
function, as well as markers of CV disease/event risk. The results provide a greater
understanding of the possible effects of continued AS use and suggests possible
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explanations for the reasons behind these changes. Due to the limitations inherent
within the field of research, however, it does limit the scope of conclusions possible
from the findings. In addition, the clinical implications of such findings should be
interpreted cautiously. Nonetheless, the findings do highlight the need for a wider
scope of research to further understand the mechanisms/processes that are
responsible for any change as well as the magnitude of possible negative effects
associated with AS use.
In study one, we were able to accept part of our hypothesis due to the observation of
significant changes in cardiac structural measures as well as systolic and diastolic
measures in the AS group. Further to this, we also observed a significant effect of
AS on CV risk factors, and more specifically, lipid profiles. Whilst these differences
did not necessarily persist across all measures, they were consistent enough to
suggest a negative effect of AS use on CV risk factors and cardiac function.
Similarly, study two also found significant cardiac structural and functional
differences in fat free mass, meaning only a partial acceptance of the original
hypothesis is possible. The decrease in RV systolic function as well as significant
reductions in diastolic LV function support the hypothesis of a significant negative
effect of AS on cardiac function.
Studies 3 and 4 had no hypotheses attached to them but were instead used to
ascertain the feasibility of CV testing during resistance exercise. Both studies
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demonstrated potential issues regarding limitations in consistency of data capture,
and more specifically cardiac data capture, during and after high-intensity resistance
exercise. However, despite these issues, the findings from both demonstrate that
further understanding the acute response to, and recovery from, exercise in AS users
and non-users is both worthwhile and feasible.
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Participant Consent forms
Health profiles of weight/strength trainers. Consent
form
You will be given a copy of this sheet to take with you.
Please tick:
o I confirm that I have read and understand the information provided for
the above study. I have had the opportunity to consider the information, ask
questions and have had these answered satisfactorily.
o I understand that my participation is voluntary and that I am free to withdraw at
any
time, without giving a reason and without my medical care or legal rights being
affected.
o I understand that any personal information collected during the study will be
anonymized and remain confidential.
o I understand that I can choose not to answer any questions which I feel
uncomfortable answering.
o I agree that quotes from my questionnaire/interview may be reported in published
documents but that this will be anonymous and no-one will be able to identify me
from this.
o I agree to complete the body composition scan (DEXA scan).
o I agree to provide blood, saliva and urine for sample testing.
o I agree to that the DNA from my blood can be used to test for the length of the
androgen receptor gene.
o I agree to allow my blood sample to be securely stored for future research.
o I agree to complete the ECHO (echocardiogram), ECG (electrocardiogram) and
blood
pressure testing.
o I agree to complete the arterial structure and function testing.
Signed:
Date:
(participant)
I, (investigator's full name) certify that
the
details of this study have been fully explained and described in writing to the
participant named above and have been understood by him/her.
Signed:
Date:
(investigator)
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Cardiac Magnetic Resonance Imaging in Strength Trainers: Consent Form
You will be given a copy of this sheet to take with you.
Please Tick:
o I confirm that I have read and understand the information provided for the above study. I have
had the opportunity to consider the information, ask questions and had these answered
satisfactorily.
o I understand that my participation is voluntary and that I am free to withdraw at any time,
without giving a reason and without my medical care or legal rights being affected.
o I understand that any personal information collected during the study will be anonymized and
remain confidential.
o I agree that quotes from my questionnaire may be reported in published documents but that
this will be anonymous and no-one will be able to identify me from this.
o I agree to complete the Cardiac MRI scan.
o I agree to provide blood and urine for sample testing.
o I agree to complete an echocardiogram, ECG (electrocardiogram) and blood pressure testing.
o I agree to complete the body composition assessment using bioelectrical impedance.
Participant Name: . Date: / /
Signature: .
I, (investigators full name) certify that the
details of this study have been fully explained and described in writing to the participant named above
and have been understood by him/her.
Signed: .. Date: / /
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LIVERPOOL JOHN MOORES UNIVERSITY
CONSENT FORM
Cardiovascular Responses to Acute Competitive Sporting Activity
Principal Investigator: Mr. Peter Angell, Research Institute for Sport and
Exercise Sciences
1. I confirm that I have read and understand the information provided for the above
study. I have had the opportunity to consider the information, ask questions and
have had these answered satisfactorily
2. I understand that my participation is voluntary and that I am free to withdraw at
any time, without giving a reason and that this will not affect my legal rights.
3. I understand that any personal information collected during the study will be
anonymised and remain confidential
4. I agree to take part in the above study and agree to my tissue (blood samples)
being used as part of the study.
Name of Participant Date Signature
Name of Researcher Date Signature
Peter Angell
Name of Person taking consent Date Signature
(if different from researcher)
Note: When completed 1copy for participant and 1 copy for researcher
D
D
D
D
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Participant Information Sheets
Health profiles of weight/strength trainers
Participant Information Sheet (Group B)
Title of study
Health profiles of weight/strength trainers
Study location:
School of Sport and Exercise Sciences, Liverpool John Moores University.
Study co-ordinator:
Mr Peter Angell
School of Sport and Exercise Sciences
Liverpool John Moores University
15-21 Webster Street
Liverpool
L32ET
Telephone: 0796 842 2497
Email: p.angell@2004.ljmu.ac.uk
Please contact Peter Angell (details above) if there is anything you do not understand or if
you would like more information. Take time to decide whether or not you wish to take
part.
What is the study about?
The effects of anabolic steroids on health when used in weight/strength training are poorly
understood. The purpose of this study is to look at the effect of these drug on the body over
I steroid cycle (and how these compare to weight/strength trainers who have never used
anabolic steroids). Some of the key areas we will be looking at will be body compo ilion and
the structure and function of the heart and blood vessels. The results of this study wi II allow
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us to better understand the effects of anabolic steroids on the body, and develop health care
and related services for anabolic steroid users.
What does the study involve?
Along with providing general information on your health, lifestyle, training and steroid use
(and related drug use), we would like to follow your health over a steroid cycle (i.e. on/off
cycle). For this we would like you to keep a daily diary (which will be provided, and will
take approximately 15 minutes per day to complete) that records steroid usc, training
regimen, diet, general health and whether you experience any side effects. We will also need
you to attend an assessment at our School of Sport and Exercise Sciences on 2 separate
occasions over the course of the cycle. The procedures that will be performed on each visit
are outlined below, and, during your first visit to School of Sport and Exercise Sciences, you
will be fully familiarised with these procedures and given the opportunity to ask any
questions that you may have.
Questionnaires: You will be asked to complete a number of questionnaires on your health,
lifestyle, training and steroid use (and related drug use). We would also like to discuss your
views and perceptions on steroid use and what health services you feel steroid users need.
Body composition: A procedure known as Dual Energy X-ray Absorptiometry (DEXA) will
be used to assess the amount and distribution of your body fat, lean tissue as well as bone
mineral density. The procedure is non-invasive and takes approximately 5 minutes. It
involves lying stationary on your back on a moving table whilst low-dose x-ray (equivalent
to the dose of radiation experienced during a 2 hour aircraft flight) arc passed through the
body. To prevent interference with the procedure, you will be required to remove any metal
or items of jewellery. Prior to DEXA we will measure your height and weight.
Blood and urine sampling: Blood samples will be collected from a vein in your arm. A
small amount (25ml) of blood will be taken. This amount is negligible and will not cause
any adverse effects. Your blood will be used to measure a number of ditTerent health
markers - including lipids, glucose, hormones and clotting factors. We will also look at the
composition of part of your androgen receptor gene by DNA analysis. A full list of tests that
will be performed on your blood is available upon request.
We will also ask you to provide a small urine sample (90ml), which will be used to measure
glucose, protein as well as any anabolic steroids and related substances present in your urine.
A full list of tests that will be performed on your urine is available upon request.
Anabolic steroid testing: We would like test some of the anabolic steroids (and any other
substances) that you are using in your training for research purposes. This will allow us to
examine things such as the dose and the drugs present in the preparations. If you are happy
for us to do this please let us know as soon as possible so that we can make the necessary
arrangements with you.
Blood pressure: Automated blood pressure measures will be taken alternately on your left
and right arm whilst at rest (either in a seated position or lying on your back on a bed). All
measurements will be taken twice. Although this procedure is non-invasive, it may cause
some mild discomfort in your arm, which will subside when the cuff pressure is released.
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Electrocardiography (ECG): An ECG will be performed where IO electrodes are placed on
your chest wall that will record the electrical activity of your heart. During this examination
you will only be required to lie on your back on a bed in a resting state.
Echocardiography: An echocardiographic examination of the heart will be performed. This
uses ultrasound technology to enable a non-invasive and painless assessment of heart
structure and function. During this examination you will only be required to lie on your back
on a bed in a resting state.
Arterial structure and function: The blood vessels of both your legs and upper arms will be
scanned (using ultrasound technology) during a number of procedures that will measure
your arteries ability to dilate (i.e. it assesses their function) whilst seated or lying on your
back on a bed. Ultrasound is a completely safe, non-invasive measurement technique. One
of the procedures will involve inflating a cuff, which will be placed around your upper arm
(i.e. above the elbow joint) to occlude the circulation for five minutes while the cuff is
inflated. Although these procedures are non-invasive, they are likely to cause mild
discomfort in your arms, which will subside when the cuff pressure is released. During
another one of the procedures, the blood vessels will be scanned before and after a small
dose of a drug called glyceryl trinitrate (GTN) is sprayed under your tongue with the acute
changes to the artery being measured. When sprayed under your tongue in this way, GTN
causes your arteries to relax, allowing a short-term increase in blood flow. Rare side effects
could include a headache or a slight lowering of blood pressure, both of which only last for a
short period of time. Although GTN has been used in this way for many decades and is
considered to be very safe in the doses we will use, you should inform us if you are taking
any forms of medication or drugs.
Are side-effects associated with any of the procedures?
The procedures we will be using are all well-established techniques which have been used in
numerous research studies (including with athletes).
In the arterial structure and function procedures, use of glyceryl trinitrate (GTN)--~
which causes your arteries to relax, allowing a short-term increase in blood flow --.~
could cause a headache or a slight lowering of blood pressure in some individuals,
both of which only last for a short period of time. Although GTN has been used in
this way for many decades and is considered to be very safe in the doses we will
use, you should inform us if you are taking any forms of medication or drugs.
How long will it take?
Completing the diary will take you approximately 15 minutes per day. Each visit to the
School of Sport and Exercise Sciences will take about 3-4 hours (-8 hours in total), typically
between 9am and lpm on a weekday.
What will I gain from taking part?
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You will have information on your body fat and lean tissue (muscle) mass as well as your
bone mineral density. From the electrocardiography, echocardiography, arterial structure and
function you will find out about the structure and function of your heart and blood vessels,
both before and after exercise (following the data analysis, a report will be provided on this).
You will also help inform the development of health care and related services for steroid
users.
Wi/Imy data be kept confidential?
All the information collected about you during the course of the study will be kept strictly
confidential. Any identifying information about you will not be disclosed to anyone outside
of the research group. You do not have to give us your full name. At the end of the study we
may ask your permission to give you a letter to take to your GP (General Practitioner) so that
they can discuss the results in more detail with you if they are important to your health.
However, we will only provide you with a letter after you have given us permission. If you
do not have a GP, we will provide you with details of where you can register with one,
It is expected that the results of this study will be published in a scientific journal and to
inform health policy, but no identifying reference will be made to those individuals who
took part. Liverpool John Moores University is registered under the Data Protection Act and
has an Information Security Policy to safeguard the collection, processing and storage of
confidential data.
However, should you suggest, imply or state that you are involved in specific serious
criminal activities (i.e. acts of terrorism, offences against children) then we will inform the
necessary authorities.
What else do I need to know?
You must be aged 18 or over to participate in this study and planning to undertake
anabolic steroid cycles in the near future.
We will pay travel/parking expenses up to a maximum of £ 15 per session attended.
Please remember to keep any receipts/tickets and bring them with you.
If you agree to participate it is essential that you do not smoke, or eat any food or
caffeine" for 12 hours before an assessment session. Restraint from exercise and
alcohol for the 24 hours prior to any assessment sessions is also mandatory.
A qualified practitioner will take your blood sample. Blood" and urine will only be
used for this study, and, following analysis, any that remains will be disposed of. ·If
you decide that you would like to participate in the University of Southampton's
growth hormone study, part of the blood sample that you give will be sent to this
research team. On the consent forms for the Southampton study you can decide if
you wish to allow them to keep your blood sample, securely, for use future research
(please see separate sheet for details).
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Please note that, unfortunately, this study will not be able to provide you with the
results of the: 1. questionnaires/discussions; 2. the blood and urine tests; and. 3. the
anabolic steroid (and related drugs) testing.
We will provide you with a list of health services that are available to you upon
request.
If you are interested in receiving the final results of this study then please get in
contact with Peter Angell. However, please bear in mind that data such as these
often take many months to analyse and prepare for publication.
You have the right to withdraw from the study at any time without giving a reason,
and without prejudice to access of services that are already being provided or may
subsequently be provided to you. However, completion of all the procedures will
greatly assist this research.
* Please note that caffeine isfound in many common food and drinks such as chocolate, lea.
coffee. soft drinks (such as cola and energy drinks). over-the-counter medications (such as
pain-relief products) and some nutritional supplements.
How do I take part in the study?
If you would like to take part, please contact Peter Angell (contact details listed above) for
further details.
What if I wish to complain about the way in which this study has been conducted?
In the first instance if you have any complaints or concerns please contact Peter Angell
(contact details listed above). Alternatively, you can contact Keith George. Professor of
Exercise & Cardiovascular Physiology on 0151 231 4088 or email k.georgetglljmu.ac.uk.
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Cardiac Magnetic Resonance Imaging in weight/strength
trainers
Participant Information Sheet
Title of study
Health profiles of weight/strength trainers
Study location:
Royal Brompton Hospital
Sydney Street
London
SW36NP
Study co-ordinator:
Mr Peter Angell
School of Sport and Exercise Sciences
Liverpool John Moores University
15-21 Webster Street
Liverpool
L32ET
Telephone: 0796 842 2497
Email: p.angell@2004.ljmu.ac.uk
Please contact Peter Angell (details above) if there is anything you do not understand or if
you would like more information. Take time to decide whether or not yo" wish to take
part.
What is the study about?
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We require weight/strength trainers who are using, or have never used, anabolic steroids.
Some of the key areas we will be looking at are the differences between body composition
and the structure and function of the heart and blood vessels. The results of this study will
allow us to better understand the effects of anabolic steroids on the body, and develop health
care and related services for anabolic steroid users.
What does the study involve?
We would like you to attend an assessment at The Royal Brompton Hospital ,Chelsea, on
one occasion. The procedures that will be performed on this visit are outlined below, and,
during your first visit you will be fully familiarised with these procedures and given the
opportunity to ask any questions that you may have.
Cardiac MRI: Magnetic resonance imaging (MRI) is a non-invasive medical test
that helps physicians diagnose and treat medical conditions.
MR imaging uses a powerful magnetic field, radio frequency pulses and a computer
to produce detailed pictures of organs, soft tissues, bone and virtually all other
internal body structures. The images can then be examined on a computer monitor,
printed or copied to CD. MRI does not use ionizing radiation (x-rays).
Detailed MR images allow physicians to better evaluate various parts of the body
and certain diseases that may not be assessed adequately with other imaging methods
such as x-ray, ultrasound or computed tomography (also called C'T or CAT
scanning).
Cardiac MRI (cMRI) is based on the same basic principles of MRl but with the visual
optimisation for use in the cardiovascular system. Using these techniques allows us to
assess the structure and function of the heart and its valves, major vessels and its
surrounding structure. It also allows for diagnosis of cardiovascular problems through
assessment of the thickness and size of heart walls and chambers.
Prior to the examination, cannular lines will be inserted in to veins in your arms. This allows
infusion of Adenosine and Gadolinium. Adenosine will be infused during part of the MRI
examination in order to measure how your heart reacts to a period of stress. The Gadolinium
is used as a contrast agent to measure the rate of perfusion within the heart, which is used as
a gauge of the health the myocardiam.
Each examination is usually completed in around 60 minutes.
Questionnaires: You will be asked to complete a number of questionnaires on your health,
lifestyle and training. We would also like to discuss your views and perceptions on topics
such as your health, lifestyle and training.
Body composition: A procedure known as bio-electrical impedance will be used to assess
the amount and distribution of your body fat and lean tissue. The procedure is non-invasive
and takes approximately 5 minutes. It involves standing on a small machine, similar to a set
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of scales and holding 2 points of contact with your hands. Prior to bio-electrical impedance
we will measure your height and weight.
Blood sampling: Blood samples will be collected from a vein in your arm. A small amount
(25ml) of blood will be taken. This amount is negligible and will not cause any adverse
effects. Your blood will be used to measure a number of different health markers -
including lipids, glucose, hormones and clotting factors. A full list of tests that will be
performed on your blood is available upon request.
Blood pressure: Automated blood pressure measures will be taken alternately on your left
and right arm whilst at rest (either in a seated position or lying on your back on a bed). All
measurements will be taken twice. Although this procedure is non-invasive. it may cause
some mild discomfort in your arm, which will subside when the cuff pressure is released.
Electrocardiography (ECG): An ECG will be performed where 10 electrodes are placed on
your chest wall that will record the electrical activity of your heart. During this examination
you will only be required to lie on your back on a bed in a resting state.
Echocardiography: An echocardiographic examination of the heart will be performed. This
uses ultrasound technology to enable a non-invasive and painless assessment of heart
structure and function. During this examination you will only be required to lie on your back
on a bed in a resting state.
Are side-effects associated with any of the procedures?
The procedures we will be using are all well-established techniques which have been used in
numerous research studies (including with athletes).
How long will it take?
Your visit to the Royal Brompton Hospital will take about 3-4 hours,
What will I gain from taking part?
You will have information on your body fat and lean tissue (muscle) mass. From the
electrocardiography, echocardiography, and cardiac MRI you will find out about the
structure and function of your heart and major blood vessels leaving the heart (following the
data analysis, a report will be provided on this). You will also help inform the development
of health care and related services for steroid users.
Will my data be kept confidential?
All the information collected about you during the course of the study will be kept strictly
confidential. Any identifying information about you will not be disclosed to anyone outside
of the research group. You do not have to give us your full name. At the end of the study we
may ask your permission to give you a letter to take to your GP (General Practitioner) so that
they can discuss the results in more detail with you if they are important to your health.
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However, we will only provide you with a letter after you have given us permission. If you
do not have a GP, we will provide you with details of where you can register with one.
It is expected that the results of this study will be published in a scientific journal and to
inform health policy, but no identifying reference will be made to those individuals who
took part. Liverpool John Moores University is registered under the Data Protection Act and
has an Information Security Policy to safeguard the collection, processing and storage of
confidential data.
However, should you suggest, imply or state that you are involved in specific serious
criminal activities (i.e. acts of terrorism, offences against children) then we will inform the
necessary authorities.
What else do I need to know?
You must be aged 18 or over to participate in this study and have never taken
anabolic steroids (or related drugs).
If you agree to participate it is essential that you do not smoke. or cat any food or
caffeine" for 12 hours before an assessment session. Restraint from exercise and
alcohol for the 24 hours prior to any assessment sessions is also mandatory.
A qualified practitioner will take your blood sample. Blood will only be used for this
study, and, following analysis. any that remains will be disposed of.
Please note that, unfortunately, this study will not be able to provide you with the
results of the: 1. questionnaires/discussions.
We will provide you with a list of health services that arc available to you upon
request.
If you are interested in receiving the final results of this study then please get in
contact with Peter Angell. However, please bear in mind that data such as these
often take many months to analyse and prepare for publication.
You have the right to withdraw from the study at any time without giving a rea.Win,
and without prejudice to access of services that are already being provided or may
subsequently be provided to you. However, completion of all the procedure." will
greatly assist this research.
* Please note that caffeine is found in many common food and drinks such as chocolate, tea,
coffee, soft drinks (such as cola and energy drinks), over-the-counter medications (such as
pain-relief products) and some nutritional supplements.
How do I take part in the study?
If you would like to take part, please contact Peter Angell (contact details listed above) for
further details.
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What if I wish to complain about the way in which this study has been conducted?
In the first instance if you have any complaints or concerns please contact Peter Angell
(contact details listed above). Alternatively, you can contact Keith George. Professor of
Exercise & Cardiovascular Physiology on 0151 231 4088 or email k.gcorgc{iVljmu.ac.uk.
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PARTICIPANT INFORMATION SHEET
LIVERPOOL JOHN MOORES UNIVERSITY
Cardiovascular Responses to Resistance Exercise
Principal Investigator: Peter Angell, Research Institute for Sport and Exercise
Sciences
You are being invited to take part in a research study about how the cardiovascular
system responds to strenuous intermittent exercise. Before you decide it is
important that you understand why the research is being done and what it involves.
Please take time to read the following information. Ask us if there is anything that is
not clear or if you would like more information. Take time to decide if you want to
take part or not.
1. What is the purpose of the study?
The purpose of the study is to assess the effects of an acute bout of resistance
exercise on the heart's electrical activity (ECG), heart structure and function
(echocardiogram scan), arterial blood flow (vascular scan of the leg), brain blood
flow, blood pressure, and the appearance of cardiac biomarkers in the blood.
Research has suggested that resistance exercise can result in transient alterations
to blood pressure, the function of the heart as well as the release into the circulation
of biomarkers of cardiac damage. It has also been suggested that this response it
exaggerated in anabolic steroid (AS) use. These issues require further exploration
in resistance trained athletes who do and do not use AS. This data should inform
athletes, coaches, scientists and medics by providing in-depth feedback regarding
cardiovascular structure and function following resistance exercise.
2. Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do you will be given
this information sheet and asked to sign a consent form. You are still free to
withdraw at any time and without giving a reason. A decision to withdraw will not
affect your rights or any future service you receive.
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3. What will happen to me if I take part?
Before performing the testing session, you will be required to attend a
screening/familiarisation session to check your health and suitability to take part in
the study as well as to attain your 1 rep maximums (1RM's).
The study will involve you participating in some tests before and after a high
intensity, full body, series of resistance exercises. This exercise session will include
Squats, Bench Press, Bench Pulls, Overhead Press and Upright Rows for 3 sets of
S reps at 80% of 1RM, with a recovery period of 1 %/2 minutes between sets. We
will perform all the tests at the LJMU CETL building. Prior to all the testing sessions
you will be required to undertake 6 hour fast, refrain from caffeine. chocolate and
alcohol for 8 hrs and strenuous physical activity for 24 hrs.
We will perform a number of measurements (described below) prior to your bout of
exercise and then again at 10 and 60 minutes following the exercise session.
Testing session 1, before and at 10 and 60 minutes following the exercise
programme:
a) We will ask you to complete a health and training questionnaire which will take
c.S min.
b) We will measure your body weight and height using electronic scales and a
stadiometer. We will ask you to remove all outer clothing and shoes and will take c.
2min.
c) We will take a recording of the electrical activity of your heart by placing 10
adhesive electrodes on the surface of your skin in the chest region. This is non-
invasive, painless and will take c. 5 min whilst you are lying down.
d) We will take pictures of the structure and function of your heart using an
ultrasound scanning machine. This uses 4 adhesive electrodes, a transducer
placed on your chest wall with some gel. This is non-invasive. painless and will take
c. 15 min whilst you are lying down.
e) We will measure the blood flow in your femoral and carotid artery using an
ultrasound scanning machine. This is non-invasive, painless and will take c.10
minutes.
f) We will also measure brain blood flow in your cerebral artery using an ultrasound
scanning machine. The probe will be fixed in position using a headframe. This is
non-invasive, painless and will take c. 5 min.
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g) We will measure your blood pressure by placing a clip over your middle finger.
This is non-invasive, painless and will take c. 2 min whilst you are lying down.
h) We will take a small (5 ml) blood sample from a vein (near your elbow) in your
arm. This will be taken whilst you are seated by a trained technician or doctor.
The second testing session wi" comprise of a single set of high intensity resistance
exercise on the leg press machine, where you will be asked to perform 5 repetitions
at 90% of your 1RM. During this exercise bout, ultrasound images will be
continuously taken of your heart and of you femoral (upper leg) and carotid (neck)
arteries. Your brain blood flow and blood pressure will also be measured throughout
the exercise set. These parameters wlll then be measured 5 minutes following
completion of the exercise bout.
Testing session 2:
a) We will measure your body weight and height on electronic scales and
stadiometer. We will ask to remove a" outer clothing and shoes and wi" take c. 2
min.
b) We will take a recording of the electrical activity of your heart before and 5
minutes post exercise, by placing 10 adhesive electrodes on the surface of your
skin in the chest region. This is non-invasive, painless and wi" take c. 5 min whilst
you are lying down.
c) We wi" take pictures of the structure and function of your heart using an
ultrasound scanning machine. This uses 4 adhesive electrodes, a transducer
placed on your chest wall with some gel. This is non-invasive, painless and will be
performed continuously throughout the exercise bout and for 5 minutes after.
d) We will measure the blood flow in your femoral and carotid artery using an
ultrasound scanning machine. This is non-invasive, painless and will be performed
continuously throughout the exercise bout and for 5 minutes after.
e) We will also measure brain blood flow in your cerebral artery using an ultrasound
scanning machine. The probe wi" be fixed in position using a headframe. This is
non-invasive, painless and wi" be measured continuously throughout the exercise
bout and for 5 minutes after.
f) We wi" measure your blood pressure throughout the exercise bout using a
portapres which clips on to the end of your finger. This is non-invasive, painless and
will be performed continuously throughout the exercise bout and for 5 minutes after.
4. Are there any risks I benefits involved?
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There is a small risk of infection due to a needle being used to take the blood
sample from your arm. This may also result in bruising at the site of needle
insertion. Your sporting activity may result in a level of muscle damage/soreness if
you are unaccustomed to the intensity and/or duration of the exercise. This can last
between 24 and 72 hours.
The benefit of being involved is that you will have a thorough assessment of cardiac
electrical activity, structure and function provided by expert clinicians and scientists.
5. Will my taking part in the study be kept confidential?
All of the data collected will be treated as confidential. When stored data will be
anonymised so that your identity will not be revealed. All data will be stored on a
password protected computer system.
Contact Details of Researcher
If you have any questions relating to any of the techniques used during the research
study please feel free to contact me to discuss this further. Participation in this
research study is voluntary and you are free to withdraw at any time without prior
explanation.
Peter Angell, BSc (Hons)
Liverpool John Moores University
Tom Reilly Building
Byrom Street
Liverpool, L3 3AF
P.Angell@2004.ljmu.ac.uk 01519046277
Note: A copy of the participant information sheet should be retained by the
participant with a copy of the signed consent form.
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Data Collection Sheet
Data Sheet
Name: .
Subject Code: .
Date of Birth: .. .1 .. .1 .
Contact Details: Telephone Number: .
e-mail: ..
Height cm
Weight: kg
BP: 1.. .
2 .
3 .
Training:
1. How many times do you train, on average, per week?
2. How long, on average, would each training session take?
If large variations between sessions, please give details:
3. What is your one repetition maximum for the bench press and squat?
(please state whether weights are in kg's or lbs)
Bench Press: Squat:
History (Delete as appropriate):
Have you recently (within last 3 months), or are you currently using anabolic steroids or
other performance-enhancing drugs? YeslNo
If Yes, please give details of types, quantities used, duration of usage and planned total
length of usage.
Have you ever used anabolic steroids or other performance-enhancing drugs? Yes/No
If Yes, please give details of types, quantities used and duration of usage.
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